

(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 764 641 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:
26.03.1997 Bulletin 1997/13

(51) Int. Cl.⁶: **C07D 239/26**, A01N 43/50

(21) Application number: 94931203.7

(86) International application number:
PCT/JP94/01847

(22) Date of filing: 01.11.1994

(87) International publication number:
WO 95/12582 (11.05.1995 Gazette 1995/20)

(84) Designated Contracting States:
CH DE ES FR GB IT LI NL

(30) Priority: 09.06.1994 JP 127456/94
14.06.1994 JP 131709/94
27.06.1994 JP 144774/94

(71) Applicant: NISSAN CHEMICAL INDUSTRIES,
LIMITED
Chiyoda-ku Tokyo 101 (JP)


(72) Inventors:
• SATOW, Jun,
Nissan Chem. Industries, Ltd.
Funabashi-shi, Chiba 274 (JP)
• KONDO, Yasuo,
Nissan Chemical Industries, Ltd.
Funabashi-shi, Chiba 274 (JP)
• KUDO, Yoshihiro,
Nissan Chemical Industries, Ltd.
Funabashi-shi, Chiba 274 (JP)
• MIKASHIMA, Takumi,
Nissan Chem. Industries, Ltd.
Funabashi-shi, Chiba 274 (JP)

- NAWAMAKI, Tsutomu
Minamisaitama-gun, Saitama 349-02 (JP)
- ITO, Yoichi,
Nissan Chem. Ind., Ltd.
Minamisaitama-gun, Saitama 349-02 (JP)
- SUDO, Kazuhisa,
Nissan Chem. Ind., Ltd.
Minamisaitama-gun, Saitama 349-02 (JP)
- NAKAHIRA, Kunimitsu,
Nissan Chem. Ind., Ltd.
Minamisaitama-gun, Saitama 349-02 (JP)
- WATANABE, Shigeomi,
Nissan Chem. Ind., Ltd.
Minamisaitama-gun, Saitama 349-02 (JP)
- ISHIKAWA, Kimihiro,
Nissan Chem. Ind., Ltd.
Minamisaitama-gun, Saitama 349-02 (JP)

(74) Representative: Wächtershäuser, Günter, Prof.
Dr.
Patentanwalt,
Tal 29
80331 München (DE)

(54) **NOVEL 4,5-DISUBSTITUTED PYRIMIDINE DERIVATIVE AND HERBICIDE**

(57) A novel 4,5-disubstituted pyrimidine derivative of the formula (I):



(I)

wherein R1 is CF₂X (X is Cl or Br), R₂ is a C₁-C₈ alkyl group, a C₃-C₈ cycloalkyl group, etc., R₃ is a halogen atom, SH, NH₂, etc., and R₄ is a hydrogen atom, a halogen atom, a C₁-C₆ alkyl group, etc., is a herbicide having excellent activities.

EP 0 764 641 A1

DescriptionTECHNICAL FIELD

5 The present invention relates to novel 4,5-disubstituted pyrimidine derivatives and herbicides containing such derivatives as active ingredients.

BACKGROUND TECHNIQUE

10 The group of compounds of the present invention which contain a pyrimidine ring having hydrogen atoms at the 2- and 6- positions and having specific substituents introduced at the 4- and 5- positions, is a group of novel compounds and, heretofore, their herbicidal activities have not been known.

In order to protect important crop plants such as rice, soybean, wheat, corn, cotton and sugar beet from weeds and to increase their productivities, many herbicides have been put into practical use. These herbicides can roughly be clas-
 15 sified into three categories, i.e. those for upland fields, for paddy fields, and for non-agricultural fields, according to the application site. Further, each category can be classified into, for example, a soil incorporation treatment type, a pre-emergence soil treatment type and a post-emergence treatment (foliage treatment) type, according to the manner of application.

With the recent global population increase, the productivities of important crop plants will undoubtedly affect the
 20 food economy of each country. With such changes, the conventional mode of agriculture will be inevitably changed toward the 21st century. Actually, it has been increasingly required than ever for persons engaged in agriculture to develop herbicides which can economically and effectively kill or control weeds detrimental to the growth of crop plants.


As such herbicides, chemicals which meet the following requirements are desired to be developed.

Preferred are those having high herbicidal effects at low doses (it is necessary to kill weeds at as low doses as pos-
 25 sible from the viewpoint of environmental protection), those having adequate residual activities (since a problem that soil-persistent chemicals damage next crops has arisen recently, it is important to show an adequate residual activity after application), those which promptly kill weeds upon application (it is possible to sow or transplant next crops soon after chemical treatment), those which do not require frequent treatment (it is important for farmers to minimize the frequency of cumbersome weed control operations), those intended to control a wide range of weeds (chemicals capable
 30 of controlling a variety of weeds having different properties such as broad-leaves weeds, graminaceous weeds and per-ennial weeds, are desirable), those which can be applied by various methods (a stronger herbicidal effect can be obtained by combining an effect of soil treatment, an effect of foliage treatment and so on), and those which do not show any problematic phytotoxicity against crop plants (in a field where a crop plant coexists with weeds, those capable of selectively killing weeds are desired). However, no existing herbicides satisfy all of these requirements.

DISCLOSURE OF THE INVENTION

The present inventors have conducted extensive studies on the herbicidal action of the novel pyrimidine derivatives under these circumstances. As a result, they have found that 4,5-disubstituted pyrimidine derivatives of the following for-
 40 mula exhibit excellent herbicidal activities. The present invention has been accomplished on the basis of this discovery.

Namely, the present invention provides a novel 4,5-disubstituted pyrimidine derivative of the formula (I) (hereinafter referred to as the compound of the present invention):



(I)

wherein R1 is a C₁ or C₂ haloalkyl group,
 55 R2 is a C₁-C₈ alkyl group, a C₃-C₈ cycloalkyl group, a C₃-C₈ cycloalkyl(C₁-C₄)alkyl group, a phenyl group which may be substituted [wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a C₁-C₄ haloalkyl group, a C₁-C₄ haloalkoxy group, a C₃-C₈ alkenyl group, a C₃-C₈ alkynyl group, a CO₂(C₁-C₄ alkyl) group, a N(C₁-C₃ alkyl)₂ group, a cyano group, a nitro group, a sulfo group, an amino group, a hydroxy group, a mercapto group, a SCH₃ group, a SO₂CH₃ group, a phenoxy group and a phenyl

group], a thienyl group, a furyl group, a pyridyl group, a C₁-C₆ haloalkyl group, a C₃-C₆ halocycloalkyl group, a C₃-C₈ alkenyl group, a C₃-C₈ alkynyl group, a C₁-C₂ sulfonyl(C₁-C₄)alkyl group or C₁-C₄ alkylthio(C₃-C₆)cycloalkyl group,

R₃ is a halogen atom, SH, NH₂.

- 5
- O-R11 [wherein R11 is a C₁-C₈ alkyl group, a C₃-C₈ alkenyl group, a C₃-C₈ alkynyl group, a C₃-C₆ cycloalkyl group, a C₃-C₆ cycloalkyl(C₁ or C₂)alkyl group, a C₁-C₆ haloalkyl group, a C₃-C₈ haloalkenyl group, a C₃-C₈ haloalkynyl group, a C₁-C₄ alkoxy(C₁-C₄)alkyl group, a cyano (C₁-C₄)alkyl group, a C₁-C₄ alkylthio(C₁-C₄)alkyl group, a C₁-C₄ alkoxy carbonyl(C₁-C₄)alkyl group, a C₁-C₄ alkoxy carbonyl group, a carboxy(C₁-C₄)alkyl group, a C₁-C₄ alkyl carbonyl group, a C(=O)NR₂₁(R₂₂) group (each of R₂₁ and R₂₂ is independently a hydrogen atom, a C₁-C₄ alkyl group, a C₃-C₈ alkenyl group or a C₃-C₈ alkynyl group), C(=S)NR₂₁(R₂₂) group (R₂₁ and R₂₂ are as defined above), a hydroxy(C₁-C₄)alkyl group, a SO₂N(C₁-C₆ alkyl)₂ group, CO(C₁-C₆ alkyl) group, a CO₂(C₁-C₆ alkyl) group, a SO(C₁-C₆ alkyl) group, a SO₂(C₁-C₆ alkyl) group, a phenethyl group, a phenacyl group, a 1- or 2-naphthyl group, a tetrahydropyranyl group, a tetrahydrothiopyranyl group, a 3-bromotetrahydropyranyl group, a 4-methoxytetrahydropyranyl group, a 4-methoxytetrahydrothiopyranyl group, a tetrahydrofuran-yl group, a tetrahydrothiofuran-yl group, a 1,4-dioxan-2-yl group, a 1-methoxycyclohexyl group, a benzoyloxymethyl group, a 2,2,2-trichloroethoxymethyl group, a bis(2-chloroethoxy)methyl group, a 1-(2-chloroethoxy)ethyl group, a 2-methoxyethoxymethyl group, a 1-methyl-1-benzyloxyethyl group, a tertiary butyldimethylsilyl group, a trimethylsilyl group, a triethylsilyl group, a 2-thenyl group, a furfuryl group, a 2-thenoyl group, a phenyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a C₁-C₄ haloalkyl group, a C₁-C₄ haloalkoxy group, a C₃-C₈ alkenyl group, a C₃-C₈ alkynyl group, a CO₂(C₁-C₄ alkyl) group, a N(C₁-C₃ alkyl)₂ group, a cyano group, a nitro group, a SCH₃ group, a SO₂CH₃ group, a phenoxy group and a phenyl group), a benzyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a C₁-C₄ haloalkyl group, a C₁-C₄ haloalkoxy group, a C₃-C₈ alkenyl group, a C₃-C₈ alkynyl group, a CO₂(C₁-C₄ alkyl) group, a N(C₁-C₃ alkyl)₂ group, a cyano group, a nitro group, a SCH₃ group, a SO₂CH₃ group, a phenoxy group and a phenyl group), a -Q-phenyl group which may be substituted (wherein Q is a C₂-C₆ saturated or unsaturated carbon chain which may be branched, and the substituent of the phenyl group is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a C₁-C₄ haloalkyl group, a C₁-C₄ haloalkoxy group, a C₃-C₈ alkenyl group, a C₃-C₈ alkynyl group, a CO₂(C₁-C₄ alkyl) group, a N(C₁-C₃ alkyl)₂ group, a cyano group, a nitro group, a SCH₃ group, a SO₂CH₃ group, a phenoxy group and a phenyl group), a -Q-CO₂R₂₃ group (wherein Q is a C₂-C₆ saturated or unsaturated carbon chain which may be branched, and R₂₃ is a C₁-C₄ alkyl group), a benzoyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a C₁-C₄ haloalkyl group, a C₁-C₄ haloalkoxy group, a C₃-C₈ alkenyl group, a C₃-C₈ alkynyl group, a CO₂(C₁-C₄ alkyl) group, a N(C₁-C₃ alkyl)₂ group, a cyano group, a nitro group, a SCH₃ group, a SO₂CH₃ group, a phenoxy group and a phenyl group)],
 - S-R11 (wherein R11 is as defined above),
 - N(R11)R12 (wherein R11 is as defined above, and R12 is a hydrogen atom, a C₁-C₈ alkyl group, a C₃-C₈ alkenyl group, a C₃-C₈ alkynyl group, a C₃-C₆ cycloalkyl group, a C₃-C₆ cycloalkyl(C₁ or C₂)alkyl group, a phenyl group, a benzyl group, a C₁-C₆ alkoxy group, a formyl group, a C₁-C₆ acyl group, a -NHR₂₄ group (wherein R₂₄ is a C₁-C₆ alkyl group), a C₁-C₆ alkylsulfonyl group or a benzoyl group), where in -N(R11)R12, R11 and R12 may form a 3- to 8-membered saturated, unsaturated or partially saturated heterocyclic ring together with the N atom to which R11 and R12 are bonded, where the constituting elements of the ring is selected from the group consisting of a nitrogen atom, an oxygen atom, a sulfur atom and a carbon atom, and the heterocyclic ring may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₈ alkyl group, a C₁-C₈ alkoxy group, a C₁-C₆ haloalkyl group, a C₁-C₆ haloalkoxy group, a C₁-C₆ acyl group, a C₃-C₈ alkenyl group, a C₃-C₈ alkynyl group, a benzoyl group and a phenyl group), or
 - NH(R12) [R12 is as defined above],

55 R4 is a hydrogen atom, a halogen atom, a C₁-C₆ alkyl group, a C₁-C₆ alkoxy group, a C₃-C₆ cycloalkyl group, a C₃-C₈ alkenyl group, a C₃-C₈ alkynyl group, a C₁-C₆ haloalkyl group, a C₃-C₆ halocycloalkyl group, a C₃-C₆ cycloalkoxy group, a C₃-C₈ alkenyloxy group, a C₃-C₈ alkynyloxy group, a C₁-C₆ haloalkoxy group, a C₃-C₆ halocycloalkoxy group, a C₁-C₆ alkylthio group, or a phenyl group which may be substituted [wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a C₁-C₃ haloalkyl

group, a C₁-C₃ haloalkoxy group, a C₃-C₈ alkenyl group, a C₃-C₈ alkynyl group, a CO₂(C₁-C₂ alkyl) group, a N(C₁-C₃ alkyl)₂ group, a phenoxy group and a phenyl group],

R3 and R4 may form a 5- to 6-membered ring which may be substituted, where the constituting elements thereof are groups selected from the group consisting of an oxygen atom, CH₂, CH₂CH₂, CH₂C(=CH₂) and CH₂CBR₂, together with the C atom to which R3 and R4 are bonded [wherein the substituent is selected from the group consisting of a halogen atom, a CH₂OH group, a CH₂SH group, a CH₂NH₂ group, a CH₂OSi(CH₃)₃ group, a CH₂O-tetrahydropyranyl group, a C₁-C₄ alkoxy C₁-C₂ alkoxymethyl group, a CH₂OCH₂-cyclopropyl group, a phenyl C₁-C₄ alkoxymethyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a C₁-C₄ haloalkyl group and a nitro group), a phenyl C₁-C₄ alkylthiomethyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a C₁-C₄ haloalkyl group and a nitro group), a phenylthiomethyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a C₁-C₄ haloalkyl group and a nitro group), a piperidyl group, a pyridylmethyl group, a pyridyl group, a morpholinomethyl group, a piperazinomethyl group, a pyrrolidinylmethyl group, a piperazinomethyl group, a pyrrolidylmethyl group, a phenylaminomethyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a C₁-C₄ haloalkyl group and a nitro group), a phenyl C₁-C₄ alkylaminomethyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a C₁-C₄ haloalkyl group and a nitro group), a 4-phenylpiperazinomethyl group, a N-benzyl-N-methylaminomethyl group, a 4-(4-acylpiperazinyl)phenoxyethyl group, a 4-(4-isopropylpiperazinyl)phenoxyethyl group, a 4-[4-[2,4-dihydro-2-(1-methylpropyl)-3H-1,2,4-triazol-3-one-4-yl]phenyl]piperazinomethyl group, a C₁-C₁₆ alkyl group, a C₁-C₁₈ alkoxy group, a C₁-C₈ haloalkyl group, a C₁-C₁₆ haloalkoxy group, a C₂-C₈ alkenyl group, a C₂-C₈ alkynyl group, a C₁-C₁₈ alkoxymethyl group, a C₂-C₁₈ alkenyloxymethyl group, a C₂-C₁₈ alkynyloxymethyl group, a C₂-C₁₈ alkenylthiomethyl group, a C₂-C₁₈ alkenylaminomethyl group, a 3-substituted-1-pyrrolidylmethyl group, a C₁-C₄ alkylthiomethyl group, a C₁-C₆ alkylaminomethyl group, a C₁-C₁₉ alkylcarbonyloxymethyl group, a C₂-C₁₉ alkenylcarbonyloxymethyl group, a phenyl C₁-C₃ alkyl group, a (C₁-C₆ alkyl)₂ aminomethyl group (wherein the alkyl groups as substituents of the amino group may form a 5- or 6-membered cycloaliphatic ring), a phenoxyethyl group which may be substituted (the substituent of the phenyl group is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a C₁-C₄ haloalkyl group, a C₁-C₄ haloalkoxy group, a C₃-C₈ alkenyl group, a C₃-C₈ alkynyl group, a CO₂(C₁-C₄ alkyl) group, a N(C₁-C₃ alkyl)₂ group, a cyano group, a nitro group, a SCH₃ group, a SO₂CH₃ group, a phenoxy group and a phenyl group), and a phenyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a nitro group, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a C₁-C₄ haloalkyl group, a C₁-C₄ haloalkoxy group, a N(C₁-C₃ alkyl)₂ group, a phenoxy group and a phenyl group)],

provided that when the carbon atom substituted by R3 and R4 is an optically active carbon atom, the racemate and both of the two isolated optical isomers are included, and when two optically active sites are present in the molecule, the diastereomer mixture and all of the isolated two diastereomers and four optical isomers are included, and R3 and R4 may together form =NH, =NNH₂, =NOH, =NOR₁₁ (wherein R₁₁ is as defined above, and the geometrical isomers include the E/Z mixture and both of the isolated E and Z), =NO-Q-R₁₁ (wherein Q and R₁₁ are as defined above, and the geometrical isomers include the E/Z mixture and both of the isolated E and Z), =NO-Q-CO₂-(C₁-C₄ alkyl group) (wherein Q is as defined above, and the geometrical isomers include the E/Z mixture and both of the isolated E and Z), or =NNR₁₁(R₁₆) (wherein R₁₁ is as defined above, R₁₆ is a hydrogen atom, a C₁-C₆ alkyl group, a C₃-C₈ alkenyl group, a C₃-C₈ alkynyl group, a benzyl group or a phenyl group, and the geometrical isomers include the E/Z mixture and both of the isolated E and Z). The present invention also provides herbicides containing the compounds of the present invention.

Preferred compounds of the present invention are as follows:


(a) A compound wherein R₁ is CF₂X (X is a chlorine atom or a bromine atom).

(b) A compound wherein R₂ is a phenyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a trifluoromethoxy group and a trifluoromethyl group), a thienyl group, a furyl group or a pyridyl group; R₃ is a halogen atom, a C₁-C₈ alkoxy group, a C₃-C₆ cycloalkyloxy group, a phenoxy group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group and a trifluoromethyl group), a tetrahydropyranyloxy group, a phenyl C₁-C₄ alkoxy group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group and a C₁-C₄ alkoxy group), a C₃-C₆ cycloalkyl C₁ or C₂ alkoxy group, a C₃-C₆ alkenyloxy group, a C₃-C₆ alkynyloxy group, a C₁-C₄ alkoxycarbonyl(C₁-C₄)alkoxy group, a C₁-C₄ alkoxycarbonyloxy group, a C₁-C₄ alkoxy(C₁-C₄)alkoxy group, a C₁-C₄ alkylthio(C₁-C₄)alkoxy group, a cyano C₁-C₄ alkoxy group, a mono or di C₁-C₄ alkylaminocarbonyloxy group, a mono or di C₁-

C₄ alkylaminothiocarbonyloxy group, a C₁-C₄ alkylcarbonyloxy group, a C₁-C₄ alkylsulfonyloxy group, a di C₁-C₄ alkylaminosulfonyloxy group, a mercapto group, a C₁-C₄ alkylthio group, a phenylthio group, a benzylthio group, a C₃-C₆ alkenylthio group, a C₃-C₆ alkynylthio group, a C₁-C₄ alkoxy carbonyl(C₁-C₃)alkylthio group, a C₁-C₄ alkoxy carbonylthio group, a C₁-C₄ alkoxy C₁-C₄ alkylthio group, a cyano C₁-C₄ alkylthio group, a mono or di C₁-C₄ alkylaminocarbonylthio group, a mono or di C₁-C₄ alkylaminothiocarbonylthio group, a C₁-C₄ alkylthiocarbonylthio group, an amino group, a mono or di C₁-C₄ alkylamino group, a methyl(methoxy)amino group, a methoxyamino group, a hydroxy C₁-C₄ alkylamino group, a mono or di C₃-C₅ alkenylamino group, a mono or di C₃-C₅ alkynylamino group, a carboxy C₁-C₄ alkylamino group, a C₁-C₄ alkoxy carbonyl C₁-C₄ alkylamino group, a C₁-C₄ alkoxy carbonyl C₁-C₄ alkyl(methyl)amino group, a C₃-C₆ cycloalkylamino group, a phenylamino group, a phenyl C₁-C₄ alkylamino group which may be substituted (wherein the substituent is selected from the group consisting of a halogen, methyl and methoxy), a benzyl(methyl)amino group, a benzyl(formyl)amino group, a phenyl(formyl)amino group, a C₁-C₄ alkylsulfonylamino group, a mono or di C₁-C₄ alkylaminosulfonylamino group, a cyano C₁-C₄ alkylamino group, a C₁-C₄ alkylcarbonylamino group, a mono or di C₁-C₄ alkylaminocarbonylamino group, a mono or di C₁-C₄ alkylaminothiocarbonylamino group, a mono or di C₁-C₄ alkylhydrazino group, a di C₁-C₄ alkylamino group, an imidazolyl group, a triazol-1-yl group, a morpholino group, a dimethyl-substituted morpholino group, a piperazino group, a piperidino group, a pyrrolidinyl group or an aziridinyl group; and R₄ is a hydrogen atom or a methyl group.

(c) A compound wherein R₂ is a phenyl group which may be substituted (wherein the substituent is a halogen, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group or a trifluoromethyl group), a thienyl group, a furyl group or a pyridyl group; and R₃ and R₄ form together with the carbon atom to which R₃ and R₄ are bonded, a 1,3-dioxane ring which may be substituted (wherein the substituent is methylene or a halogen), or a 1,3-dioxolan ring which may be substituted (wherein the substituent is a C₁-C₈ alkyl group, a halo C₁-C₄ alkyl group, a methoxymethyl group or a C₃-C₆ alkenyl group).

(d) A compound wherein R₂ is a C₁-C₈ alkyl group, a C₃-C₆ halocycloalkyl group, a C₃-C₆ cycloalkyl group or a C₃-C₆ cycloalkyl C₁ or C₂ alkyl group; and R₃ and R₄ together form a formula



together with the carbon atom to which R₃ and R₄ are bonded, wherein R₈ is a hydrogen atom, a C₁-C₂₀ alkyl group, a phenyl group which may be substituted by a nitro group, a phenyl C₁-C₃ alkyl group, a C₃-C₆ alkenyl group, a halo C₁-C₈ alkyl group, a C₁-C₁₈ alkoxy methyl group, a benzyloxymethyl group which may be substituted (the substituent is selected from the group consisting of a methoxy group, a methyl group and a halogen atom), a phenoxymethyl group which may be substituted (wherein the substituent is selected from the group consisting of a methoxy group, a C₁-C₄ alkyl group, a halogen atom and a nitro group), an allyloxymethyl group, a propinyloxymethyl group, a hydroxymethyl group, a trimethylsilyloxymethyl group, a tetrahydropyranyloxymethyl group, a methoxymethoxymethyl group, a cyclopropylmethoxymethyl group, a mono or di C₁-C₁₂ alkylaminomethyl group, an aminomethyl group, a phenylamino C₁-C₄ alkyl group which may be substituted by a nitro group, a phenyl C₁-C₄ alkylaminomethyl group which may be substituted by a halogen atom, a C₃-C₆ cycloalkylaminomethyl group, a pyrrolidinylmethyl group, a piperazinomethyl group, a morpholinomethyl group, a piperidinomethyl group, a C₁-C₄ alkylthiomethyl group, a mercaptomethyl group, a phenylthiomethyl group which may be substituted by a halogen atom, a phenyl C₁-C₄ alkylthiomethyl group which may be substituted by a halogen atom, a C₁-C₁₇ alkylcarbonyloxymethyl group, a C₃-C₆ alkenylcarbonyloxymethyl group, a benzyloxymethyl group, a piperidyl group, a 4-phenylpiperazinomethyl group, a 4-(4-acylpiperazinyl)phenoxymethyl group, a 3-substituted-1-pyrrolylmethyl group, a 4-[4-[4-[2,4-dihydro-2-(1-methylpropyl)-3H-1,2,4-triazol-3-one-4-yl]phenyl]piperazino]phenoxymethyl group, a pyridyl group or a pyridylmethyl group.

(e) A compound wherein R₂ is a C₁-C₈ alkyl group or a C₃-C₆ cycloalkyl group; and R₃ and R₄ together form a 1,3-dioxane ring which may be substituted (wherein the substituent is a methylene group or a halogen atom) together with the carbon atom to which R₃ and R₄ are bonded.

(f) A compound wherein R₂ is a C₁-C₈ alkyl group, a C₃-C₆ cycloalkyl group or a C₃-C₆ cycloalkyl C₁ or C₂ alkyl group; R₃ is an amino group, a mono or di C₁-C₄ alkylamino group, a hydroxy C₁-C₄ alkylamino group, a cyano C₁-C₄ alkylamino group, a C₁-C₄ alkoxy carbonyl(methyl)amino group, a C₃-C₆ alkenylamino group, a C₃-C₆ alkynylamino group, a phenylamino group which may be substituted by a halogen atom, a phenyl C₁-C₄ alkylamino group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a trifluoromethyl group and a methoxy group), a phenyl C₁-C₄ alkyl(formyl)amino group which

may be substituted by a halogen atom, a C₁-C₄ alkyl(formyl)amino group, a phenyl C₁₋₄ alkyl(C₁-C₄ alkyl)amino group which may be substituted by a halogen atom, a diphenylmethylamino group, a thienylmethylamino group, a morpholino group, a dimethyl-substituted morpholino group, a thiomorpholino group, a piperidino group, a dimethyl-substituted piperidino group, an aziridyl group, a dimethylaziridyl group, a pyrrolyl group, a pyrrolidyl group, a C₁-C₃ alkyl-substituted piperidyl group, a methyl-substituted piperazyl group, a phenyl-substituted piperazyl group, a C₆ or C₇ alkyleneimino group, an imidazol-1-yl group, a pyrazol-1-yl group, a triazol-1-yl group, a phenyl-substituted piperidyl group, a benzyl-substituted piperidyl group, a dimethylamino-substituted piperidyl group, a trifluoromethylpiperidyl group, a perhydroquinolyl group, a tetrahydroquinolyl group, a tetrahydro-mono or dimethyl-substituted quinolyl group, a dihydro-dimethyl-substituted quinolyl group or a dihydro-dimethyl-chloroquinolyl group; and R₄ is a hydrogen atom.

(g) A compound wherein R₂ is a C₁-C₆ alkyl group, a C₃-C₆ cycloalkyl group or a C₃-C₆ cycloalkyl C₁ or C₂ alkyl group; R₃ is an O-R₆ group, wherein R₆ is a C₁-C₆ alkyl group, a C₃-C₆ cycloalkyl group, a C₃-C₅ alkenyl group, a C₃-C₅ alkynyl group, a halo C₁-C₄ alkyl group, a halo C₃-C₅ alkenyl group, a phenyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group and a methoxy group), a phenyl C₁-C₄ alkyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group and a methoxy group), a C₁-C₄ alkylcarbonyl group, a phenylcarbonyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group and a methoxy group), a benzylcarbonyl group, a C₁-C₄ alkylsulfonyl group, a phenylsulfonyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group and a methoxy group), a C₁-C₄ alkoxy C₁₋₄ alkyl group which may be substituted by a halogen, a C₁-C₄ alkylthiomethyl group, a mono or di C₁-C₄ alkylaminocarbonyl group, a mono or di C₁-C₄ alkylaminothiocarbonyl group, a C₁-C₄ alkoxy carbonyl group, a C₁-C₄ alkoxy carbonyl C₁-C₂ alkyl group, a cyanomethyl group, a tetrahydropyranyl group, a 3-bromotetrahydropyranyl group, a methoxytetrahydropyranyl group, a tetrahydrothiopyranyl group which may be substituted by a methoxy group, a tetrahydrofuranyl group, a tetrahydrothiofuranyl group, a 1,4-dioxan-2-yl group, a methoxy-substituted cyclohexyl group, a C₁-C₂ alkoxy C₁-C₂ alkoxy methyl group, a benzyloxymethyl group or a C₁₋₄ trialkylsilyl group; and R₄ is a hydrogen atom.

(h) A compound wherein R₂ is a C₁₋₆ alkyl group, a phenyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group and a trifluoromethyl group), a thienyl group, a furyl group or a pyridyl group; and R₃ and R₄ together form a formula =N-R₅, wherein R₅ is a C₁-C₆ alkoxy group, a C₃-C₆ cycloalkyloxy group, a C₃-C₆ alkenyloxy group, a C₃-C₆ alkynyloxy group, a C₁-C₄ alkoxy carbonyl C₁-C₄ alkoxy group, a carbonylmethoxy group, a benzyloxy group which may be substituted by a halogen atom, a hydroxy group, a mono or di C₁-C₄ alkylamino group, a phenylamino group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a methoxy group and a trifluoromethyl group), a benzylamino group which may be substituted by a halogen atom or a benzyloxy group which may be substituted (wherein the substituent is selected from the group consisting of a C₁-C₄ alkyl group, a halogen atom and a methoxy group).

The compounds of the present invention exhibit high herbicidal activities as a herbicide for upland fields and non-agricultural fields, either in soil treatment or in foliage treatment at low doses against broad-leaved weeds such as Solanaceous weeds (Solanaceae) represented by black nightshade (*Solanum nigrum*) and jimsonweed (*Datura stramonium*), Malvaceous weeds (Malvaceae) represented by velvetleaf (*Abutilon theophrasti*) and prickly sida (*Sida spinosa*), Convolvulaceous weeds (Convolvulaceae) represented by morningglories (*Ipomoea* spp.) including common morningglory (*Ipomoea purpurea*) and bindweeds (*Calystegia* spp.), Amaranthaceous weeds (Amaranthaceae) represented by livid amaranth (*Amaranthus lividus*) and redroot pigweed (*Amaranthus retroflexus*), Composite weeds (Compositae) represented by common cocklebur (*Xanthium pensylvanicum*), common ragweed (*Ambrosia artemisiifolia*), sunflower (*Helianthus annuus*), hairy galinsoga (*Galinsoga ciliata*), creeping thistle (*Cirsium arvense*), common groundsel (*Senecio vulgaris*) and annual fleabane (*Erigeron annuus*), Cruciferous weeds (Cruciferae) represented by India field cress (*Rorippa indica*), kedlock (*Sinapis arvensis*) and shepherd's purse (*Capsella Bursapastoris*), Polygonaceous weeds (Polygonaceae) represented by posumbu knotweed (*Polygonum Blumei*) and wild buckwheat (*Polygonum convolvulus*), Portulacaceous weeds (Portulacaceae) represented by common purslane (*Portulaca oleracea*), Chenopodiaceous weeds (Chenopodiaceae) represented by common lambsquarter (*Chenopodium album*), figleaved goosefoot (*Chenopodium ficifolium*) and kochia (*Kochia scoparia*), Caryophyllaceous weeds (Caryophyllaceae) represented by common chickweed (*Stellaria media*), Scrophulariaceaceous weeds (Scrophulariaceae) represented by persian speedwell (*Veronica persica*), Commelinaceous weeds (Commelinaceae) represented by asiatic dayflower (*Commelina communis*), Labiate weeds (Labiatae) represented by dead-nettle (*Lamium amplexicaule*) and red deadnettle (*Lamium purpureum*), Euphorbiaceous weeds (Euphorbiaceae) represented by prostrate spurge (*Euphorbia supina*) and spotted spurge (*Euphorbia maculata*), Rubiaceaceous weeds (Rubiaceae) represented by bed straw (*Galium spurium*) and indian madder (*Rubia akane*), Violaceous weeds (Violaceae) represented by violet (*Viola mandshurica*), and Leguminous weeds (Leguminosae) represented by hempesbania (*Sesbania exaltata*) and sicklepod (*Cassia obtusifolia*); and

various cropland weeds such as Gramineous weeds represented by shattercane (*Sorghum bicolor*), fall panicum (*Panicum dichotomiflorum*), johnsongrass (*Sorghum halepense*), barnyardgrass (*Echinochloa crus-galli* var. *crus-galli*), barnyardgrass (*Echinochloa crus-galli* var. *praticola*), barnyardgrass (crop) (*Echinochloa utilis*), large crabgrass (*Digitaria adscendens*), wild oat (*Avena fatua*), goosegrass (*Eleusine indica*), green foxtail (*Setaria viridis*) and water foxtail (*Alopecurus aequalis*), and Cyperaceous weeds represented by purple nutsedge (*Cyperus rotundus*, *Cyperus esculentus*).


Further, the compounds of the present invention exhibit high herbicidal activities as a herbicide for paddy fields either in submerged soil treatment or in foliage treatment at low doses against various paddy weeds such as Alismataceous weeds (Alismataceae) represented by narrow leaf waterplantain (*Alisma canaliculatum*), arrowhead (*Sagittaria trifolia*) and japanese ribbon wapato (*Sagittaria pygmaea*), Cyperaceous weeds (Cyperaceae) represented by small-flower umbrellaplant (*Cyperus difformis*), perennial flat sedge (*Cyperus serotinus*), bulrush (*Scirpus juncooides*) and water chestnut (*Eleocharis kuroguwai*), Scrophulariaceous weeds (Scrophulariaceae) represented by false pimpernel (*Lindemia pyxidaria*), Potenderiaceous weeds (Potenderiaceae) represented by ducksalad (*Monochoria vaginalis*), Potamogetonaceous weeds (Potamogetonaceae) represented by roundleaf pondweed (*Potamogeton distinctus*), Lythraceous weeds (Lythraceae) represented by toothcup (*Rotala indica*), barnyardgrass (*Echinochloa oryzicola*), barnyardgrass (*Echinochloa crus-galli* var. *formosensis*) and barnyardgrass (*Echinochloa crus-galli* var. *crus-galli*).

Therefore, the compounds of the present invention can be used as an active ingredient of herbicides for upland fields, paddy fields, lawns, orchards, pastures and other non-agricultural fields. Now, various methods for producing them will be described in detail.

The compounds of the present invention can be synthesized by the methods represented by the following Schemes 1 to 6 (in Schemes 1 to 6, R1 to R4 are as defined above, each of Ra and Rb is a C₁-C₃ alkyl group, L is a leaving group, Met is a metal atom such as Mg or Zn, and Hal is a halogen atom).

The starting material, 2,4-dicarbonyl compound (II), can be easily synthesized in accordance with the methods disclosed in "The Chemistry of the Carbonyl Group", p. 273, written by D.P.N. Satchell and R.S. Satchell, edited by Saul Patai (published by Wiley-Interscience, 1966) and "Organic Reactions Vol. 1", p. 266, written by C.R. Hauser and B.E. Hudson, Jr. (published by John Wiley & Sons, Inc., 1942).

Synthesis route (1)




(1) Synthesis route (1) in Scheme 1 indicates a method of producing a pyrimidine derivative (V) which comprises reacting a 2,4-dicarbonyl compound (II) with an orthoformic ester derivative and, as a case requires, a catalytic amount of zinc chloride (ZnCl₂), and then reacting the resulting 3-alkoxy methylene-2,4-dicarbonyl derivative (III) with a formamidine.

(2) Synthesis route (2) in Scheme 1 indicates a method of producing a pyrimidine derivative (V) which comprises

EP 0 764 641 A1


reacting a 2,4-dicarbonyl compound (II) with a N,N-dimethylformamide dialkylacetal or tert-butoxy-bis(dimethyl-amino)methane and then reacting the resulting 3-dimethylaminomethylene-2,4-dicarbonyl derivative (IV) with a formamidine.



(Scheme 2)


(3) Scheme 2 indicates a method wherein a pyrimidine derivative (V) is converted into a corresponding alcohol (VI) by a suitable reduction method (for example, reduction with a reagent such as NaBH₄, BH₃ or a BH₃ amine complex) or asymmetric reduction.

When the resulting alcohol (VI) is racemic, each of the optically active alcohols can be obtained through a suitable optical resolution, if necessary.



(Scheme 3)

(4) Scheme 3 indicates a method of producing a compound (VII), which comprises reacting a pyrimidine derivative (V) with an organic metal reagent R₄-Met-Hal (provided that the case that R₄ is a hydrogen atom is excluded).




30 (5) The synthesis route (VI→VIII→IX) in Scheme 4 indicates a method which comprises reacting an alcohol (VI) with a suitable halogenating agent such as phosphorus oxychloride, phosphorus oxybromide, phosphorus pentachloride, thionyl chloride, thionyl bromide or concentrated hydrochloric acid to synthesize a corresponding halogenated compound (VIII), and a method which comprises subsequently reacting the compound (VIII) with a nucleophilic reagent (such as O, N or S) in the presence or absence of a base to produce the compound (IX) of the present invention.

35 The synthesis route ((a) VI→IX) indicates a method for producing a compound (IX) of the present invention by reacting the alcohol (VI) with an olefin in the presence of a suitable acid catalyst, for example, sulfuric acid, paratoluenesulfonic acid, trifluoroacetic acid or Lewis acid (such as TiCl_4 , EtAlCl_2 , BF_3 etherate or AlCl_3) (provided that, in this case, R3 is limited to a substituent bonding with an oxygen atom).

40 The synthesis route ((b) VI→IX) indicates a method for producing the compound (IX) of the present invention by reacting the alcohol (VI) with an electrophilic reagent in the presence of a basic catalyst such as sodium hydride, potassium tertiary butoxide, potassium hydride or potassium carbonate (provided that, in this case, R3 is limited to a substituent bonding with an oxygen atom).

45 The synthesis route (VI→X→IX) indicates a method for producing the compound (IX) of the present invention by reacting the alcohol (VI) with a suitable leaving group such as a methanesulfonyl group, a paratoluenesulfonyl group or a trifluoromethylsulfonyl group to synthesize a compound (X) and subsequently reacting the compound (X) with a nucleophilic reagent (such as O, N and S).




(6) The synthesis route (XI→XII) in Scheme 5 provides a method for obtaining a compound (XII) of the present invention from an alcohol (XI) in the same manner as in Scheme 4.

5

10

15

20



Scheme 6

25

(7) By the synthesis route (V→XIII) in Scheme 6, a compound (XIII) of the present invention can be produced by a method of reacting the pyrimidine derivative (V) by a suitable acetalization reaction, for example, a) with an alcohol in the presence of an acid catalyst (such as paratoluenesulfonic acid), b) with an orthoester in the presence of an acid catalyst, or c) with an alcohol in the presence of trimethylsilyl chloride (Me₃SiCl).

30

In the synthesis route (V→XIV), a compound (XIV) of the present invention can be produced by dehydrating the pyrimidine derivative with R5-NH₂ (R5 means a substituent in claims which forms an imino group).

BEST MODE OF AN EMBODIMENT OF THE PRESENT INVENTION

35


Now, the syntheses of the compounds of the present invention and their intermediates will be described in detail with reference to Examples. However, it should be understood that the present invention is by no means restricted by such specific Examples.

EXAMPLE 1

Synthesis of 1-chloro-4-(4-chlorophenyl)-1,1-difluoro-2,4-butanedione

45

50



55


38 g of ethyl chlorodifluoroacetate was added to 22.7 g of sodium methoxide and 300 ml of dry ethyl ether under cooling with ice. 31 g of p-chloroacetophenone was gradually added thereto under cooling with ice. The mixture was stirred at room temperature for 12 hours. The solvent was distilled off under reduced pressure. 150 ml of 6N hydrochloric acid was added under cooling with ice, and extraction with ethyl acetate was carried out. The extract layer was washed with water, and the solvent was distilled off under reduced pressure. The resulting crude product was purified

EP 0 764 641 A1

by silica gel column chromatography (developing solvent: chloroform), to obtain 49.5 g of the desired product as a pale yellow viscous liquid.

EXAMPLE 2


Synthesis of 1-chloro-4-(4-chlorophenyl)-1,1-difluoro-3-ethoxymethylene-2,4-butanedione



A mixture of 49.5 g of 1-chloro-4-(4-chlorophenyl)-1,1-difluoro-2,4-butanedione, 41.3 g of ethyl orthoformate and 57 g of acetic anhydride was refluxed under heating for 4 days. The solvent was distilled off under reduced pressure to obtain 60.4 g of a crude product, which was used for the next reaction as it is.

EXAMPLE 3

Synthesis of 5-(4-chlorobenzoyl)-4-chlorodifluoromethylpyrimidine (Compound No. 1-1)




6 g of metal sodium and 500 ml of dry ethanol were mixed to prepare a sodium ethoxide solution. 23.3 g of formamidine acetate was added to the solution, and the mixture was stirred at room temperature for 15 minutes. 60.4 g of 1-chloro-4-(4-chlorophenyl)-1,1-difluoro-3-ethoxymethylene-2,4-butanedione (crude product) was gradually added under cooling with ice. The mixture was refluxed under heating for 2 hours. The solvent was distilled off under reduced pressure. 300 ml of ice water was added, and then extraction with ethyl acetate was carried out. The extract layer was washed with water, and the solvent was distilled off under reduced pressure.

The resulting crude product was purified by silica gel column chromatography (developing solvent: chloroform/hexane = 1/1) to obtain 27 g of the desired product as a pale yellow liquid. Refractive index n_D^{20} 1.5742

EP 0 764 641 A1

EXAMPLE 4


Synthesis of 4-chlorodifluoromethyl-5-[1-(4-chlorophenyl)-1-hydroxymethyl]pyrimidine (Compound No. 1-2)



15 12 g of 5-(4-chlorobenzoyl)-4-chlorodifluoromethylpyrimidine and 6 g of a t-butylamine borane complex were added to 100 ml of ethanol, and the resulting mixture was stirred at 0°C for 2 hours. Then, 20 ml of acetone was added thereto, and the mixture was stirred at 0°C for 1 hour. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (developing solvent: chloroform) to obtain 11.1 g of the desired product as a pale yellow viscous liquid. Refractive index $n_D^{20.3} 1.5563$

EXAMPLE 5


Synthesis of 4-chlorodifluoromethyl-5-[1-(4-chlorophenyl)-1-chloromethyl]pyrimidine (Compound No. 1-5)



35 11.1 g of 4-chlorodifluoromethyl-5-[1-(4-chlorophenyl)-1-hydroxymethyl]pyrimidine was dissolved in 100 ml of chloroform. 30 ml of thionyl chloride was added thereto. The mixture was refluxed under heating for 1 hour. The solvent and an excess amount of thionyl chloride were distilled off under reduced pressure, and the residue was used for the next reaction as it is. Refractive index $n_D^{19.3} 1.5653$

EXAMPLE 6

Synthesis of 4-chlorodifluoromethyl-5-[1-(4-chlorophenyl)-1-(1,1-dimethylethoxy)methyl]pyrimidine (Compound No. 1-9)




0.8 g of 4-chlorodifluoromethyl-5-[1-(4-chlorophenyl)-1-chloromethyl]pyrimidine was dissolved in 30 ml of t-butyl alcohol. 1 g of potassium t-butoxide was added thereto. The mixture was stirred at room temperature for 3 hours, and 100 ml of water was added thereto, followed by extraction with ethyl acetate. The solvent was distilled off under reduced

EP 0 764 641 A1

pressure, and the residue was purified by silica gel column chromatography (developing solvent; chloroform:ethyl acetate = 7:3) to obtain 0.4 g of the desired product. Refractive index $n_D^{20.1}$ 1.5291

EXAMPLE 7


Synthesis of 4-chlorodifluoromethyl-5-[1-(4-chlorophenyl)-1-(1,1-dimethylethoxy)methyl]pyrimidine (Compound No. 1-9)



2.44 g of phenyl-1-hydroxymethyl]pyrimidine was dissolved in 150 ml of chloroform, and 3.5 g of isobutylene was blown thereinto at 0°C. 1.2 ml of boron trifluoride etherate was added thereto. The mixture was sealed and left to stand for three days. The reaction solution was purified directly by silica gel column chromatography (developing solvent: chloroform) (Ø35x400 mm) to obtain 1.61 g of the desired product.

EXAMPLE 8

Synthesis of 4-chlorodifluoromethyl-5-[1-(4-chlorophenyl)-1-(N,N-dimethylamino)methyl]pyrimidine (Compound No. 1-15)




0.7 g of 4-chlorodifluoromethyl-5-[1-(4-chlorophenyl)-1-chloromethyl]pyrimidine was dissolved in 30 ml of isopropyl alcohol, and 3 ml of a 50% dimethylamine aqueous solution was added thereto. The mixture was stirred at room temperature for 1 hour and then at 50°C for 2 hours. The solvent was distilled off under reduced pressure and 100 ml of water was added thereto, followed by extraction with ethyl acetate. The solvent was distilled off under reduced pressure, and the residue was purified by preparative thin-layer chromatography (developing solvent; chloroform:ethyl acetate = 8:2) to obtain 0.2 g of the desired product. Melting point 60-61°C

EP 0 764 641 A1

EXAMPLE 9

Synthesis of 4-chlorodifluoromethyl-5-[1-(4-fluorophenyl)-1-(1-methylethoxy)methyl]pyrimidine (Compound No. 1-36)

5




20 0.41 g of 4-chlorodifluoromethyl-5-[1-(4-fluorophenyl)-1-chloromethyl]pyrimidine was dissolved in 50 ml of isopropyl alcohol, and the mixture was refluxed under heating at 100°C for 14.5 hours. The solvent was distilled off under reduced pressure and the residue was purified by preparative thin-layer chromatography (developing solvent; hexane:ethyl acetate = 5:1) to obtain 0.47 g of the desired product. Refractive index $n_D^{20.0}$ 1.5106

EXAMPLE 10

25

Synthesis of 4-chlorodifluoro-5-[1-(4-chlorophenyl)-1-(N,N-dimethylcarbamoyloxy)methyl]pyrimidine (Compound No. 1-68)

30



45 1.64 g of 4-chlorodifluoromethyl-5-[1-(4-chlorophenyl)-1-hydroxymethyl]pyrimidine was dissolved in 30 ml of dry ethyl ether. 0.75 ml of N,N-dimethylcarbamoyl chloride was added thereto, and 0.33 g of a 60% sodium hydride was added under cooling with water. The mixture was stirred at room temperature for 3 hours and then 50 ml of ice water was added thereto. The solution was extracted with 100 ml of ethyl ether, and after drying over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography (developing solvent: chloroform/hexane = 7:3) to obtain 1.32 g of the desired product. Refractive index $n_D^{19.7}$ 1.5358

50


55

EXAMPLE 11

Synthesis 4-chlorodifluoromethyl-5-[1-(4-chlorophenyl)-1-(cyanomethoxy)methyl]pyrimidine (Compound No. 1-76)

5

10



15

20

1.1 g of 4-chlorodifluoromethyl-5-[1-(4-chlorophenyl)-1-hydroxymethyl]pyrimidine was dissolved in a mixture solvent of DMF and ethyl ether (5 ml, 30 ml), and 0.43 g of a 60% sodium hydride was added thereto under cooling with water. The mixture was stirred for 10 minutes. 1.73 g of bromoacetonitrile was added thereto. The mixture was stirred at room temperature for 3 hours and then 50 ml of water was added. The mixture was extracted with 100 ml of ethyl ether and dried over anhydrous sodium sulfate, and then the solvent was distilled off under reduced pressure. The residue was purified by preparative thin-layer chromatography (developing solvent: chloroform/hexane = 7:3) to obtain 0.4 g of the desired product. Refractive index $n_D^{20.9}$ 1.5535


EXAMPLE 12

25

Synthesis of 4-chlorodifluoromethyl-5-[1-(4-chlorophenyl)-1-(ethylcarbamoyloxy)methyl]pyrimidine (Compound No. 1-77)

30

35



40

45

0.9 g of 4-chlorodifluoromethyl-5-[1-(4-chlorophenyl)-1-hydroxymethyl]pyrimidine and 0.5 g of ethyl isocyanate were dissolved in 30 ml of dry ethyl ether. 0.05 g of potassium *t*-butoxide was added thereto and the mixture was stirred at room temperature for 12 hours. The solvent was distilled off and the residue was purified by silica gel column chromatography (developing solvent: chloroform) to obtain 0.88 g of the desired product. Refractive index $n_D^{20.8}$ 1.5315

50

55


EP 0 764 641 A1

EXAMPLE 13

Synthesis of 1-chloro-1,1-difluoro-3-ethoxymethylene-2,4-pentanedione

5

10



15

20


A mixed solution of 50 g of 1-chloro-1,1-difluoro-2,4-pentanedione, 60 g of ethyl orthoformate and 82 g of acetic anhydride was refluxed under stirring for 2 hours. Then, a Dean-Stark apparatus (water separator) was fixed, and the solution was further refluxed under heating for 4 hours to distill about 100 ml of solvent off. After leaving to cool, distillation was carried out under reduced pressure to obtain 32.2g of the desired product as a pale red liquid. Boiling point: 95-118°C/1.6 mmHg.

EXAMPLE 14

Synthesis of 1-chloro-1,1-difluoro-3-ethoxymethylene-2,4-heptanedione

25

30



35

40

A catalytic amount of dried zinc chloride was added to a mixed solution of 5 g of 1-chloro-1,1-difluoro-2,4-heptanedione, 4.5 g of ethyl orthoformate and 5.4 g of acetic anhydride, and the mixture was stirred at 125°C for 1.5 hours. Then, a Dean-Stark apparatus was fixed, and the mixture was further stirred at 125°C for 4 hours to distill about 30 ml of the solvent off.

After leaving to cool, filtration was carried out under reduced pressure. Then, a reduced pressure distillation apparatus was fabricated. A low boiling fraction of at most 100°C/3 mmHg was removed to obtain 5.3 g of the desired product (yield: 83%). A part thereof was distilled and the following boiling point was confirmed. Boiling point 118 to 123°C/2 mmHg


45

EXAMPLE 15

Synthesis of 5-acetyl-4-chlorodifluoromethylpyrimidine

50

55




EP 0 764 641 A1

To 50 ml of dry ethanol, 0.9 g of metal sodium was added under cooling with ice to prepare sodium ethoxide. To this solution, 8.4 g of formamidine acetate which had been fully dried by means of a vacuum pump was added under stirring. Then, a solution of 8 g of 1-chloro-1,1-difluoro-3-ethoxymethylene-2,4-pentanedione dissolved in 20 ml of ethanol was dropwise added under cooling with ice. After the dropwise addition, the reaction solution was left to return to room temperature, and refluxed under heating for 1.5 hours. The reaction solution was left to cool and water was added, followed by extraction with ethyl ether. After drying over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure. The residue was subjected to distillation under reduced pressure, and purified by column chromatography (developing solvent: CHCl_3) to obtain 2.5 g of the desired product. Boiling point $65-70^\circ\text{C}/1.3\text{ mmHg}$, Refractive index $n_D^{20.7} 1.4787$

EXAMPLE 16


Synthesis of 4-chlorodifluoromethyl-5-(2,4-dipropyl-1,3-dioxolan-2-yl)pyrimidine (Compound No. 2-8)



0.4 g of 5-butyl-4-chlorodifluoromethylpyrimidine, 1 ml of 1,2-pentanediol and a catalytic amount of P-toluenesulfonic acid monohydrate were dissolved in 100 ml of toluene, and the mixture was refluxed under heating while dehydrating by means of a Dean-Stark apparatus. After completion of the reaction, water was added thereto and extraction was carried out with ethyl ether, followed by drying over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and the crude product was purified by preparative thin-layer chromatography of alumina (developing solvent: chloroform) to obtain quantitatively the desired product. Refractive index $n_D^{20.4} 1.4701$

EXAMPLE 17

Synthesis of 4-chlorodifluoromethyl-5-(4-butyl-2-methyl-1,3-dioxolan-2-yl)pyrimidine (Compound No. 2-13)



A mixed solution of 0.4 g of 5-acetyl-4-chlorodifluoromethylpyrimidine, 5 ml of 1,2-hexanediol and 0.84 g of trimethylsilyl chloride was stirred at room temperature for 16 hours.

After completion of the reaction, 100 ml of a 5% NaHCO_3 aqueous solution was added thereto and extraction was carried out with ethyl ether. The ethyl ether layer was washed with saturated aqueous salt solution and then dried over

EP 0 764 641 A1


anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained oil was purified by thin-layer chromatography of alumina (developing solvent: hexane/ethyl acetate = 10/1) to obtain 0.48 g of the desired product as a liquid. Refractive index $n_D^{20.1}$ 1.4761

5 EXAMPLE 18

Synthesis of 1-chloro-4-cyclohexyl-1,1-difluoro-2,4-butanedione

10

15



20


74.8 g of sodium methoxide was added to 1 l of ethyl ether, and a solution of 200 g of ethyl chlorodifluoroacetate in 300 ml of ethyl ether was dropwise added thereto under stirring at 0°C. Then, a solution of 106 g of cyclopropyl methyl ketone in 300 ml of ethyl ether was gradually dropwise added to the reaction solution, and after completion of the dropwise addition, the mixture was stirred at room temperature for 8 hours. The solvent was distilled off under reduced pressure, 300 ml of 6N hydrochloric acid was added to the residue, and extraction with ethyl acetate was carried out. The extract layer was washed with water, and the solvent was distilled off under reduced pressure to obtain 235.9 g of the desired product as a pale yellow liquid. Refractive index $n_D^{20.6}$ 1.4788

25

EXAMPLE 19

30 Synthesis of 1-chloro-4-cyclohexyl-3-ethoxymethylene-1,1-difluoro-2,4-butanedione

35



40

A mixture of 235.9 g of 1-chloro-4-cyclohexyl-1,1-difluoro-2,4-butanedione, 266.4 g of ethyl orthoformate and 367.2 g of acetic anhydride was refluxed under heating for 12 hours. The solvent was distilled off under reduced pressure to obtain 280.3 g of the desired product (crude product), which was then used for the next reaction as it is.


45

EXAMPLE 20

Synthesis of 4-chlorodifluoromethyl-5-cyclopropylcarbonylpyrimidine

50

55




EP 0 764 641 A1

71.9 g of sodium methoxide was added to 1 l of ethanol, and then 121.2 g of formamidine acetate was added thereto. To the resulting mixture, 280 g of 1-chloro-4-cyclohexyl-3-ethoxymethylene-1,1-difluoro-2,4-butanedione was gradually added dropwise under cooling with ice. The mixture was refluxed under heating for 1 hour, and the solvent was distilled off under reduced pressure. 500 ml of water was added to the residue, and extraction with ethyl acetate was carried out. The solvent in the extract layer was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (developing solvent: chloroform/hexane = 1/1) to obtain 101 g of the desired product. Refractive index $n_D^{20.5}$ 1.4998

EXAMPLE 21


Synthesis of 4-chlorodifluoromethyl-5-(1-hydroxy-1-cyclopropylmethyl)pyrimidine



70 g of 4-chlorodifluoromethyl-5-cyclopropylcarbonylpyrimidine was added to 100 ml of ethanol, and 15 g of a t-butylamine borane complex was further added under cooling with ice, followed by stirring at room temperature for 2 hours. After addition of 30 ml of acetone, the mixture was stirred at room temperature for 1 hour, and the solvent was distilled off under reduced pressure. 100 ml of water was added to the residue, and extraction with ethyl acetate was carried out. The extract layer was washed with water, and the solvent was distilled off under reduced pressure. The residue was dried in vacuum to obtain 45 g of the desired product. Refractive index $n_D^{20.5}$ 1.5020

EXAMPLE 22

Synthesis of 4-chlorodifluoromethyl-5-(1-chloro-1-cyclopropylmethyl)pyrimidine



A mixture of 7 g of 4-chlorodifluoromethyl-5-(1-hydroxy-1-cyclopropylmethyl)pyrimidine, 10 ml of thionyl chloride and 50 ml of chloroform was refluxed under heating for 1 hour. Then, the solvent and excess amount of thionyl chloride were distilled off under reduced pressure. The resulting crude product was purified by silica gel column chromatography (developing solvent: chloroform/hexane = 1/1) to obtain 5 g of the desired product as a viscous liquid. Refractive index $n_D^{21.3}$ 1.5076


EXAMPLE 23

Synthesis of 4-chlorodifluoromethyl-5-(1-morpholino-1-cyclopropylmethyl)pyrimidine (Compound No. 3-2)

5

10

15



20

A mixture of 0.5 g of 4-chlorodifluoromethyl-5-(1-chloro-1-cyclopropylmethyl)pyrimidine, 1 g of morpholine and 20 ml of isopropyl alcohol was refluxed under heating for 1 hour and then the solvent was distilled off under reduced pressure. The resulting crude product was purified by preparative thin-layer chromatography (alumina, developing solvent: chloroform/hexane = 7/3) to obtain 0.45 g of the desired product as a viscous liquid. Refractive index $n_D^{21.2}$ 1.5132


25 EXAMPLE 24

Synthesis of 4-chlorodifluoromethyl-5-(1-benzylamino-1-cyclopropylmethyl)pyrimidine (Compound No. 3-1)

30

35

40



0.5 of 4-chlorodifluoromethyl-5-(1-chloro-1-cyclopropylmethyl)pyrimidine was dissolved in 20 ml of isopropyl alcohol. 2 ml of benzylamine was added thereto and the mixture was refluxed under heating for 1 hour. The solvent was distilled off under reduced pressure and the residue was purified by preparative thin-layer chromatography (alumina, developing solvent: chloroform/hexane = 7/3) to obtain 0.57 g of the desired product. Refractive index $n_D^{21.3}$ 1.5478

50


55

EXAMPLE 25

Synthesis of 1-chloro-1,1-difluoro-5,5-dimethyl-2,4-hexanedione

5

10



15

20

25

7.1 g of sodium methoxide was added to 100 ml of dry ethyl ether, and the mixture was stirred. A solution of 20 g of ethyl chlorodifluoroacetate and 25 ml of dry ethyl ether was dropwise added at room temperature. Further, a solution of 12.5 g of pinacolone diluted with 25 ml of dry ethyl ether was dropwise added, and the mixture was stirred overnight at room temperature. Then, to the reaction solution, a solution of 8.4 g of glacial acetic acid diluted with 100 ml of water and a solution of 23.6 g of copper (II) acetate dissolved in a proper amount of water were dropwise added successively. After the dropwise addition, the mixture was stirred for about 10 minutes. Then, the ethyl ether was distilled off under reduced pressure and a solid was filtered off. After drying under reduced pressure, 100 ml of 6N hydrochloric acid was added, and extraction with ethyl acetate was carried out. After drying over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure. Then, the residue was subjected to distillation under reduced pressure to obtain 13 g of the desired product. b.p. 54-57°C/5 mmHg


EXAMPLE 26

Synthesis of 1-chloro-1,1-difluoro-5,5-dimethyl-3-ethoxymethylene-2,4-hexanedione

30

35

40



45


12.4 g of 1-chloro-1,1-difluoro-5,5-dimethyl-2,4-hexanedione and 12.4 g of ethyl orthoformate were added to 50 ml of acetic anhydride, and the mixture was refluxed under heating for 2 hours. After the solvent was distilled off under reduced pressure, the residue was subjected to distillation under reduced pressure to obtain 6.8 g of the desired product. b.p. 105-107°C/2 mmHg

50

55

EXAMPLE 27

Synthesis of 4-chlorodifluoromethyl-5-pivaloylpyrimidine




20 0.7 g of sodium methoxide and 1.25 g of formamidine acetate were added to 30 ml of dry methanol, and the mixture was stirred at room temperature for 30 minutes. A solution of 3 g of 1-chloro-1,1-difluoro-5,5-dimethyl-3-ethoxymethyl-ene-2,4-hexanedione diluted with 5 ml of dry methanol was dropwise added. After completion of the dropwise addition, the mixture was refluxed under heating for 2 hours. The solvent was distilled off under reduced pressure, and water was added thereto, and then extraction with ethyl acetate was carried out. After drying over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure. The residue was purified by thin-layer chromatography (developing solvent: hexane 80%, ethyl acetate 20%) to obtain 0.6 g of the desired product. Refractive index $n_D^{20.0}$ 1.4675

25

EXAMPLE 28

Synthesis of 4-chlorodifluoromethyl-5-(2,2-dimethyl-1-hydroxypropyl)pyrimidine



45 1.5 g of 4-chlorodifluoromethyl-5-(2,2-dimethyl-1-oxopropyl)pyrimidine was dissolved in 50 ml of ethanol, and 1 g of a borane ammonia complex was added, followed by stirring at room temperature for 1 hour. The solvent was distilled off under reduced pressure, and water was added thereto, followed by extraction with chloroform. The extract layer was washed with water and then dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by thin-layer chromatography (developing solvent: chloroform/ethyl acetate = 7/3) to obtain 1.1 g of the desired product as a viscous liquid. Refractive index $n_D^{19.8}$ 1.4623


50

55

EP 0 764 641 A1

EXAMPLE 29


Synthesis of 4-chlorodifluoromethyl-5-(1-acetyloxy-2,2-dimethylpropyl)pyrimidine (Compound No. 4-1)



1.5 g of 4-chlorodifluoromethyl-5-(2,2-dimethyl-1-hydroxypropyl)pyrimidine and 3 ml of acetic anhydride were dissolved in 30 ml of pyridine, followed by stirring at 50°C for 90 minutes. The solvent was distilled off under reduced pressure, and the residue was purified by thin-layer chromatography (developing solvent: chloroform). 0.7 g of the desired product as a viscous liquid was obtained. Refractive index $n_D^{20.0}$ 1.4644

EXAMPLE 30


Synthesis of 4-chlorodifluoromethyl-5-(1-hydroxyethyl)pyrimidine



0.4 g of 5-acetyl-4-chlorodifluoromethylpyrimidine was dissolved in 10 ml of dry diethyl ether, and an excess amount of a borane ammonia complex was added under cooling with ice, and then the mixture was stirred overnight at room temperature. Water was added thereto and extraction with diethyl ether was carried out. After drying over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure to obtain 0.32 g of the desired product as a viscous liquid. Refractive index $n_D^{19.9}$ 1.4899

EXAMPLE 31

Synthesis of 4-chlorodifluoromethyl-5-(1-methanesulfonyloxyethyl)pyrimidine (Compound No. 4-7)



A mixed solution of 0.4 g of 4-chlorodifluoromethyl-5-(1-hydroxyethyl)pyrimidine, 0.27 g of methanesulfonyl chloride and 8 ml of pyridine was stirred at room temperature for 1 day.

After completion of the reaction, the pyridine was distilled off under reduced pressure and water was added, fol-

EP 0 764 641 A1


lowed by extraction with chloroform. After drying over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure. The resulting crude product was purified by preparative thin-layer chromatography (developing solvent: chloroform) to obtain 0.25 g of a solid as the desired product. m.p. 96-100°C

5 EXAMPLE 32

Synthesis of 5-(1-tert-butyltrimethylsilyloxyethyl)-4-chlorodifluoromethylpyrimidine (Compound No. 4-9)

10

15



20

Into a mixed solution of 0.5 g of 4-chlorodifluoromethyl-5-(1-hydroxyethyl)pyrimidine, 0.78 g of imidazole and 50 ml of dimethylformamide, 0.83 g of t-butyldimethylsilyl chloride was dropwise added, followed by stirring at room temperature for 1 day. After completion of the reaction, water was added thereto and extraction with ethyl ether was carried out. After drying over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure. The resulting crude product was purified by preparative thin-layer chromatography (developing solvent: chloroform) to obtain the

25


desired product quantitatively. Refractive index $n_D^{20.2} 1.4602$

EXAMPLE 33

Synthesis of 4-chlorodifluoromethyl-5-(1-cyclopropyl-1-phenoxyethyl)pyrimidine (Compound No. 4-12)

30

35



40

45


A mixture of 1 g of phenol, 0.2 g of sodium hydride and 20 ml of dimethylformamide was stirred at room temperature for 1 hour. 0.5 g of 4-chlorodifluoromethyl-5-(1-chloro-1-cyclopropylmethyl)pyrimidine was added thereto, and the mixture was stirred at room temperature for 3 hours. The mixture was poured into 200 ml of water and extraction with ethyl acetate was carried out. The extract layer was washed with water and the solvent was distilled off under reduced pressure. The resulting crude product was purified by preparative thin-layer chromatography (developing solvent: chloroform/hexane = 1/1) to obtain 0.3 g of the desired product as a viscous liquid. Refractive index $n_D^{21.4} 1.5472$

50

55

EXAMPLE 34

Synthesis of 4-chlorodifluoromethyl-5-[1-(tetrahydropyran-2-yl-oxy)ethyl]pyrimidine (Compound No. 4-14)




0.3 g of 4-chlorodifluoromethyl-5-(1-hydroxyethyl)pyrimidine and 0.26 g of 3,4-dihydro-2H-pyran were dissolved in 20 ml of dehydrated methylene chloride and a catalytic amount of p-toluenesulfonic acid was added thereto, followed by stirring at room temperature overnight.

After completion of the reaction, 100 ml of ethyl ether was added thereto, washing was carried out with a saturated sodium bicarbonate aqueous solution and saturated aqueous salt solution, and water, respectively, followed by drying over anhydrous sodium sulfate. The solvent was distilled off, and the purification was carried out by thin-layer chromatography of alumina to obtain 0.38 g of the desired product as oil. Refractive index $n_D^{20.6}$ 1.4812

EXAMPLE 35

Synthesis of 4-difluorochloromethyl-5-(1-methoxyiminoethyl)pyrimidine (Compound No. 5-1)



0.3 g of 5-acetyl-4-chlorodifluoromethylpyrimidine was dissolved in 10 ml of ethanol and 0.12 g of methoxyamine hydrochloride was added thereto, followed by reflux under heating. After completion of the reaction, the solvent was distilled off and 0.2 g of the desired product as a liquid was obtained by column chromatography (developing solvent: CHCl_3). Refractive index $n_D^{20.2}$ 1.4865


EP 0 764 641 A1

EXAMPLE 36

Synthesis of 4-chlorodifluoromethyl-5-[1-(4-trifluoromethylphenylhydrazono)ethyl]pyrimidine (Compound No. 5-4)

5

10



15

20

A mixture of 500 mg of 5-acetyl-4-chlorodifluoromethylpyrimidine, 420 mg of 4-trifluoromethylphenylhydrazine and 30 ml of dehydrated ethanol was stirred at room temperature for 1 day, and further reflux was carried out for 8 hours. The solvent was distilled off under reduced pressure. The resulting crude product was purified by preparative thin-layer chromatography (developing solvent: chloroform) to obtain 129 mg of the desired product as a pale brown liquid.

The structures, the physical properties and the spectral data of the compounds of the present invention synthesized in accordance with the above Examples, including the compounds synthesized in the above Examples, are shown in the following Tables.

25

30

35


40

45

50

55

(Table 1-1)



Compound No.	X	R 3	R 4	R 2
1-1	Cl	= O		4-Cl-Ph
1-2	Cl	OH	H	4-Cl-Ph
1-3	Cl	= O		2,4-Cl ₂ -Ph
1-4	Cl	OH	H	2,4-Cl ₂ -Ph
1-5	Cl	Cl	H	4-Cl-Ph
1-6	Cl	O-Ph	H	4-Cl-Ph
1-7	Cl	2,6-Dimethyl-morpholino	H	4-Cl-Ph
1-8	Cl	Morpholino	H	4-Cl-Ph
1-9	Cl	O-Bu	H	4-Cl-Ph
1-10	Cl	Pipéridino	H	4-Cl-Ph
1-11	Cl	Pyrrolidino	H	4-Cl-Ph
1-12	Cl	NHCH ₂ -Ph	H	4-Cl-Ph
1-13	Cl	1,2,4-Triazol-1-yl	H	4-Cl-Ph
1-14	Cl	NHMe	H	4-Cl-Ph
1-15	Cl	N(Me) ₂	H	4-Cl-Ph
1-16	Cl	OMe	H	4-Cl-Ph
1-17	Cl	= O		Ph
1-18	Cl	OH	H	Ph
1-19	Cl	Cl	H	Ph
1-20	Cl	= O		4-F-Ph
1-21	Cl	N(Me) ₂	H	Ph
1-22	Cl	OH	H	4-F-Ph
1-23	Cl	Cl	H	4-F-Ph

EP 0 764 641 A1

(Table 1-1) continued

Compound No.	X	R 3	R 4	R 2
1-24	C 1	N (Me) i	H	4-F-Ph
1-25	C 1	NHMe	H	Ph
1-26	C 1	NHEt	H	Ph
1-27	C 1	NHMe	H	4-F-Ph
1-28	C 1	N (Me) Et	H	4-F-Ph
1-29	C 1	OMe	H	Ph
1-30	C 1	N (Me) Et	H	Ph
1-31	C 1	NHCH ₂ CH ₂ OH	H	4-F-Ph
1-32	C 1	NHCH ₂ CH=CH ₂	H	4-F-Ph
1-33	C 1	=O		2-F-Ph
1-34	C 1	NH-Bu ^{tert}	H	Ph
1-35	C 1	NH-Bu ^{tert}	H	4-F-Ph
1-36	C 1	O-Pr ^{iso}	H	4-F-Ph
1-37	C 1	OH	H	2-F-Ph
1-38	C 1	Cl	H	2-F-Ph
1-39	C 1	=O		3-F-Ph
1-40	C 1	NHOMe	H	Ph
1-41	C 1	NHC (Me) ₂ CO ₂ H	H	Ph
1-42	C 1	NH-Pr ^{tert}	H	4-F-Ph
1-43	C 1	NHCH ₂ C≡CH	H	4-F-Ph
1-44	C 1	N (Me)CH ₂ CO ₂ Et	H	Ph
1-45	C 1	O-Bu ^{tert}	H	2-Cl-Ph
1-46	C 1	O-Bu ^{tert}	H	3-Cl-Ph
1-47	C 1	O-Bu ^{tert}	H	3,4-Cl ₂ -Ph

EP 0 764 641 A1

(Table 1-1) continued

Compound No.	X	R 3	R 4	R 2
1-48	C 1	OH	H	2-Cl-Ph
1-49	C 1	OH	H	3-Cl-Ph
1-50	C 1	OH	H	3,4-Cl ₂ -Ph
1-51	C 1	=O		2-Cl-Ph
1-52	C 1	=O		3-Cl-Ph
1-53	C 1	=O		3,4-Cl ₂ -Ph
1-54	C 1	O-Pn***	H	4-Cl-Ph
1-55	C 1	N(Me) ₂	H	2-F-Ph
1-56	C 1	N(Me) ₂	H	3-F-Ph
1-57	C 1	OH	H	3-F-Ph
1-58	C 1	Cl	H	3-F-Ph
1-59	C 1	OCH ₂ -Pr ^{cylo}	H	3-F-Ph
1-60	C 1	O-Bu ^{tert}	H	2-F-Ph
1-61	C 1	O-Bu ^{tert}	H	4-F-Ph
1-62	C 1	O-Bu ^{tert}	H	Ph
1-63	C 1	O-C(Me) ₂ OMe	H	4-Cl-Ph
1-64	C 1	O-C(Me) ₂ OMe	H	3-Cl-Ph
1-65	C 1	O-C(Me) ₂ OMe	H	2-Cl-Ph
1-66	C 1	O-C(Me) ₂ Pr ⁿ	H	4-Cl-Ph
1-67	C 1	NH-Bu ^{tert}	H	4-Cl-Ph
1-68	C 1	OC(=O)N(Me) ₂	H	4-Cl-Ph
1-69	C 1	OC(=O)N(Me) ₂	H	3-Cl-Ph
1-70	C 1	OC(=O)N(Me) ₂	H	2-Cl-Ph
1-71	C 1	O-Bu ^{tert}	H	3-F-Ph

EP 0 764 641 A1

(Table 1-1) continued

Compound No.	X	R 3	R 4	R 2
1-72	Cl	=O		2-Me-Ph
1-73	Cl	O-C (Me), Et	H	4-Cl-Ph
1-74	Cl	OC (=O) Bu ^{***}	H	4-Cl-Ph
1-75	Cl	OCH ₂ C≡CH	H	4-Cl-Ph
1-76	Cl	OCH ₂ C≡N	H	4-Cl-Ph
1-77	Cl	OC (=O) NHEt	H	4-Cl-Ph
1-78	Cl	OC (=S) NHPr ^{***}	H	4-Cl-Ph
1-79	Cl	OCO ₂ Et	H	4-Cl-Ph
1-80	Cl	OCH ₂ CO ₂ Et	H	4-Cl-Ph
1-81	Cl	OCH ₂ OMe	H	4-Cl-Ph
1-82	Cl	OCH ₂ SMe	H	4-Cl-Ph
1-83	Cl	OH	H	2-Me-Ph
1-84	Cl	Cl	H	2-Me-Ph
1-85	Cl	O-Bu ^{***}	H	2-Me-Ph
1-86	Cl	OC (=O) NMe ₂	H	2-Me-Ph
1-87	Cl	OCH ₂ CH (Pr ^o) O		3-F-Ph
1-88	Cl	OCH ₂ CH (Pr ^o) O		2-F-Ph
1-89	Cl	OCH ₂ CH (Pr ^o) O		2-Me-Ph
1-90	Cl	=O		2-CF ₃ -Ph
1-91	Cl	N (Me),	H	2-Me-Ph
1-92	Cl	OCH ₂ CH (Pr ^o) O		4-Cl-Ph
1-93	Cl	O-Bu ^{***}		2,4-Cl ₂ -Ph
1-94	Cl	O-Bu ^{***}		2,5-Cl ₂ -Ph
1-95	Cl	OH	H	2,5-Cl ₂ -Ph

EP 0 764 641 A1

(Table 1-1) continued

Compound No.	X	R 3	R 4	R 2
1 - 96	C 1	= O		2,5 - Cl ₂ - Ph
1 - 97	C 1	OH	H	2 - CF ₃ - Ph
1 - 98	C 1	= O		3 - Thienyl
1 - 99	C 1	= O		2 - Thienyl
1 - 100	C 1	OH	H	2 - Thienyl
1 - 101	C 1	OC (=O) NMe ₂	H	2 - Thienyl
1 - 102	C 1	Cl	H	2 - CF ₃ - Ph
1 - 103	C 1	NMe ₂	H	2 - CF ₃ - Ph
1 - 104	C 1	O - Bu ^{tert}	H	2 - CF ₃ - Ph
1 - 105	C 1	OC (=O) NH Bu ^{tert}	H	4 - Cl - Ph
1 - 106	C 1	OC (=O) NEt ₂	H	4 - Cl - Ph
1 - 107	C 1	= O		2 - Furyl
1 - 108	C 1	NH ₂	H	4 - F - Ph
1 - 109	C 1	OC (=O) NMe ₂	H	3 - Thienyl
1 - 110	C 1	OC (=O) NMe ₂	H	2 - Furyl
1 - 111	C 1	OH	H	3 - Thienyl
1 - 112	C 1	OH	H	2 - Furyl
1 - 113	C 1	NH - Bu ^{tert}	H	3 - F - Ph
1 - 114	C 1	= O		2 - MeO - Ph
1 - 115	C 1	OH	H	2 - MeO - Ph
1 - 116	C 1	Cl	H	2 - MeO - Ph
1 - 117	C 1	NMe ₂	H	2 - MeO - Ph

EP 0 764 641 A1

(Table 1-2)

Compound No.	Spectral data	Physical properties
1-1	¹ H-NMR δ (ppm) [solvent] : 7.51 (d, $J=9$ Hz, 2 H, Benzene ring) 7.72 (d, $J=9$ Hz, 2 H, Benzene ring) 8.88 (s, 1 H, Pyrimidine ring) 9.50 (s, 1 H, Pyrimidine ring) [CDCl ₃]	$n_D^{20.5}$ 1.5742
1-2	¹ H-NMR δ (ppm) [solvent] : 3.40 (br s, 1 H, OH) 6.34 (s, 1 H, ϕ CH) 7.29 (s, 4 H, Benzene ring) 9.09 (s, 1 H, Pyrimidine ring) 9.14 (s, 1 H, Pyrimidine ring) [CDCl ₃]	$n_D^{20.5}$ 1.5563
1-3	¹ H-NMR δ (ppm) [solvent] : 7.19~7.69 (m, 3 H, Benzene ring) 8.78 (s, 1 H, Pyrimidine ring) 9.36 (s, 1 H, Pyrimidine ring) [CDCl ₃]	$n_D^{20.5}$ 1.5837
1-4	¹ H-NMR δ (ppm) [solvent] : 3.42 (br d, $J=5$ Hz, 1 H, OH) 6.58 (d, $J=5$ Hz, 1 H, ϕ CH) 7.30~7.45 (m, 3 H, Benzene ring) 8.82 (s, 1 H, Pyrimidine ring) 9.20 (s, 1 H, Pyrimidine ring) [CDCl ₃]	mp 141-142°C

EP 0 764 641 A1

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-5	¹ H-NMR δ (ppm) [solvent] : 6.53 (s, 1H, ϕ CH) 7.28 (s, 4H, Benzene ring) 9.06 (s, 1H, Pyrimidine ring) 9.15 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5653
1-6	¹ H-NMR δ (ppm) [solvent] : 4.14 (s, 1H, ϕ CH) 6.88~7.30 (m, 10H, Benzene ring+ Pyrimidine ring) 8.23 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5773
1-7	¹ H-NMR δ (ppm) [solvent] : 1.24 (d, J=6Hz, 6H, Morpholine CH ₃) 2.39~2.78 (m, 4H, Morpholine ring) 3.43~3.83 (m, 2H, Morpholine ring) 6.57 (s, 1H, ϕ CH) 6.99 (d, J=9Hz, 2H, Benzene ring) 7.22 (d, J=9Hz, 2H, Benzene ring) 7.31 (s, 1H, Pyrimidine ring) 8.12 (s, 1H, Pyrimidine ring) [CDCl ₃]	mp 74-76°C

10

15

25

4050

EP 0 764 641 A1

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-11	¹ H-NMR δ (ppm) (solvent) :	
	1. 83~2. 10 (m. 4 H. Pyrrolidine ring)	
	3. 41~3. 70 (m. 4 H. Pyrrolidine ring)	
	6. 90~7. 32 (m. 6 H. Benzene ring+ Pyrimidine ring+ ϕ CH)	
	8. 12 (s. 1 H. Pyrimidine ring)	
	[CDCl ₃]	mp 59-61°C
1-12	¹ H-NMR δ (ppm) (solvent) :	
	1. 10~1. 39 (m. 2 H. NHCH ₂ Ph)	
	1. 75~1. 88 (m. 1 H. NH)	
	5. 37~5. 50 (m. 1 H. ϕ CH)	
	7. 07~7. 37 (m. 9 H. Benzene ring)	
	9. 13 (s. 1 H. Pyrimidine ring)	
	9. 33 (s. 1 H. Pyrimidine ring)	
	[CDCl ₃]	n _D ²⁰ 1. 5876
1-13	¹ H-NMR δ (ppm) (solvent) :	
	4. 69 (s. 1 H. ϕ CH)	
	7. 01 (d. $J=9$ Hz. 2 H. Benzene ring)	
	7. 26 (d. $J=9$ Hz. 2 H. Benzene ring)	
	7. 95 (s. 1 H. Pyrimidine ring or Triazole ring)	
	8. 05 (s. 1 H. Pyrimidine ring or Triazole ring)	
	8. 66 (s. 1 H. Pyrimidine ring or Triazole ring)	
	8. 94 (s. 1 H. Pyrimidine ring or Triazole ring)	
	[CDCl ₃]	mp 110-112°C

EP 0 764 641 A1

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-14	¹ H-NMR δ (ppm) (solvent) : 1. 63 (br s, 1H, NH) 2. 41 (s, 3H, NHCH ₃) 5. 28 (br s, 1H, φCH) 7. 31 (br s, 4H, Benzene ring) 9. 15 (s, 1H, Pyrimidine ring) 9. 25 (s, 1H, Pyrimidine ring) [CDC1 ₃]	no 19.41. 5592
1-15	¹ H-NMR δ (ppm) (solvent) : 2. 18 (s, 6H, N(CH ₃) ₂) 4. 62~4. 73 (m, 1H, φCH) 7. 33 (br s, 4H, Benzene ring) 9. 08 (s, 1H, Pyrimidine ring) 9. 48 (s, 1H, Pyrimidine ring) [CDC1 ₃]	mp 60-61°C
1-16	¹ H-NMR δ (ppm) (solvent) : 3. 37 (s, 3H, OCH ₃) 5. 64 (s, 1H, φCH) 7. 26 (br s, 4H, Benzene ring) 9. 05 (s, 1H, Pyrimidine ring) 9. 17 (s, 1H, Pyrimidine ring) [CDC1 ₃]	no 19.21. 5462

EP 0 764 641 A1

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-17	$^1\text{H-NMR}$ δ (ppm) [solvent] :	
	7.34~7.84 (m, 5H, Benzene ring)	
	8.76 (s, 1H, Pyrimidine ring)	
	8.87 (s, 1H, Pyrimidine ring)	
	[CDCl ₃]	n_D^{20} 1.5571
1-18	$^1\text{H-NMR}$ δ (ppm) [solvent] :	
	4.79~5.04 (m, 1H, OH)	
	6.23 (br s, 1H, ϕCH)	
	7.17 (br s, 5H, Benzene ring)	
	8.82 (s, 1H, Pyrimidine ring)	
	8.97 (s, 1H, Pyrimidine ring)	
	[CDCl ₃]	n_D^{20} 1.5566
1-19	$^1\text{H-NMR}$ δ (ppm) [solvent] :	
	6.59 (s, 1H, CHCl)	
	7.34~7.38 (m, 5H, Benzene ring)	
	8.76 (s, 1H, Pyrimidine ring)	
	8.87 (s, 1H, Pyrimidine ring)	
	[CDCl ₃]	n_D^{20} 1.5496
1-20	$^1\text{H-NMR}$ δ (ppm) [solvent] :	
	6.95~8.00 (m, 4H, Benzene ring)	
	8.82 (s, 1H, Pyrimidine ring)	
	9.43 (s, 1H, Pyrimidine ring)	
	[CDCl ₃]	mp 63-64°C

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-21	¹ H-NMR δ (ppm) [solvent] : 2. 15 (s. 6H. N (CH ₃) ₂) 4. 57~4. 70 (m. 1H. CHN (CH ₃) ₂) 7. 07~7. 45 (m. 5H. Benzene ring) 9. 05 (s. 1H. Pyrimidine ring) 9. 53 (s. 1H. Pyrimidine ring) [CDCl ₃]	mp 75-76°C
1-22	¹ H-NMR δ (ppm) [solvent] : 3. 68 (d. J=6Hz. 1H. OH) 6. 20~6. 40 (m. 1H. CHOH) 6. 90~7. 53 (m. 4H. Benzene ring) 9. 06 (s. 2H. Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5394
1-23	¹ H-NMR δ (ppm) [solvent] : 6. 61 (s. 1H. CHCl) 6. 75~7. 57 (m. 4H. Benzene ring) 9. 18 (br s. 2H. Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5409

EP 0 764 641 A1

(Table 1-2) continued

Compound No.	Spectral data.	Physical properties
1-24	¹ H-NMR δ (ppm) [solvent] :	
	2. 18 (s, 6H, N(CH ₃) ₂)	
	4. 60~4. 80 (m, 1H, CHN(CH ₃) ₂)	
	6. 70~7. 05 (m, 4H, Benzene ring)	
	9. 05 (s, 1H, Pyrimidine ring)	
	9. 50 (s, 1H, Pyrimidine ring)	
	[CDCl ₃]	mp 62-63°C
1-25	¹ H-NMR δ (ppm) [solvent] :	
	1. 70 (br s, 1H, NH)	
	2. 41 (s, 3H, NHCH ₃)	
	4. 95~5. 10 (m, 1H, CHNHCH ₃)	
	7. 25~7. 75 (m, 5H, Benzene ring)	
	9. 30 (s, 1H, Pyrimidine ring)	
	9. 50 (s, 1H, Pyrimidine ring)	
	[CDCl ₃]	n _D ²⁰ 1.5464
1-26	¹ H-NMR δ (ppm) [solvent] :	
	1. 10 (t, $J=7$ Hz, 3H, CH ₂ CH ₃)	
	2. 40~2. 60 (m, 2H, NHCH ₂ CH ₃)	
	4. 85~5. 00 (m, 1H, CHNH)	
	7. 05~7. 50 (m, 5H, Benzene ring)	
	9. 03 (s, 1H, Pyrimidine ring)	
	9. 30 (s, 1H, Pyrimidine ring)	
	[CDCl ₃]	n _D ²⁰ 1.5384

EP 0 764 641 A1

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-27	¹ H-NMR δ (ppm) [solvent] :	
	1. 70 (s. 1H. NHCH ₃ .)	
	2. 40 (s. 3H. NHCH ₃ .)	
	5. 20~5. 40 (m. 1H. CHNHCH ₃ .)	
	6. 70~7. 60 (m. 4H. Benzene ring)	
	9. 10 (s. 1H. Pyrimidine ring)	
	9. 23 (s. 1H. Pyrimidine ring)	
	[CDCl ₃]	n _D ^{20.5} 1. 5342
1-28	¹ H-NMR δ (ppm) [solvent] :	
	1. 03 (t. J=7Hz. 3H. CH ₂ CH ₃ .)	
	2. 12 (s. 3H. CH ₃ .)	
	2. 39 (q. J=7Hz. 2H. CH ₂ CH ₃ .)	
	4. 85~5. 10 (m. 1H. CH)	
	6. 70~7. 55 (m. 4H. Benzene ring)	
	9. 09 (s. 1H. Pyrimidine ring)	
	9. 52 (s. 1H. Pyrimidine ring)	
	[CDCl ₃]	n _D ^{20.6} 1. 5214
1-29	¹ H-NMR δ (ppm) [solvent] :	
	3. 35 (s. 3H. OCH ₃ .)	
	5. 65~5. 80 (m. 1H. CH)	
	7. 12~7. 42 (m. 5H. Benzene ring)	
	9. 00 (s. 1H. Pyrimidine ring)	
	9. 08 (s. 1H. Pyrimidine ring)	
	[CDCl ₃]	n _D ^{20.0} 1. 5343

EP 0 764 641 A1

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-30	¹ H-NMR δ (ppm) [solvent] :	
	1. 02 (t. J=7 Hz. 3H. CH ₂ CH ₃)	
	2. 12 (s. 3H. CH ₃)	
	2. 38 (q. J=7 Hz. 2H. CH ₂ CH ₃)	
	4. 80~5. 00 (m. 1H. CH)	
	7. 00~7. 55 (m. 5H. Benzene ring)	
	9. 08 (s. 1H. Pyrimidine ring)	
	9. 57 (s. 1H. Pyrimidine ring)	
	[CDCl ₃]	n _D ^{20.0} 1. 5347
1-31	¹ H-NMR δ (ppm) [solvent] :	
	2. 17 (s. 2H. NH. OH)	
	2. 52~2. 90 (m. 2H. CH ₂ CH ₂)	
	3. 57~3. 82 (m. 2H. CH ₂ CH ₂)	
	5. 32~5. 50 (m. 1H. CH)	
	6. 75~7. 55 (m. 4H. Benzene ring)	
	9. 05 (s. 1H. Pyrimidine ring)	
	9. 20 (s. 1H. Pyrimidine ring)	
	[CDCl ₃]	n _D ^{20.0} 1. 5402
1-32	¹ H-NMR δ (ppm) [solvent] :	
	1. 50~1. 80 (m. 1H. NH)	
	3. 05~3. 30 (m. 2H. CH ₂ CH=CH ₂)	
	4. 85~6. 20 (m. 4H. CH. CH ₂ CH=CH ₂)	
	6. 70~7. 60 (m. 4H. Benzene ring)	
	9. 08 (s. 1H. Pyrimidine ring)	
	9. 28 (s. 1H. Pyrimidine ring)	
	[CDCl ₃]	n _D ^{20.0} 1. 5366

EP 0 764 641 A1

(Table 1-2) continued

5	Compound No.	Spectral data	Physical properties
10	1-33	¹ H-NMR δ (ppm) [solvent] : 6.85~8.10 (m, 4H, Benzene ring) 8.77 (s, 1H, Pyrimidine ring) 9.34 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5468
20	1-34	¹ H-NMR δ (ppm) [solvent] : 1.10 (s, 9H, C(CH ₃) ₃) 1.35~1.55 (m, 1H, NH-C(CH ₃) ₃) 5.50~5.65 (m, 1H, CH) 7.00~7.30 (m, 5H, Benzene ring) 9.15 (s, 1H, Pyrimidine ring) 9.88 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5311
35	1-35	¹ H-NMR δ (ppm) [solvent] : 1.08 (s, 9H, C(CH ₃) ₃) 1.40~1.50 (m, 1H, NH) 5.48~5.58 (m, 1H, CH) 6.80~7.30 (m, 4H, Benzene ring) 9.10 (s, 1H, Pyrimidine ring) 9.78 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5162
55			

EP 0 764 641 A1

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-36	¹ H-NMR δ (ppm) [solvent] : 1. 16 (d, J=7 Hz, 3H, OCH(CH ₃) ₂) 1. 26 (d, J=7 Hz, 3H, OCH(CH ₃) ₂) 3. 30~4. 00 (m, 1H, OCH(CH ₃) ₂) 5. 85~6. 10 (m, 1H, CH) 6. 70~7. 50 (m, 4H, Benzene ring) 9. 20 (s, 1H, Pyrimidine ring) 9. 30 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ^{20.0} 1. 5106
1-37	¹ H-NMR δ (ppm) [solvent] : 3. 38~4. 08 (m, 1H, OH) 6. 55 (s, 1H, CH) 6. 68~7. 58 (m, 4H, Benzene ring) 9. 06 (s, 2H, Pyrimidine ring) [CDCl ₃]	n _D ^{19.7} 1. 5434
1-38	¹ H-NMR δ (ppm) [solvent] : 6. 81 (s, 1H, CH) 6. 90~7. 65 (m, 4H, Benzene ring) 9. 15 (s, 1H, Pyrimidine ring) 9. 18 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ^{19.7} 1. 5436

EP 0 764 641 A1

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-39	¹ H-NMR δ (ppm) [solvent] : 7. 10~7. 82 (m. 4 H. Benzene ring) 8. 75 (s. 1 H. Pyrimidine ring) 9. 46 (s. 1 H. Pyrimidine ring) [CDCl ₃]	mp 40~42°C
1-40	¹ H-NMR δ (ppm) [solvent] : 3. 42 (s. 3 H. OCH ₃) 5. 65~5. 80 (m. 1 H. CH) 7. 07~7. 37 (m. 5 H. Benzene ring) 9. 10 (s. 1 H. Pyrimidine ring) 9. 37 (s. 1 H. Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1. 5452
1-41	¹ H-NMR δ (ppm) [solvent] : 1. 19 (s. 3 H. C (CH ₃) ₂ COOH) 1. 41 (s. 3 H. C (CH ₃) ₂ COOH) 5. 50~5. 65 (m. 1 H. CH) 6. 20~6. 40 (m. 2 H. NH. COOH) 7. 18~7. 38 (m. 5 H. Benzene ring) 9. 24 (s. 1 H. Pyrimidine ring) 9. 85~10. 00 (m. 1 H. Pyrimidine ring) [CDCl ₃]	mp 114~116°C

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-42	¹ H-NMR δ (ppm) [solvent] : 0.10~0.60 (m, 4H, cyclo-propyl CH ₂) 0.70~1.00 (m, 1H, cyclo-propyl CH) 2.15~2.30 (m, 1H, NH) 5.40~5.65 (m, 1H, CH) 6.70~7.55 (m, 4H, Benzene ring) 9.07 (s, 1H, Pyrimidine ring) 9.16 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5377
1-43	¹ H-NMR δ (ppm) [solvent] : 1.90~2.20 (m, 1H, NH) 2.30~2.50 (m, 1H, CH ₂ C≡CH) 5.35 (d, J=2Hz, 2H, CH ₂ C≡CH) 5.60~5.85 (m, 1H, CH) 6.80~7.65 (m, 4H, Benzene ring) 9.12 (s, 1H, Pyrimidine ring) 9.41 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5417

EP 0 764 641 A1

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-44	¹ H-NMR δ (ppm) [solvent] : 2.27 (t, J=7 Hz, 3H, CH ₂ CH ₂) 2.37 (s, 3H, NCH ₃) 3.24 (s, 2H, CH ₂ CO ₂ CH ₂ CH ₂) 4.10 (q, J=7 Hz, 2H, CH ₂ CH ₂) 5.45~5.65 (m, 1H, CH) 7.00~7.60 (m, 5H, Benzene ring) 9.08 (s, 1H, Pyrimidine ring) 9.62 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5237
1-45	¹ H-NMR δ (ppm) [solvent] : 1.25 (s, 9H, OC(CH ₃) ₃) 6.51 (s, 1H, CH) 7.07~7.41 (m, 4H, Benzene ring) 9.14 (s, 1H, Pyrimidine ring) 9.39 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5300
1-46	¹ H-NMR δ (ppm) [solvent] : 1.22 (s, 9H, OC(CH ₃) ₃) 6.04 (s, 1H, CH) 7.06~7.34 (m, 4H, Benzene ring) 9.16 (s, 1H, Pyrimidine ring) 9.33 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²² 1.5252

EP 0 764 641 A1

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-47	¹ H-NMR δ (ppm) [solvent] : 1. 22 (s. 9H. O ^o C (CH ₃),) 6. 02 (s. 1H. CH) 6. 94~7. 40 (m. 3H. Benzene ring) 9. 16 (s. 1H. Pyrimidine ring) 9. 31 (s. 1H. Pyrimidine ring) [CDC1,]	n _D ^{22.5} 1. 5293
1-48	¹ H-NMR δ (ppm) [solvent] : 4. 20~4. 41 (br m. 1H. OH) 6. 53~6. 67 (br m. 1H. CH) 7. 12~7. 56 (m. 4H. Benzene ring) 8. 85 (s. 1H. Pyrimidine ring) 9. 12 (s. 1H. Pyrimidine ring) [CDC1,]	n _D ^{20.5} 1. 5378
1-49	¹ H-NMR δ (ppm) [solvent] : 4. 22~4. 43 (br m. 1H. OH) 6. 21~6. 35 (br m. 1H. CH) 7. 06~7. 35 (m. 4H. Benzene ring) 8. 99 (s. 1H. Pyrimidine ring) 9. 02 (s. 1H. Pyrimidine ring) [CDC1,]	n _D ^{19.5} 1. 5402

EP 0 764 641 A1

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-50	¹ H-NMR δ (ppm) [solvent] :	
	3. 10~3. 50 (br m. 1H. OH)	
	6. 23~6. 32 (br m. 1H. CH)	
	6. 97~7. 48 (m. 3H. Benzene ring)	
	8. 98 (s. 1H. Pyrimidine ring)	
	9. 10 (s. 1H. Pyrimidine ring)	
	[CDC1 ₂]	mp 66~68°C
1-51	¹ H-NMR δ (ppm) [solvent] :	
	7. 17~7. 76 (m. 4H. Benzene ring)	
	8. 77 (s. 1H. Pyrimidine ring)	
	9. 35 (s. 1H. Pyrimidine ring)	
	[CDC1 ₂]	n _D ²⁰ 1.5612
1-52	¹ H-NMR δ (ppm) [solvent] :	
	7. 34~7. 76 (m. 4H. Benzene ring)	
	8. 79 (s. 1H. Pyrimidine ring)	
	9. 39 (s. 1H. Pyrimidine ring)	
	[CDC1 ₂]	n _D ²⁰ 1.5756
1-53	¹ H-NMR δ (ppm) [solvent] :	
	7. 37~7. 91 (m. 3H. Benzene ring)	
	8. 73 (s. 1H. Pyrimidine ring)	
	9. 36 (s. 1H. Pyrimidine ring)	
	[CDC1 ₂]	mp 51~53°C

EP 0 764 641 A1

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-54	¹ H-NMR δ (ppm) [solvent] : 0.92 (s, 9H, C(CH ₃) ₃) 3.11 (q, J=11Hz, 8Hz, 2H, CH ₂) 5.79 (d, J=1.5Hz, 1H, CH) 7.19~7.27 (m, 4H, Benzene ring) 9.07 (s, 1H, Pyrimidine ring) 9.15 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5159
1-55	¹ H-NMR δ (ppm) [solvent] : 2.20 (s, 6H, N(CH ₃) ₂) 5.05~5.35 (m, 1H, CH) 6.75~7.35 (m, 4H, Benzene ring) 9.05~9.15 (m, 1H, Pyrimidine ring) 9.57 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5338
1-56	¹ H-NMR δ (ppm) [solvent] : 2.19 (s, 6H, N(CH ₃) ₂) 4.10~4.30 (m, 1H, CH) 6.60~7.40 (m, 4H, Benzene ring) 9.08 (s, 1H, Pyrimidine ring) 9.47 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5358

EP 0 764 641 A1

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-57	¹ H-NMR δ (ppm) (solvent) : 3.40~3.80 (m. 1H. OH) 6.28~6.38 (m. 1H. CH) 6.74~7.60 (m. 4H. Benzene ring) 9.01 (s. 1H. Pyrimidine ring) 9.09 (s. 1H. Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5438
1-58	¹ H-NMR δ (ppm) (solvent) : 6.01 (s. 1H. CH) 6.70~7.50 (m. 4H. Benzene ring) 9.00 (s. 1H. Pyrimidine ring) 9.11 (s. 1H. Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5496
1-59	¹ H-NMR δ (ppm) (solvent) : 0.11~0.87 (m. 4H. cyclo-propyl CH ₂) 0.90~1.50 (m. 1H. cyclo-propyl CH) 3.28~3.60 (m. 2H. OCH ₂) 5.87~6.07 (m. 1H. CH) 6.73~7.57 (m. 4H. Benzene ring) 9.07 (s. 1H. Pyrimidine ring) 9.16 (s. 1H. Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5240

EP 0 764 641 A1

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-60	¹ H-NMR δ (ppm) [solvent] : 1. 23 (s, 9H, OC (CH ₃) ₃) 6. 33~6. 50 (m, 1H, CH) 6. 71~7. 30 (m, 4H, Benzene ring) 9. 17 (s, 1H, Pyrimidine ring) 9. 52 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ^{20.0} 1. 5140
1-61	¹ H-NMR δ (ppm) [solvent] : 1. 23 (s, 9H, OC (CH ₃) ₃) 6. 00~6. 15 (m, 1H, CH) 6. 70~7. 40 (m, 4H, Benzene ring) 9. 01 (s, 1H, Pyrimidine ring) 9. 35 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ^{20.2} 1. 5048
1-62	¹ H-NMR δ (ppm) [solvent] : 1. 23 (s, 9H, OC (CH ₃) ₃) 6. 00~6. 15 (m, 1H, CH) 7. 00~7. 35 (m, 5H, Benzene ring) 9. 12 (s, 1H, Pyrimidine ring) 9. 37 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ^{20.2} 1. 5154

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-63	¹ H-NMR δ (ppm) (solvent) : 1. 28 (s. 3H. CH_3) 1. 37 (s. 3H. CH_3) 2. 94 (s. 3H. OCH_3) 6. 22 (s. 1H. CH) 7. 11~7. 27 (m. 4H. Benzene ring) 9. 12 (s. 1H. Pyrimidine ring) 9. 33 (s. 1H. Pyrimidine ring) [CDCl ₃]	$n_D^{21.7}$ 1. 5285
1-64	¹ H-NMR δ (ppm) (solvent) : 1. 30 (s. 3H. CH_3) 1. 38 (s. 3H. CH_3) 2. 94 (s. 3H. OCH_3) 6. 24 (s. 1H. CH) 7. 12~7. 40 (m. 4H. Benzene ring) 9. 13 (s. 1H. Pyrimidine ring) 9. 34 (s. 1H. Pyrimidine ring) [CDCl ₃]	$n_D^{20.1}$ 1. 5371
1-65	¹ H-NMR δ (ppm) (solvent) : 1. 32 (s. 3H. CH_3) 1. 39 (s. 3H. CH_3) 2. 97 (s. 3H. OCH_3) 6. 69 (s. 1H. CH) 7. 04~7. 39 (m. 4H. Benzene ring) 9. 14 (s. 1H. Pyrimidine ring) 9. 35 (s. 1H. Pyrimidine ring) [CDCl ₃]	$n_D^{19.8}$ 1. 5317

EP 0 764 641 A1

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-66	¹ H-NMR δ (ppm) [solvent] :	
	0.82~1.03 (m. 3H. CH ₂ CH ₂ CH ₃)	
	1.15 (s. 3H. CH ₃)	
	1.22 (s. 3H. CH ₃)	
	1.34~1.93 (m. 4H. CH ₂ CH ₂ CH ₃)	
	6.06 (s. 1H. CH)	
	7.18~7.27 (m. 4H. Benzene ring)	
	9.17 (s. 1H. Pyrimidine ring)	
	9.37 (s. 1H. Pyrimidine ring)	
	[CDCl ₃]	n _D ²⁰ 1.5282
1-67	¹ H-NMR δ (ppm) [solvent] :	
	1.05 (s. 9H. NHC (CH ₃) ₃)	
	1.93~2.64 (br m. 1H. NH)	
	5.47~5.60 (br m. 1H. CH)	
	7.07~7.35 (m. 4H. Benzene ring)	
	9.11 (s. 1H. Pyrimidine ring)	
	9.78 (s. 1H. Pyrimidine ring)	
	[CDCl ₃]	n _D ²⁰ 1.5344
1-68	¹ H-NMR δ (ppm) [solvent] :	
	2.93 (s. 6H. N (CH ₃) ₂)	
	7.01~7.35 (m. 5H. CH + Benzene ring)	
	8.99 (s. 1H. Pyrimidine ring)	
	9.15 (s. 1H. Pyrimidine ring)	
	[CDCl ₃]	n _D ²⁰ 1.5358

(Table 1-2) continued

5	Compound No.	Spectral data	Physical properties
10	1-69	¹ H-NMR δ (ppm) [solvent] :	
		2.93 (s, 6H, N(CH ₃) ₂)	
15		7.04~7.26 (m, 5H, CH+Benzene ring)	
		8.97 (s, 1H, Pyrimidine ring)	
		9.16 (s, 1H, Pyrimidine ring)	
20		[CDCl ₃]	n _D ²⁰ 1.5443
25	1-70	¹ H-NMR δ (ppm) [solvent] :	
		2.92 (s, 6H, N(CH ₃) ₂)	
		7.00~7.42 (m, 5H, CH+Benzene ring)	
30		8.71 (s, 1H, Pyrimidine ring)	
		9.16 (s, 1H, Pyrimidine ring)	
35		[CDCl ₃]	n _D ²⁰ 1.5375
40	1-71	¹ H-NMR δ (ppm) [solvent] :	
		1.22 (s, 9H, OC(CH ₃) ₃)	
		5.95~6.11 (m, 1H, CH)	
45		6.60~7.40 (m, 4H, Benzene ring)	
		9.05 (s, 1H, Pyrimidine ring)	
		9.23 (s, 1H, Pyrimidine ring)	
50		[CDCl ₃]	n _D ²⁰ 1.5136

55

EP 0 764 641 A1

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-72	¹ H-NMR δ (ppm) [solvent] : 2.67 (s, 3H, CH ₃) 7.15~7.45 (m, 4H, Benzene ring) 8.88 (s, 1H, Pyrimidine ring) 9.46 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5588
1-73	¹ H-NMR δ (ppm) [solvent] : 0.90~1.08 (m, 3H, CH ₂ CH ₃) 1.22 (s, 3H, CH ₃) 1.28 (s, 3H, CH ₃) 1.52~1.92 (m, 2H, CH ₂ CH ₃) 6.22 (s, 1H, CH) 7.34~7.47 (m, 4H, Benzene ring) 9.34 (s, 1H, Pyrimidine ring) 9.56 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5284
1-74	¹ H-NMR δ (ppm) [solvent] : 1.23 (s, 9H, C(CH ₃) ₃) 7.05~7.42 (m, 5H, CH + Benzene ring) 9.07 (s, 1H, Pyrimidine ring) 9.25 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5215

EP 0 764 641 A1

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-75	¹ H-NMR δ (ppm) [solvent] : 2. 39~2. 53 (m. 1 H. C≡CH) 4. 12 (d. J=2. 5 Hz. 2 H. OCH ₂) 6. 10 (s. 1 H. CH) 7. 16~7. 30 (m. 4 H. Benzene ring) 9. 09 (s. 1 H. Pyrimidine ring) 9. 13 (s. 1 H. Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1. 5526
1-76	¹ H-NMR δ (ppm) [solvent] : 4. 23 (s. 2 H. OCH ₂ CN) 6. 12 (s. 1 H. CH) 7. 18~7. 34 (m. 4 H. Benzene ring) 9. 07 (s. 1 H. Pyrimidine ring) 9. 19 (s. 1 H. Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1. 5535
1-77	¹ H-NMR δ (ppm) [solvent] : 1. 11 (t. J=7 Hz. 3 H. NHCH ₂ CH ₃) 2. 97~3. 41 (m. 2 H. NHCH ₂ CH ₃) 4. 97~5. 86 (br m. 1 H. NHCH ₂ CH ₃) 7. 11~7. 27 (m. 5 H. CH+Benzene ring) 8. 98 (s. 1 H. Pyrimidine ring) 9. 16 (s. 1 H. Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1. 5315

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-78	¹ H-NMR δ (ppm) [solvent] :	
	1. 22 (d. $J=6$ Hz. 6H. CH (CH ₃) ₂)	
	3. 87~4. 40 (m. 1H. CH (CH ₃) ₂)	
	6. 57~6. 76 (br m. 1H. NH)	
	7. 14~7. 31 (m. 4H. Benzene ring)	
	7. 90 (s. 1H. CH)	
	9. 02 (s. 1H. Pyrimidine ring)	
	9. 19 (s. 1H. Pyrimidine ring)	
	[CDCl ₃]	$n_D^{20.0}$ 1. 5588
1-79	¹ H-NMR δ (ppm) [solvent] :	
	1. 28 (t. $J=7$ Hz. 3H. CH ₂ CH ₃)	
	4. 38 (q. $J=7$ Hz. 2H. CH ₂ CH ₃)	
	7. 11 (s. 1H. CH)	
	7. 19~7. 30 (m. 4H. Benzene ring)	
	9. 05 (s. 1H. Pyrimidine ring)	
	9. 19 (s. 1H. Pyrimidine ring)	
	[CDCl ₃]	$n_D^{21.0}$ 1. 5318
1-80	¹ H-NMR δ (ppm) [solvent] :	
	1. 25 (t. $J=7$ Hz. 3H. CH ₂ CH ₃)	
	4. 05 (s. 2H. OCH ₂ CO ₂ Et)	
	4. 18 (q. $J=7$ Hz. 2H. CH ₂ CH ₃)	
	6. 05 (s. 1H. CH)	
	7. 23~7. 29 (m. 4H. Benzene ring)	
	9. 16 (s. 2H. Pyrimidine ring)	
	[CDCl ₃]	$n_D^{21.0}$ 1. 5335

EP 0 764 641 A1

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-81	¹ H-NMR δ (ppm) (solvent) : 3. 27 (s. 3H. OCH ₂ OCH ₂) 4. 59 (s. 2H. OCH ₂ OCH ₂) 6. 10 (s. 1H. CH) 7. 14~7. 22 (m. 4H. Benzene ring) 9. 11 (s. 2H. Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1. 5282
1-82	¹ H-NMR δ (ppm) (solvent) : 2. 11 (s. 3H. OCH ₂ SCH ₃) 4. 61 (s. 2H. OCH ₂ SCH ₃) 6. 33 (s. 1H. CH) 7. 32~7. 41 (m. 4H. Benzene ring) 9. 29 (s. 2H. Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1. 5655
1-83	¹ H-NMR δ (ppm) (solvent) : 2. 21 (s. 3H. CH ₃) 3. 60~3. 75 (m. 1H. OH) 6. 10~6. 35 (m. 1H. CH) 6. 50~7. 20 (m. 4H. Benzene ring) 8. 30 (s. 1H. Pyrimidine ring) 8. 92 (s. 1H. Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1. 5616

EP 0 764 641 A1

(Table 1-2) continued

5	Compound No.	Spectral data	Physical properties
10	1-84	¹ H-NMR δ (ppm) (solvent) : 2.41 (s, 3H, CH ₃) 6.65~6.80 (m, 1H, CH) 6.95~7.40 (m, 4H, Benzene ring) 9.17 (s, 1H, Pyrimidine ring) 9.26 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5431
25	1-85	¹ H-NMR δ (ppm) (solvent) : 1.21 (s, 9H, C(CH ₃) ₃) 2.41 (s, 3H, CH ₃) 6.20~6.35 (m, 1H, CH) 6.90~7.40 (m, 4H, Benzene ring) 9.11 (s, 1H, Pyrimidine ring) 9.43 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²¹ 1.5322
40	1-86	¹ H-NMR δ (ppm) (solvent) : 2.33 (s, 3H, CH ₃) 3.10 (s, 6H, N(CH ₃) ₂) 6.70~7.45 (m, 5H, Benzene ring, CH) 8.82 (s, 1H, Pyrimidine ring) 9.25 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²¹ 1.5354

55

EP 0 764 641 A1

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-87	¹ H-NMR δ (ppm) (solvent) :	
	0. 70~1. 25 (m. 3H. CH ₂ CH ₂ CH ₃)	
	1. 25~2. 15 (m. 4H. CH ₂ CH ₂ CH ₃)	
	3. 30~4. 60 (m. 3H. OCH ₂ CHO)	
	6. 80~7. 70 (m. 4H. Benzene ring)	
	9. 20~9. 70 (m. 2H. Pyrimidine ring)	
	[CDCl ₃]	n _D ^{20.0} 1. 5072
1-88	¹ H-NMR δ (ppm) (solvent) :	
	0. 70~1. 18 (m. 3H. CH ₂ CH ₂ CH ₃)	
	1. 18~2. 00 (m. 4H. CH ₂ CH ₂ CH ₃)	
	3. 35~4. 45 (m. 3H. OCH ₂ CHO)	
	6. 55~7. 80 (m. 4H. Benzene ring)	
	9. 19 (s. 1H. Pyrimidine ring)	
	9. 32~9. 60 (m. 1H. Pyrimidine ring)	
	[CDCl ₃]	n _D ^{19.0} 1. 5117
1-89	¹ H-NMR δ (ppm) (solvent) :	
	0. 68~1. 13 (m. 3H. CH ₂ CH ₂ CH ₃)	
	1. 13~1. 83 (m. 4H. CH ₂ CH ₂ CH ₃)	
	2. 13 (s. 3H. CH ₃)	
	3. 33~4. 33 (m. 3H. OCH ₂ CHO)	
	6. 83~7. 53 (m. 4H. Benzene ring)	
	9. 03 (s. 1H. Pyrimidine ring)	
	9. 16 (s. 1H. Pyrimidine ring)	
	[CDCl ₃]	n _D ^{19.0} 1. 5203

EP 0 764 641 A1

(Table 1-2) continued

5

Compound No.	Spectral data	Physical properties
--------------	---------------	---------------------

10

1-90 ¹H-NMR δ (ppm) [solvent] :

7. 20~8. 00 (m. 4H. Benzene ring)

8. 90 (s. 1H. Pyrimidine ring)

15

9. 48 (s. 1H. Pyrimidine ring)

[CDCl₃]

n_D^{20.0} 1. 5174

20

1-91 ¹H-NMR δ (ppm) [solvent] :

2. 18 (s. 6H. N (CH₃)₂)

25

2. 41 (s. 3H. CH₃)

5. 10~5. 15 (m. 1H. CH)

6. 90~7. 30 (m. 4H. Benzene ring)

30

9. 06 (s. 1H. Pyrimidine ring)

9. 54 (s. 1H. Pyrimidine ring)

[CDCl₃]

n_D^{20.0} 1. 5447

35

1-92 ¹H-NMR δ (ppm) [solvent] :

40

0. 70~1. 15 (m. 3H. CH₂ CH₂ CH₃)

1. 15~1. 80 (m. 4H. CH₂ CH₂ CH₃)

3. 50~4. 41 (m. 3H. OCH₂ CHO)

45

7. 18 (s. 4H. Benzene ring)

9. 12~9. 40 (m. 2H. Pyrimidine ring)

50

[CDCl₃]

n_D^{20.1} 1. 5330

55

EP 0 764 641 A1

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-93	¹ H-NMR δ (ppm) [solvent] : 1. 22 (s. 9H. C (CH ₃),) 6. 44 (s. 1H. CHOC (CH ₃),) 7. 06~7. 14 (m. 2H. Benzene ring) 7. 27~7. 35 (m. 1H. Benzene ring) 9. 12 (s. 1H. Pyrimidine ring) 9. 34 (s. 1H. Pyrimidine ring) [CDC1 ₃]	n _D ²⁰ 1. 5421
1-94	¹ H-NMR δ (ppm) [solvent] : 1. 23 (s. 9H. C (CH ₃),) 6. 42 (s. 1H. CHOC (CH ₃),) 7. 12~7. 21 (m. 3H. Benzene ring) 9. 14 (s. 1H. Pyrimidine ring) 9. 31 (s. 1H. Pyrimidine ring) [CDC1 ₃]	mp 73~75°C
1-95	¹ H-NMR δ (ppm) [solvent] : 3. 66~3. 87 (br m. 1H. OH) 6. 48~6. 54 (m. 1H. CHOH) 7. 12~7. 45 (m. 3H. Benzene ring) 8. 73 (s. 1H. Pyrimidine ring) 9. 13 (s. 1H. Pyrimidine ring) [CDC1 ₃]	mp 39~41°C

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-96	¹ H-NMR δ (ppm) [solvent] : 7.29~7.74 (m. 3H. Benzene ring) 8.89 (s. 1H. Pyrimidine ring) 9.48 (s. 1H. Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5722
1-97	¹ H-NMR δ (ppm) [solvent] : 3.40~3.80 (m. 1H. OH) 6.50~6.80 (m. 1H. CH) 7.10~7.80 (m. 4H. Benzene ring) 8.86 (s. 1H. Pyrimidine ring) 9.08 (s. 1H. Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5139
1-98	¹ H-NMR δ (ppm) [solvent] : 7.24~7.48 (m. 2H. Thiophene ring) 7.61~7.70 (m. 1H. Thiophene ring) 8.78 (s. 1H. Pyrimidine ring) 9.26 (s. 1H. Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5854
1-99	¹ H-NMR δ (ppm) [solvent] : 6.95~7.29 (m. 2H. Thiophene ring) 7.66~7.80 (m. 1H. Thiophene ring) 8.81 (s. 1H. Pyrimidine ring) 9.30 (s. 1H. Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5920

EP 0 764 641 A1

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-100	¹ H-NMR δ (ppm) [solvent] : 4. 20~4. 31 (br m, 1H, OH) 6. 52~6. 61 (m, 1H, CHOH) 6. 82~7. 03 (m, 2H, Thiophene ring) 7. 26~7. 36 (m, 1H, Thiophene ring) 9. 15 (s, 1H, Pyrimidine ring) 9. 32 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1. 5702
1-101	¹ H-NMR δ (ppm) [solvent] : 2. 94 (s, 6H, N(CH ₃) ₂) 6. 74~6. 96 (m, 2H, Thiophene ring) 7. 17~7. 29 (m, 1H, Thiophene ring) 7. 37 (s, 1H, CHOCON) 9. 14 (s, 1H, Pyrimidine ring) 9. 18 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1. 5422
1-102	¹ H-NMR δ (ppm) [solvent] : 6. 90~7. 10 (m, 1H, CH) 7. 15~7. 90 (m, 4H, Benzene ring) 8. 97 (s, 1H, Pyrimidine ring) 9. 16 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1. 5164

EP 0 764 641 A1

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-103	¹ H-NMR δ (ppm) (solvent) : 2.22 (s, 6H, N(CH ₃) ₂) 5.45~5.60 (m, 1H, CH) 7.10~7.80 (m, 4H, Benzene ring) 9.06 (s, 1H, Pyrimidine ring) 9.16 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5089
1-104	¹ H-NMR δ (ppm) (solvent) : 2.26 (s, 9H, O(CH ₃) ₃) 6.65~6.80 (m, 1H, CH) 7.15~8.05 (m, 4H, Benzene ring) 8.85 (s, 1H, Pyrimidine ring) 9.12 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.4937
1-105	¹ H-NMR δ (ppm) (solvent) : 1.30 (s, 9H, C(CH ₃) ₃) 4.81~4.89 (br s, 1H, NH) 7.03~7.38 (m, 4H, Benzene ring) 7.18 (s, 1H, CHOCO) 9.00 (s, 1H, Pyrimidine ring) 9.20 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5197

EP 0 764 641 A1

(Table 1-2) continued

5	Compound No.	Spectral data	Physical properties
10	1-106	$^1\text{H-NMR}$ δ (ppm) [solvent] : 1. 12 (t, $J=7\text{ Hz}$, 6H, N(CH ₂ CH ₃) ₂) 3. 10~3. 64 (m, 4H, N(CH ₂ CH ₃) ₂) 7. 13~7. 28 (m, 5H, CHOCO+Benzene ring) 9. 01 (s, 1H, Pyrimidine ring) 9. 17 (s, 1H, Pyrimidine ring) [CDCl ₃]	$n_D^{20.0}$ 1. 5323
25	1-107	$^1\text{H-NMR}$ δ (ppm) [solvent] : 6. 57 (q, $J=4\text{ Hz}$, 2 Hz, 1H, Furan ring) 7. 15 (d, $J=4\text{ Hz}$, 1H, Furan ring) 7. 61 (d, $J=2\text{ Hz}$, 1H, Furan ring) 8. 84 (s, 1H, Pyrimidine ring) 9. 34 (s, 1H, Pyrimidine ring) [CDCl ₃]	$n_D^{20.0}$ 1. 5589
40	1-108	$^1\text{H-NMR}$ δ (ppm) [solvent] : 1. 80~2. 80 (m, 2H, NH ₂) 5. 60~5. 90 (m, 1H, CH) 6. 50~7. 60 (m, 4H, Benzene ring) 9. 01 (s, 1H, Pyrimidine ring) [CDCl ₃]	$n_D^{20.1}$ 1. 5528

55

EP 0 764 641 A1

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-109	¹ H-NMR δ (ppm) [solvent] : 2.93 (s, 6H, N(CH ₃) ₂) 6.87~7.29 (m, 4H, CHOCO+Thiophene ring) 9.03 (s, 1H, Pyrimidine ring) 9.13 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ^{20.0} 1.5279
1-110	¹ H-NMR δ (ppm) [solvent] : 2.93 (s, 6H, N(CH ₃) ₂) 6.19~6.32 (m, 2H, Furan ring) 7.20 (s, 1H, CHOCO) 7.29~7.37 (m, 1H, Furan ring) 9.16~9.26 (m, 2H, Pyrimidine ring) [CDCl ₃]	n _D ^{20.2} 1.5116
1-111	¹ H-NMR δ (ppm) [solvent] : 3.88~4.02 (br m, 1H, OH) 6.32~6.41 (m, 1H, CHOH) 6.78~7.01 (m, 1H, Thiophene ring) 7.02~7.30 (m, 2H, Thiophene ring) 9.05 (s, 1H, Pyrimidine ring) 9.11 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ^{20.2} 1.5351

EP 0 764 641 A1

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-112	¹ H-NMR δ (ppm) (solvent) : 2.94~3.07 (br m, 1H, OH) 6.07~6.15 (m, 1H, CHOH) 6.19~6.32 (m, 2H, Furan ring) 7.27~7.35 (m, 1H, Furan ring) 9.14 (s, 1H, Pyrimidine ring) 9.30 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ^{20.2} 1.5224
1-113	¹ H-NMR δ (ppm) (solvent) : 1.08 (s, 9H, NHC(CH ₃) ₃) 1.40~1.60 (m, 1H, NH) 5.45~5.60 (m, 1H, CH) 6.50~7.45 (m, 4H, Benzene ring) 9.13 (s, 1H, Pyrimidine ring) 9.78 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ^{20.1} 1.5236
1-114	¹ H-NMR δ (ppm) (solvent) : 3.54 (s, 3H, OCH ₃) 6.80~8.10 (m, 4H, Benzene ring) 8.79 (s, 1H, Pyrimidine ring) 9.39 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ^{20.4} 1.5597

EP 0 764 641 A1

(Table 1-2) continued

Compound No.	Spectral data	Physical properties
1-115	¹ H-NMR δ (ppm) (solvent) : 3.30~3.60 (m, 1H, OH) 3.69 (s, 3H, OCH ₃) 6.30~6.50 (m, 1H, CH) 6.60~7.40 (m, 4H, Benzene ring) 8.85 (s, 1H, Pyrimidine ring) 9.00 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ^{21.7} 1.5403
1-116	¹ H-NMR δ (ppm) (solvent) : 3.74 (s, 3H, OH) 6.60~7.80 (m, 5H, Benzene ring, CH) 9.06 (s, 1H, Pyrimidine ring) 9.23 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ^{22.0} 1.5518
1-117	¹ H-NMR δ (ppm) (solvent) : 2.18 (s, 6H, N(CH ₃) ₂) 3.75 (s, 3H, OCH ₃) 5.25~5.40 (m, 1H, CH) 6.60~7.40 (m, Benzene ring) 9.03 (s, 1H, Pyrimidine ring) 9.41 (s, 1H, Pyrimidine ring) [CDCl ₃]	mp 47~49°C

(Table 2-1)



Compound No.	R 1	R 2	R 3	R 4
2-1	CF ₂ Cl	Me	-OCH ₂ CH ₂ O-	
2-2	CF ₂ Cl	Bu ^{tert}	-OCH ₂ CH ₂ O-	
2-3	CF ₂ Cl	Me	-OCH (Et) CH ₂ O-	
2-4	CF ₂ Cl	Me	-OCH ₂ CH ₂ CH ₂ O-	
2-5	CF ₂ Cl	Me	-OCH (Pr ⁿ) CH ₂ O-	
2-6	CF ₂ Cl	Et	-OCH ₂ CH ₂ O-	
2-7	CF ₂ Cl	Pr ⁿ	-OCH ₂ CH ₂ O-	
2-8	CF ₂ Cl	Pr ⁿ	-OCH (Pr ⁿ) CH ₂ O-	
2-9	CF ₂ Cl	Pr ⁿ	-OCH (Et) CH ₂ O-	
2-10	CF ₂ Cl	Me	-OCH (Bu ^{tert}) CH ₂ O-	
2-11	CF ₂ Br	Me	-OCH (Pr ⁿ) CH ₂ O-	
2-12	CF ₂ Cl	Me	-OCH (CH ₂ CH ₂ CH=CH ₂) CH ₂ O-	
2-13	CF ₂ Cl	Me	-OCH (Bu ⁿ) CH ₂ O-	
2-14	CF ₂ Cl	Me	-OCH (CH ₂ OCH ₃) CH ₂ O-	
2-15	CF ₂ Cl	Pr ^{cyclo}	-OCH ₂ CH ₂ O-	
2-16	CF ₂ CF ₃	Me	-OCH ₂ CH ₂ O-	
2-17	CF ₂ CF ₂ Cl	Me	-OCH (Pr ⁿ) CH ₂ O-	
2-18	CHFCl	Pr ⁿ	-OCH (Pr ⁿ) CH ₂ O-	
2-19	CHF ₂	Pr ⁿ	-OCH (Pr ⁿ) CH ₂ O-	
2-20	CF ₂ Cl	Pr ^{cyclo}	-OCH (Pr ⁿ) CH ₂ O-	
2-21	CF ₂ Cl	Pr ^{iso}	-OCH (Pr ⁿ) CH ₂ O-	
2-22	CF ₂ Cl	Pr ⁿ	-OCH (CH ₂ Br) CH ₂ O-	
2-23	CF ₂ Cl	Bu ^{iso}	-OCH (Pr ⁿ) CH ₂ O-	
2-24	CF ₂ Cl	Pr ⁿ	-OCH (Bu ⁿ) CH ₂ O-	
2-25	CF ₂ Cl	Pr ⁿ	-OCH (CH ₂ CH ₂ CH=CH ₂) CH ₂ O-	
2-26	CF ₂ Cl	Pr ⁿ	-OCH (Hex ⁿ) CH ₂ O-	

EP 0 764 641 A1

(Table 2-2)

5	Compound No.	Spectral data	Physical properties
10	2-1	$^1\text{H-NMR } \delta \text{ (ppm) [solvent] ;}$ 1. 79 (s. 3H. CH_3). 3. 60~4. 20 (m. 4H. $\text{OCH}_2\text{CH}_2\text{O}$). 9. 13 (s. 1H. Pyrimidine ring). 9. 23 (s. 1H. Pyrimidine ring). [CDCl ₃]	$n_D^{20.3} 1.4895$
25	2-2	$^1\text{H-NMR } \delta \text{ (ppm) [solvent] ;}$ 0. 93~1. 01 (m. 9H. $\text{C}(\text{CH}_3)_3$). 3. 81~3. 93 (m. 4H. $\text{OCH}_2\text{CH}_2\text{O}$). 9. 08 (s. 1H. Pyrimidine ring). 9. 12 (s. 1H. Pyrimidine ring). [CDCl ₃]	$n_D^{20.0} 1.4775$
40	2-3	$^1\text{H-NMR } \delta \text{ (ppm) [solvent] ;}$ 0. 98 (t. $J=7\text{Hz}$. 3H. CH_2CH_3). 1. 79 (s. 3H. CH_3). 1. 29~2. 19 (m. 2H. CH_2CH_3). 3. 38~4. 38 (m. 3H. $\text{OCH}_2\text{CH}_2\text{(EtO)}$). 9. 08 (s. 1H. Pyrimidine ring). 9. 16 (s. 1H. Pyrimidine ring). [CDCl ₃]	$n_D^{20.0} 1.4769$

55

EP 0 764 641 A1

(Table 2-2) continued

5	Compound No.	Spectral data	Physical properties
10	2-4	¹ H-NMR δ (ppm) [solvent] : 1. 72 (s, 3H, CH ₃) . 1. 1~2. 5 (m, 2H, CH ₂ CH ₂ CH ₃) . 3. 3~4. 3 (m, 4H, OCH ₂) . 9. 05 (s, 1H, Pyrimidine ring) . 9. 23 (s, 1H, Pyrimidine ring) . [CDCl ₃]	n _D ^{20.3} 1. 4923
25	2-5	¹ H-NMR δ (ppm) [solvent] : 0. 6~1. 15 (m, 3H, CH ₂ CH ₂ CH ₃) . 1. 15~1. 9 (m, 4H, CH ₂ CH ₂ CH ₃) . 1. 76 (s, 3H, CH ₃) . 3. 3~4. 5 (m, 3H, CH ₂ CH (Pr ⁿ) O) . 9. 02 (s, 1H, Pyrimidine ring) . 9. 12 (s, 1H, Pyrimidine ring) . [CDCl ₃]	n _D ^{20.3} 1. 4689
40	2-6	¹ H-NMR δ (ppm) [solvent] : 0. 95 (t, J=7Hz, 3H, CH ₂ CH ₃) . 2. 02 (q, J=7Hz, 2H, CH ₂ CH ₃) . 3. 05~4. 32 (m, 4H, OCH ₂) . 9. 0 (s, 1H, Pyrimidine ring) . 9. 13 (s, 1H, Pyrimidine ring) . [CDCl ₃]	n _D ^{21.6} 1. 4884

55

(Table 2-2) continued

5	Compound No.	Spectral data	Physical properties
10	2-7	¹ H-NMR δ (ppm) [solvent] :	
		0. 9 (t, <u>J</u> =6 Hz, 3H, CH ₂ CH ₂ CH ₃) .	
		1. 12~2. 18 (m, 4H, CH ₂ CH ₂ CH ₃) .	
15		3. 62~4. 15 (m, 4H, OCH ₂) .	
		9. 04 (s, 1H, Pyrimidine ring) .	
20		9. 17 (s, 1H, Pyrimidine ring) .	
		[CDCl ₃]	n _D ^{20.7} 1. 4852
25	2-8	¹ H-NMR δ (ppm) [solvent] :	
		0. 68 (m, 14H, CH ₂ CH ₂ CH ₃) .	
30		3. 28~4. 33 (m, 3H, OCH ₂ CH ₂ O) .	
		9. 06 (s, 1H, Pyrimidine) .	
		9. 20 (s, 1H, Pyrimidine) .	
35		[CDCl ₃]	n _D ^{20.4} 1. 4701
40	2-9	¹ H-NMR δ (ppm) [solvent] :	
		0. 68~1. 18 (m, 6H, CH ₂) .	
		1. 18~2. 20 (m, 6H, CH ₂) .	
45		3. 13~4. 38 (m, 3H, OCH ₂ CH ₂ O) .	
		9. 06 (s, 1H, Pyrimidine ring) .	
		9. 19 (s, 1H, Pyrimidine ring) .	
50		[CDCl ₃]	n _D ^{20.5} 1. 4769

55

(Table 2-2) continued

Compound No.	Spectral data	Physical properties
2-10	¹ H-NMR δ (ppm) (solvent) : 0.94 (s, 9H, C(CH ₃)). 1.74 (s, 3H, CH ₃). 3.27~4.20 (m, 3H, OCH ₂ CHO). 9.0 (s, 1H, Pyrimidine ring). 9.11 (s, 1H, Pyrimidine ring). [CDC1 ₃]	n _D ^{20.3} 1.4782
2-11	¹ H-NMR δ (ppm) (solvent) : 0.67~1.14 (m, 3H, CH ₂ CH ₂ CH ₃). 1.14~1.92 (m, 4H, CH ₂ CH ₂ CH ₃). 1.75 (t, J=1Hz, 3H, CH ₃). 3.42~4.42 (m, 3H, OCH ₂ CHO). 9.08 (s, 1H, Pyrimidine ring). 9.20 (s, 1H, Pyrimidine ring). [CDC1 ₃]	n _D ^{20.2} 1.4894
2-12	¹ H-NMR δ (ppm) (solvent) : 1.4~2.5 (m, 4H, CH ₂ CH ₂). 1.79 (s, 3H, CH ₃). 3.34~4.42 (m, 3H, OCH ₂ CHO). 4.85 (dd, J _{BX} =2Hz, J _{AB} =1Hz, 1H, CH _X =C(H _B)H _A (provided that H _X and H _B are in a cis configuration) 5.09 (dd, J _{AX} =6Hz, J _{AB} =1Hz, 1H, CH _X =C(H _B)H _A (provided that H _X and H _B are in a cis configuration) 5.35~6.06 (m, 1H, CH _X =C(H _B)H _A (provided that H _X and H _B are in a cis configuration) 9.1 (s, 1H, Pyrimidine ring). 9.21 (s, 1H, Pyrimidine ring). [CDC1 ₃]	n _D ^{20.0} 1.4877

10

15254050

EP 0 764 641 A1

(Table 2-2) continued

Compound No.	Spectral data	Physical properties
2-16	¹ H-NMR δ (ppm) [solvent] : 1. 78 (br s, 3H, CH ₃) 3. 48~4. 18 (m, 4H, OCH ₂ CH ₂ O) 9. 08 (s, 1H, Pyrimidine ring) 9. 13 (s, 1H, Pyrimidine ring) [CDC1 ₃]	n _D ²⁰ 1. 4417
2-17	¹ H-NMR δ (ppm) [solvent] : 0. 60~1. 15 (m, 3H, CH ₂ CH ₂ CH ₃) 1. 15~1. 91 (m, 4H, CH ₂ CH ₂ CH ₃) 1. 76 (s, 3H, CH ₃) 3. 10~4. 36 (m, 3H, OCH ₂ CH ₂ O) 9. 05~9. 25 (m, 2H, Pyrimidine ring) [CDC1 ₃]	n _D ²⁰ 1. 4574
2-18	¹ H-NMR δ (ppm) [solvent] : 0. 67~1. 15 (m, 6H, CH ₂ CH ₂ CH ₃ , CH ₂ CH ₂ CH ₃) 1. 15~2. 08 (m, 8H, CH ₂ CH ₂ CH ₃ , CH ₂ CH ₂ CH ₃) 3. 17~4. 36 (m, 3H, OCH ₂ CH ₂ O) 7. 63 (d, J=48. 5Hz, 1H, CHFC1) 8. 81 (s, 1H, Pyrimidine ring) 9. 18 (s, 1H, Pyrimidine ring) [CDC1 ₃]	n _D ²⁰ 1. 4823

(Table 2-2) continued

Compound No.	Spectral data	Physical properties
2-19	¹ H-NMR δ (ppm) [solvent] : 0.69~1.18 (m, 6H, CH ₂ CH ₂ CH ₂ , CH ₂ CH ₂ CH ₂) 1.18~2.08 (m, 8H, CH ₂ CH ₂ CH ₂ , CH ₂ CH ₂ CH ₂) 3.20~4.36 (m, 3H, OCH ₂ CHO) 7.23, 7.26 (each data is t; J=54Hz, including 1H, CHF ₂) 8.94 (s, 1H, Pyrimidine ring) 9.26 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.4664
2-20	¹ H-NMR δ (ppm) [solvent] : 0.70~1.15 (m, 3H, CH ₂ CH ₂ CH ₂) 1.15~1.80 (m, 4H, CH ₂ CH ₂ CH ₂) 1.80~2.35 (m, 4H, cyclo-propyl CH ₂) 3.40~4.00 (m, 4H, cyclo-propyl CH, OCH ₂ CHO) 9.00 (s, 1H, Pyrimidine ring) 9.15 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.4863

EP 0 764 641 A1

(Table 2-2) continued

Compound No.	Spectral data	Physical properties
2-21	¹ H-NMR δ (ppm) [solvent] : 0. 60~1. 10 (m. 3H. CH ₂ CH ₂ CH ₃) 1. 42 (br s. 6H. iso-propyl CH ₃) 1. 70~2. 10 (m. 4H. CH ₂ CH ₂) 3. 10~3. 70 (m. 4H. cyclo-propyl CH ₂ . OCH ₂ CHO) 8. 72 (s. 1H. Pyrimidine ring) 9. 30 (s. 1H. Pyrimidine ring) [CDCl ₃]	n _D ^{20.0} 1. 4814
2-22	¹ H-NMR δ (ppm) [solvent] : 0. 72~1. 24 (m. 3H. CH ₂ CH ₂ CH ₃) 1. 24~2. 25 (m. 4H. CH ₂ CH ₂ CH ₃) 3. 30~4. 58 (m. 5H. OCH ₂ CHO. CH ₂ Br) 9. 16. 9. 20 (各s. 1H. Pyrimidine ring) 9. 32 (s. 1H. Pyrimidine ring) [CDCl ₃]	n _D ^{20.0} 1. 5011
2-23	¹ H-NMR δ (ppm) [solvent] : 0. 66~1. 16 (m. 9H. CH ₃ . CH ₂ . CH ₃) 1. 16~1. 71 (m. 4H. CH ₂ CH ₂ CH ₃) 1. 71~2. 10 (m. 3H. CH ₂ CH (CH ₃) ₂) 3. 26~4. 35 (m. 3H. OCH ₂ CHO) 9. 01 (s. 1H. Pyrimidine ring) 9. 12 (s. 1H. Pyrimidine ring) [CDCl ₃]	n _D ^{20.2} 1. 4737


EP 0 764 641 A1

(Table 2-2) continued

Compound No.	Spectral data	Physical properties
2-24	¹ H-NMR δ (ppm) (solvent) : 0.62~1.09 (m. 6H. CH ₂ , CH ₂) 1.09~2.14 (m. 10H. CH ₂ , CH ₂ , CH ₂ , CH ₂ , CH ₂ , CH ₂ , CH ₂) 3.24~4.31 (m. 3H. OCH ₂ , CH ₂ O) 8.98 (s. 1H. Pyrimidine ring) 9.12 (s. 1H. Pyrimidine ring) [CDCl ₃]	n _D ^{20.1} 1.4715
2-25	¹ H-NMR δ (ppm) (solvent) : 0.68~1.08 (m. 3H. CH ₂) 1.08~2.48 (m. 8H. CH ₂ , CH ₂ , CH ₂ , CH ₂ , CH ₂ , CH=CH ₂) 3.28~4.28 (m. 3H. OCH ₂ , CH ₂ O) 4.68~4.90 (m. 1H. CH=CH ₂) 4.90~5.18 (m. 1H. CH=CH ₂) 5.28~6.08 (m. 1H. CH=CH ₂) 8.98 (s. 1H. Pyrimidine ring) 9.11 (s. 1H. Pyrimidine ring) [CDCl ₃]	n _D ^{20.0} 1.4805
2-26	¹ H-NMR δ (ppm) (solvent) : 0.60~1.08 (m. 6H. CH ₂ , CH ₂) 1.08~2.14 (m. 14H. CH ₂ , CH ₂ , CH ₂ , CH ₂ , CH ₂ , CH ₂ , CH ₂ , CH ₂ , CH ₂ , CH ₂ , CH ₂) 3.35~4.35 (m. 3H. OCH ₂ , CH ₂ O) 8.95 (s. 1H. Pyrimidine ring) 9.10 (s. 1H. Pyrimidine ring) [CDCl ₃]	n _D ^{20.0} 1.4737

EP 0 764 641 A1

(Table 3-1)



Compound No.	X	R 3	R 2
3-1	Cl	NHCH ₂ Ph	Pr ^{cyclo}
3-2	Cl	morphorino	Pr ^{cyclo}
3-3	Cl	4-phenylpiperazinyl	Pr ^{cyclo}
3-4	Cl	heptamethyleneimino	Pr ^{cyclo}
3-5	Cl	2,6-dimethylmorphorino	Pr ^{cyclo}
3-6	Cl	NH(2-Cl-benzyl)	Pr ^{cyclo}
3-7	Cl	NH(3-Cl-benzyl)	Pr ^{cyclo}
3-8	Cl	NH(4-Cl-benzyl)	Pr ^{cyclo}
3-9	Cl	NH(4-Me-benzyl)	Pr ^{cyclo}
3-10	Cl	NH(2-Cl-phenetyl)	Pr ^{cyclo}
3-11	Cl	NH(2,4-Cl ₂ -benzyl)	Pr ^{cyclo}
3-12	Cl	3,3-Me ₂ -piperidino	Pr ^{cyclo}
3-13	Cl	NH(CH(Ph) ₂)	Pr ^{cyclo}
3-14	Cl	N(Me)CH ₂ Ph	Pr ^{cyclo}
3-15	Cl	NHCH ₂ Ph	Pr ⁿ
3-16	Cl	NH ₂	Pr ^{cyclo}
3-17	Cl	NHEt	Pr ^{cyclo}
3-18	Cl	NHMe·HCl	Pr ^{cyclo}
3-19	Cl	NHMe	Pr ^{cyclo}
3-20	Cl	NMe ₂	Pr ^{cyclo}
3-21	Cl	NHCH ₂ Ph	Pr ^{iso}

EP 0 764 641 A1

(Table 3-2)

Compound No.	Spectral data	Physical properties
3-1	¹ H-NMR δ (ppm) [solvent] : 0. 23~0. 72 (m. 4H. cyclo-propyl CH ₂) 0. 94~1. 32 (m. 1H. cyclo-propyl CH) 1. 70~1. 90 (m. 1H. NH) 3. 55~3. 70 (m. 3H. NHCH ₂ Ph + φ CH) 7. 15 (s. 5H. Benzene ring) 9. 03 (s. 1H. Pyrimidine ring) 9. 28 (s. 1H. Pyrimidine ring) [CDCl ₃]	n _D ^{21.3} 1. 5478
3-2	¹ H-NMR δ (ppm) [solvent] : 0. 17~0. 50 (m. 4H. cyclo-Propyl CH ₂) 0. 72~1. 12 (m. 1H. cyclo-Propyl CH) 2. 09~2. 83 (m. 4H. Morpholine ring) 2. 93~3. 12 (m. 1H. φ CH) 3. 53~3. 74 (m. 4H. Morpholine ring) 9. 08 (s. 1H. Pyrimidine ring) 9. 19 (s. 1H. Pyrimidine ring) [CDCl ₃]	n _D ^{21.2} 1. 5132
3-3	¹ H-NMR δ (ppm) [solvent] : 0. 15~1. 15 (m. 5H. cyclo-Propyl) 2. 50~3. 35 (m. 9H. NCH ₂ CH ₂ Nand NCH) 6. 51~7. 35 (m. 5H. Benzene ring) 9. 05 (s. 1H. Pyrimidine ring) 9. 18 (s. 1H. Pyrimidine ring) [CDCl ₃]	mp 75-79°C

(Table 3-2) continued

Compound No.	Spectral data	Physical properties
3-4	¹ H-NMR δ (ppm) [solvent] : 0. 10~1. 20 (m. 5H. cyclo-Propyl) 1. 48 (br s. 10H. CH ₂) 2. 15~3. 55 (m. 5H. NCH ₂ and NCH) 9. 10 (s. 1H. Pyrimidine ring) 9. 27 (s. 1H. Pyrimidine ring) [CDCl ₃]	n _D ^{20.0} 1. 5168
3-5	¹ H-NMR δ (ppm) [solvent] : 0. 12~0. 63 (m. 4H. cyclo-Propyl CH ₂) 0. 63~1. 40 (m. 1H. cyclo-Propyl CH) 1. 00 (d. J=6Hz. 3H. CH ₃) 1. 18 (d. J=6Hz. 3H. CH ₃) 1. 53~2. 49 (m. 3H) 2. 63~4. 01 (m. 4H) 9. 11 (s. 1H. Pyrimidine ring) 9. 19 (s. 1H. Pyrimidine ring) [CDCl ₃]	n _D ^{19.8} 1. 5008

(Table 3-2) continued

Compound No.	Spectral data	Physical properties
3-6	¹ H-NMR δ (ppm) [solvent] : 0.21~0.82 (m, 4H, cyclo-Propyl CH ₂) 0.82~1.50 (m, 1H, cyclo-Propyl CH) 2.4~3.0 (m, 1H, N-H) 3.17~3.84 (m, 3H, NCH ₂ and NCH ₂) 7.17 (br d, J=2Hz, 4H, Benzene ring) 9.12 (s, 1H, Pyrimidine ring) 9.38 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ^{20.2} 1.5503
3-7	¹ H-NMR δ (ppm) [solvent] : 0.22~0.8 (m, 4H, cyclo-Propyl CH ₂) 0.8~1.42 (m, 1H, cyclo-Propyl CH) 1.82 (br s, 1H, NH) 3.58 (d, J=5Hz, 2H, NCH ₂) 3.33~3.75 (m, 1H, NCH) 6.92~7.34 (m, 4H, Benzene ring) 9.08 (s, 1H, Pyrimidine ring) 9.3 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ^{20.3} 1.5337

EP 0 764 641 A1

(Table 3-2) continued

Compound No.	Spectral data	Physical properties
3-8	¹ H-NMR δ (ppm) (solvent) : 0.25~0.85 (m, 4H, cyclo-Propyl CH ₂) 0.85~1.49 (m, 1H, cyclo-Propyl CH) 1.88 (br s, 1H, NH) 3.45~3.85 (m, 1H, NCH) 3.63 (br d, J=6Hz, 2H, NCH ₂) 7.19 (s, 4H, Benzene ring) 9.16 (s, 1H, Pyrimidine ring) 9.38 (s, 1H, Pyrimidine) [CDCl ₃]	n _D ²⁰ 1.5419
3-9	¹ H-NMR δ (ppm) (solvent) : 0.22~0.75 (m, 4H, cyclo-Propyl CH ₂) 0.75~1.42 (m, 1H, cyclo-Propyl CH) 1.8 (br s, 1H, NH) 2.28 (s, 3H, CH ₃) 3.34~3.85 (m, 1H, NCH) 3.56 (d, J=4Hz, 2H, NCH ₂) 7.04 (s, 4H, Benzene ring) 9.10 (s, 1H, Pyrimidine ring) 9.34 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5245

EP 0 764 641 A1

(Table 3-2) continued

Compound No.	Spectral data	Physical properties
3-10	¹ H-NMR δ (ppm) [solvent] : 0. 2~0. 77 (m. 4H. cyclo-Propyl CH ₂) 0. 77~1. 3 (m. 1H. cyclo-Propyl CH) 1. 58 (br s. 1H. NH) 2. 5~3. 25 (m. 4H. NCH ₂ CH ₂) 3. 5~3. 82 (m. 1H. NCH) 7. 0~7. 5 (m. 4H. Benzene ring) 9. 19 (s. 1H. Pyrimidine ring) 9. 27 (s. 1H. Pyrimidine ring) [CDCl ₃]	n _D ^{20.3} 1. 5302
3-11	¹ H-NMR δ (ppm) [solvent] : 0. 18~0. 79 (m. 4H. cyclo-Propyl CH ₂) 0. 79~1. 53 (m. 1H. cyclo-Propyl CH) 1. 88 (br s. 1H. NH) 3. 29~3. 83 (m. 3H. NCH ₂ and NCH) 7. 05~7. 38 (m. 3H. Benzene ring) 9. 09 (s. 1H. Pyrimidine ring) 9. 30 (s. 1H. Pyrimidine ring) [CDCl ₃]	n _D ^{20.2} 1. 5499
3-12	¹ H-NMR δ (ppm) [solvent] : 0. 13~0. 63 (m. 4H. cyclo-Propyl CH ₂) 0. 88 (s. 6H. CH ₃) 0. 63~3. 75 (m. 10H) 9. 20 (s. 1H. Pyrimidine ring) 9. 34 (s. 1H. Pyrimidine ring) [CDCl ₃]	n _D ^{20.1} 1. 4914

(Table 3-2) continued

Compound No.	Spectral data	Physical properties
3-13	¹ H-NMR δ (ppm) [solvent] : 0.12~0.82 (m, 4H, cyclo-Propyl CH ₂) 0.82~1.47 (m, 1H, cyclo-Propyl CH) 1.79~2.52 (br s, 1H, NH) 3.52~3.81 (m, 1H, NCH) 4.73 (s, 1H, NCH) 7.18 (s, 5H, Benzene ring) 7.29 (s, 5H, Benzene ring) 9.16 (s, 1H, Pyrimidine ring) 9.45 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ^{20.0} 1.5538
3-14	¹ H-NMR δ (ppm) [solvent] : 0.10~1.45 (m, 5H, cyclo-Propyl CH ₂) 2.20 (s, 3H, CH ₃) 3.10~3.70 (m, 3H, CH, CH ₂) 7.18 (s, 5H, Benzene ring) 9.08 (s, 1H, Pyrimidine ring) 9.33 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ^{20.3} 1.5245

EP 0 764 641 A1

(Table 3-2) continued

Compound No.	Spectral data	Physical properties
3-15	¹ H-NMR δ (ppm) [solvent] : 0. 67~1. 17 (m. 3H. CH_2) 1. 17~2. 07 (m. 5H. CHCH_2CH_2) 3. 57 (br s. 2H. CH_2) 4. 14~4. 56 (br s. 1H. NH) 7. 17 (s. 5H. Benzene ring) 9. 06 (s. 1H. Pyrimidine ring) 9. 23 (s. 1H. Pyrimidine ring) [CDCl ₃]	$n_D^{20.4}$ 1. 5274
3-16	¹ H-NMR δ (ppm) [solvent] : 0. 23~0. 78 (m. 4H. cyclo-Propyl CH_2) 1. 03~1. 37 (m. 1H. cyclo-Propyl CH) 1. 69 (s. 2H. NH_2) 3. 81 (m. 1H. ϕCH) 9. 13 (s. 1H. Pyrimidine ring) 9. 26 (s. 1H. Pyrimidine ring) [CDCl ₃]	$n_D^{21.4}$ 1. 5095
3-17	¹ H-NMR δ (ppm) [solvent] : 0. 34~0. 74 (m. 4H. cyclo-Propyl CH_2) 0. 87~1. 36 (m. 1H. cyclo-Propyl CH) 1. 04 (t. $J=7\text{Hz}$. 3H. NHCH_2CH_2) 1. 60 (br s. 1H. NH) 2. 17~2. 82 (m. 2H. NHCH_2CH_2) 3. 42~3. 62 (m. 1H. ϕCH) 9. 07 (s. 1H. Pyrimidine ring) 9. 24 (s. 1H. Pyrimidine ring) [CDCl ₃]	$n_D^{21.4}$ 1. 4947

EP 0 764 641 A1


(Table 3-2) continued

Compound No.	Spectral data	Physical properties
3-18	¹ H-NMR δ (ppm) [solvent] : 0. 37~1. 26 (m, 4 H, cyclo-Propyl CH ₂) 1. 47~2. 12 (m, 1 H, cyclo-Propyl CH) 2. 50~2. 86 (m, 3 H, CH ₃) 9. 29 (s, 1 H, Pyrimidine ring) 9. 90 (s, 1 H, Pyrimidine ring) 10. 27~10. 67 (m, 2 H, NH ₂ CH ₃) [DMSO-d ₆ +CDCl ₃]	mp 197-199°C
3-19	¹ H-NMR δ (ppm) [solvent] : 0. 20~0. 74 (m, 4 H, cyclo-Propyl CH ₂) 0. 86~1. 29 (m, 1 H, cyclo-Propyl CH) 1. 64 (br s, 1 H, NH) 2. 29 (s, 3 H, NHCH ₃) 3. 29~3. 55 (m, 1 H, φ CH) 9. 07 (s, 1 H, Pyrimidine ring) 9. 18 (s, 1 H, Pyrimidine ring) [CDCl ₃]	n _D ^{20.5} 1.5002
3-20	0. 18~0. 62 (m, 4 H, cyclo-Propyl CH ₂) 0. 95~1. 33 (m, 1 H, cyclo-Propyl CH) 2. 31 (s, 6 H, N(CH ₃) ₂) 2. 91 (d, J=8 Hz, 1 H, φ CH) 9. 15 (s, 1 H, Pyrimidine ring) 9. 23 (s, 1 H, Pyrimidine ring) [CDCl ₃]	n _D ^{21.2} 1.4975

(Table 3-2) continued

Compound No.	Spectral data	Physical properties
3-21	¹ H-NMR δ (ppm) [solvent] ; 0.90 (d, $J=6$ Hz, 3H, CH ₃) 1.00 (d, $J=6$ Hz, 3H, CH ₃) 1.70 (br s, 1H, NH) 1.95 (qq, $J=6$ Hz, 1H, CH) 3.52 (s, 2H, CH ₂) 3.99~4.20 (m, 1H, CH) 6.72 (s, 5H, Benzene ring) 9.09 (s, 1H, Pyrimidine ring) 9.21 (s, 1H, Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5285

(Table 4-1)



Compound No.	X	R 3	R 2
4 - 1	Cl	OCOMe	Bu ^{tert}
4 - 2	Cl	OCOMe	Pr ^{cyclo}
4 - 3	Cl	OCH ₂ OMe	Me
4 - 4	Cl	OCOMe	Me
4 - 5	Cl	OCOEt	Me
4 - 6	Cl	OCOPh	Me
4 - 7	Cl	OSO ₂ Me	Me
4 - 8	Cl	OSO ₂ - (4 - F - Phenyl)	Me
4 - 9	Cl	OSi (Me) ₂ Bu ^{tert}	Me
4 - 10	Cl	OMe	Pr ^{cyclo}
4 - 11	Cl	OCH ₂ CH=CH ₂	Pr ^{cyclo}
4 - 12	Cl	OPh	Pr ^{cyclo}
4 - 13	Cl	OBu ^{tert}	Pr ^{cyclo}
4 - 14	Cl	OTHP	Me
4 - 15	Cl	OPh	Pr ⁿ
4 - 16	Cl	OTHP	Pr ^{cyclo}

(Table 4-2)

Compound No.	Spectral data	Physical properties
4-1	¹ H-NMR δ (ppm) [solvent] : 0.88~1.18 (m. 9H. C(CH ₃) ₃). 2.08 (s. 3H. OCOCH ₃). 6.09 (s. 1H. CH ₂ OAc). 8.95 (s. 1H. Pyrimidine ring). 9.18 (s. 1H. Pyrimidine ring). [CDCl ₃]	n _D ²⁰ 1.4644
4-2	¹ H-NMR δ (ppm) [solvent] : 0.51~0.72 (m. 4H. cyclo-propyl CH ₂). 1.06~1.38 (m. 1H. cyclo-propyl CH). 2.08 (s. 3H. COCH ₃). 5.83 (d. J=7Hz. 1H. φCH). 9.09 (s. 1H. Pyrimidine ring). 9.20 (s. 1H. Pyrimidine ring). [CDCl ₃]	n _D ²⁰ 1.4841
4-3	¹ H-NMR δ (ppm) [solvent] : 1.53 (d. J=6Hz. 3H. CHCH ₃). 3.28 (s. 3H. OCH ₃). 4.47 (d. J=7Hz. 1H. CH ₂). 4.65 (d. J=7Hz. 1H. CH ₂). 5.01~5.51 (m. 1H. CH). 9.10 (s. 2H. Pyrimidine ring). [CDCl ₃]	n _D ²⁰ 1.4654

EP 0 764 641 A1

(Table 4-2) continued

Compound No.	Spectral data	Physical properties
4-4	¹ H-NMR δ (ppm) (solvent) : 1. 59 (d. \underline{J} =6 Hz. 3H. $\underline{\text{CH}}_3$) 2. 09 (s. 3H. $\underline{\text{CH}}_3$, CO) 6. 01~6. 44 (m. 1H. $\underline{\text{CH}}$) 8. 97 (s. 1H. Pyrimidine ring) 9. 12 (s. 1H. Pyrimidine ring)	$n_D^{21.6}$ 1. 4720 [CDCl ₃]
4-5	¹ H-NMR δ (ppm) (solvent) : 1. 14 (t. \underline{J} =7 Hz. 3H. $\underline{\text{CH}}_2 \underline{\text{CH}}_3$) 1. 60 (d. \underline{J} =6 Hz. 3H. $\underline{\text{CHCH}}_3$) 2. 38 (q. \underline{J} =7 Hz. 2H. $\underline{\text{CH}}_2 \underline{\text{CH}}_3$) 6. 26 (q. \underline{J} =6 Hz. 1H. $\underline{\text{CHCH}}_3$) 9. 00 (s. 1H. Pyrimidine ring) 9. 15 (s. 1H. Pyrimidine ring)	$n_D^{20.4}$ 1. 4646 [CDCl ₃]
4-6	¹ H-NMR δ (ppm) (solvent) : 1. 74 (t. \underline{J} =7 Hz. 3H. $\underline{\text{CHCH}}_3$) 6. 46 (q. \underline{J} =7 Hz. 1H. $\underline{\text{CHCH}}_3$) 7. 08~8. 12 (m. 5H. Benzene ring) 9. 07 (s. 1H. Pyrimidine ring) 9. 12 (s. 1H. Pyrimidine ring)	$n_D^{20.5}$ 1. 5309 [CDCl ₃]

EP 0 764 641 A1

(Table 4-2) continued

Compound No.	Spectral data	Physical properties
4-7	¹ H-NMR δ (ppm) [solvent] : 1. 74 (d. $J=6$ Hz. 3H. CHCH ₃) 3. 24 (s. 3H. SO ₂ CH ₃) 6. 12 (q. $J=6$ Hz. 1H. CHCH ₃) 9. 04 (s. 1H. Pyrimidine ring) 9. 16 (s. 1H. Pyrimidine ring) [CDCl ₃]	mp 96-100°C
4-8	¹ H-NMR δ (ppm) [solvent] : 1. 69 (d. $J=7$ Hz. 3H. CHCH ₃) 6. 01 (q. $J=7$ Hz. 1H. CHCH ₃) 6. 89~8. 05 (m. 4H. Benzene ring) 8. 99 (s. 1H. Pyrimidine ring) 9. 15 (s. 1H. Pyrimidine ring) [CDCl ₃]	viscous oil
4-9	¹ H-NMR δ (ppm) [solvent] : -0. 03 (s. 3H. Si-CH ₃) 0. 11 (s. 3H. Si-CH ₃) 0. 89 (s. 9H. C(CH ₃) ₃) 1. 47 (d. $J=6$ Hz. 3H. CHCH ₃) 5. 06~5. 59 (m. 1H. CHCH ₃) 9. 09 (s. 1H. Pyrimidine ring) 9. 17 (s. 1H. Pyrimidine ring) [CDCl ₃]	$n_D^{20.2}$ 1.4602

EP 0 764 641 A1

(Table 4-2) continued

Compound No.	Spectral data	Physical properties
4-10	¹ H-NMR δ (ppm) (solvent) : 0.33~0.70 (m, 4H, cyclo-propyl CH ₂) 1.04~1.41 (m, 1H, cyclo-propyl CH) 3.32 (s, 3H, OCH ₃) 4.47 (d, J=6Hz, 1H, φCH) 9.16 (s, 1H, Pyrimidine ring) 9.24 (s, 1H, Pyrimidine ring) (CDCl ₃)	n _D ²⁰ 1.4885
4-11	¹ H-NMR δ (ppm) (solvent) : 0.45~0.69 (m, 4H, cyclo-propyl CH ₂) 0.89~1.36 (m, 1H, cyclo-propyl CH) 2.86 (d, J=6Hz, 2H, OCH ₂ CH=CH ₂) 4.47~4.66 (m, 1H, φCH) 4.92~5.06 (m, 1H, OCH ₂ CH=CH ₂) 5.16~5.34 (m, 2H, OCH ₂ CH=CH ₂) 9.12 (s, 1H, Pyrimidine ring) 9.13 (s, 1H, Pyrimidine ring) (CDCl ₃)	n _D ²⁰ 1.4912
4-12	¹ H-NMR δ (ppm) (solvent) : 0.51~0.74 (m, 4H, cyclo-propyl CH ₂) 1.15~1.44 (m, 1H, cyclo-propyl CH) 5.42~5.64 (m, 1H, φCH) 6.67~7.27 (m, 6H, Benzene ring+ Pyrimidine ring) 9.14 (s, 1H, Pyrimidine ring) (CDCl ₃)	n _D ²⁰ 1.5472


(Table 4-2) continued

Compound No.	Spectral data	Physical properties
4-13	¹ H-NMR δ (ppm) [solvent] : 0.31~0.53 (m, 4H, cyclo-propyl <u>CH</u> ₂) 0.87~1.24 (m, 1H, cyclo-propyl <u>CH</u>) 1.09 (s, 9H, C (<u>CH</u> ₃)) 4.95~5.10 (m, 1H, ϕ <u>CH</u>) 9.17 (s, 1H, Pyrimidine ring) 9.20 (s, 1H, Pyrimidine ring)	[CDCl ₃] n_D²⁰ 1.4770
4-14	¹ H-NMR δ (ppm) [solvent] : 1.17~1.97 (m, 9H, CHCH ₃ , <u>CH</u> ₂) 3.17~4.18 (m, 3H, OCH ₃ , O <u>CH</u> ₂) 5.07~5.67 (m, 1H, <u>CH</u> CH ₃) 9.07~9.27 (m, 2H, Pyrimidine ring)	[CDCl ₃] n_D²⁰ 1.4812
4-15	¹ H-NMR δ (ppm) [solvent] : 0.96 (t, <u>J</u> =7Hz, 3H, <u>CH</u> ₃) 1.27~2.14 (m, 4H, <u>CH</u> ₂ <u>CH</u> ₂) 5.37~5.77 (m, 1H, <u>CH</u>) 6.63~7.35 (m, 5H, Benzene ring) 9.05 (s, 1H, Pyrimidine ring) 9.10 (s, 1H, Pyrimidine ring)	[CDCl ₃] n_D²⁰ 1.5237

(Table 4-2) continued

Compound No.	Spectral data	Physical properties
4-16	¹ H-NMR δ (ppm) [solvent] : 0.41~0.70 (m, 4H, cyclo-propylCH ₂) 0.94~1.29 (m, 1H, cyclo-propylCH)) 1.29~1.94 (m, 6H, CH ₂ × 3) 3.22~3.87 (m, 2H, OCH ₂) 4.78~5.04 (m, 2H, φCH+OCHO) 9.12 (br s, 2H, Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.4874

(Table 5-1)



Compound No.	R.1	R 2	R 5
5-1	CF ₃ C1	Me	OMe
5-2	CF ₃	Me	OCH ₂ CO ₂ Et
5-3	CF ₃ C1	Me	OCH ₂ CO ₂ Et
5-4	CF ₃ C1	Me	NH- (4-CF ₃ -phenyl)
5-5	CF ₃ C1	Et	OCH ₂ CO ₂ Et
5-6	CF ₃ C1	Pr ⁿ	OCH ₂ CO ₂ Et
5-7	CF ₃ CF ₃ C1	Me	OCH ₂ CO ₂ Et
5-8	CF ₃ C1	2-F-Phenyl	N (Me) ₂

(Table 5-2)

Compound No.	Spectral data	Physical properties
5-1	¹ H-NMR δ (ppm) [solvent] ; 2. 10~2. 40 (m. 3H. C (CH ₃) =NO) . 3. 26. 3. 97 (each data is s; including both peaks, 3H, OCH ₃) 8. 10. 8. 76 (each data is s; including both peaks, 1H, Pyrimidine ring 6-position), 9. 25 (s. 1H. Pyrimidine ring 2-position), [CDC l,] n _D ²⁰ 1. 4865	
5-2	¹ H-NMR δ (ppm) [solvent] ; 1. 30 (t. J=8Hz. 3H. CH ₂ CH ₃) . 2. 26. 2. 33 (each data is s; including both peaks, 3H, C (CH ₃) =NO) . 4. 27 (q. J=8Hz. 2H. CH ₂ CH ₃) . 4. 57 4. 78 (each data is s; including both peaks, 2H, OCH ₂ CO ₂) . 8. 94 (s. 1H. Pyrimidine ring) . 9. 42 (s. 1H. Pyrimidine ring) . [CDC l,] n _D ²⁰ 1. 4640	
5-3	¹ H-NMR δ (ppm) [solvent] ; 1. 30 (t. J=7Hz. 3H. CH ₂ CH ₃) . 2. 24. 2. 28 (each data is t; J=1Hz, including both peaks, 3H. C (CH ₃) =NO) . 4. 23 (q. J=7Hz. 2H. CH ₂ CH ₃) . 4. 53. 4. 70 (each data is s; including both peaks, 2H, OCH ₂ CO ₂) . 8. 80. 8. 82 (each data is s; including both peaks, 1H, Pyrimidine ring 6-position), 9. 30 (s. 1H. Pyrimidine ring 2-position), [CDC l,] n _D ²⁰ 1. 4851	

(Table 5-2) continued

5	Compound No.	Spectral data	Physical properties
10	5 - 4	<p>¹H-NMR δ (ppm) [solvent] :</p> <p>2. 32. 2. 65 (each data is s; including both peaks, 3H, CH₃)</p> <p>7. 21 (d, $J=9$ Hz. 2 H. Benzene ring)</p> <p>7. 57 (d, $J=9$ Hz. 2 H. Benzene ring)</p> <p>7. 91 (s. 1 H. NH)</p> <p>8. 94. 9. 02 (each data is s; including both peaks, 1H, Pyrimidine ring)</p> <p>9. 38. 9. 46 (each data is s; including both peaks, 1H, Pyrimidine ring)</p> <p>[CDCl₃]</p>	oil
30	5 - 5	<p>¹H-NMR δ (ppm) [solvent] :</p> <p>1. 06 (t, $J=8$ Hz. 3 H. CH₃)</p> <p>1. 28 (t, $J=7$ Hz. 3 H. CH₃)</p> <p>2. 80 (q, $J=8$ Hz. 2 H. CH₂)</p> <p>4. 22 (q, $J=7$ Hz. 2 H. CH₂)</p> <p>4. 68 (s. 2 H. OCH₂)</p> <p>8. 73 (s. 1 H. Pyrimidine ring)</p> <p>9. 29 (s. 1 H. Pyrimidine ring)</p> <p>[CDCl₃]</p>	n _D ²⁰ 1.4808

50

55

(Table 5-2) continued

Compound No.	Spectral data	Physical properties
5-6	¹ H-NMR δ (ppm) [solvent] : 0.95 (t, \underline{J} =7 Hz, 3H, CH ₂ CH ₂ CH ₃) 1.27 (t, \underline{J} =7 Hz, 3H, CH ₂ CH ₃) 0.75~1.95 (m, 2H, CH ₂ CH ₂ CH ₃) 2.33~2.97 (m, 2H, CH ₂ CH ₂ CH ₃) 4.20 (q, \underline{J} =7 Hz, 2H, CH ₂ CH ₃) 4.66 (s, 2H, OCH ₂) 8.69 (s, 1H, Pyrimidine ring) 9.25 (s, 1H, Pyrimidine ring) [CDCl ₃] n_D^{20.5} 1.4780	
5-7	¹ H-NMR δ (ppm) [solvent] : 1.29 (t, \underline{J} =7 Hz, 3H, CH ₂ CH ₃) 2.01~2.46 (m, 3H, =C-CH ₃) 4.23 (q, \underline{J} =7 Hz, 2H, CH ₂ CH ₃) 4.70 (s, 2H, OCH ₂) 8.76 (s, 1H, Pyrimidine ring) 9.30 (s, 1H, Pyrimidine ring) [CDCl ₃] n_D^{19.8} 1.4574	

(Table 5-2) continued

5

10

15

20

25

30

35

40

45

50

55

Compound No.	Spectral data	Physical properties
5-8	¹ H-NMR δ (ppm) [solvent] : 2.59 (s. 6H. N(CH ₃) ₂) 6.7-7.6 (m. 4H. Benzene ring) 8.72 (s. 1H. Pyrimidine ring) 9.23 (s. 1H. Pyrimidine ring) [CDCl ₃]	n _D ²⁰ 1.5732

Tables 1-3, 1-4, 2-3, 2-4, 3-3, 4-3 and 5-3 show the compounds of the present invention which can be synthesized in accordance with the above-mentioned Schemes for synthesis and Examples, including the compounds synthesized in the above Examples. However, it should be understood that the present invention is by no means restricted by such specific Examples.

(Table 1-3)

5

10

15

20

25

30









35

40

45

50

55



(Table 1-3) continued

5

10

15

20

25

30









35

40

45

50

55



(Table 1-3). continued

5

10

15

20

25

30









35

40

45

50

55



(Table 1-3) continued

5

10

15

20

25

30









35

40

45

50

55



(Table 1-3) continued

5

10

15

20

25

30









35

40

45

50

55



(Table 1-3) continued

5

10

15

20

25

30









35

40

45

50



55



(Table 1-3) continued



5

10





15

20





25

30



35

40



45



50

55

(Table 1-3) continued



5

10





15

20





25

30



35

40



45


50

55

(Table 1-3) continued


5

10




15

20




25

30



35





40



45

50


55




(Table 1-3) continued

5


10




15




20




25




30




35



40



45



50

55

(Table 1-3) continued

5

R 3

10

Cl, Br, I,

OMe, OEt, OPrⁿ, OPr^{iso}, OBuⁿ, OBu^{sec},OPr^{tert}, OBu^{iso}, OBu^{sec}, OBu^{tert}, OPnⁿ,

15

OPn^{sec}, OPn^{tert}, OPn^{iso}, OPn^{sec}, OHexⁿ, OHepⁿ,OOctⁿ, OHex^{sec}, OPh, O(4-Cl-Ph),

O-(3-Cl-Ph), O-(2-Cl-Ph), O-(4-F-Ph),

20

O-(3-F-Ph), O-(2-F-Ph), O-(4-Br-Ph),

O-(3-Br-Ph), O-(2-Br-Ph), O-(4-Me-Ph),

O-(3-Me-Ph), O-(2-Me-Ph), O-(4-MeO-Ph),

25

O-(3-MeO-Ph), O-(2-MeO-Ph),

O-(4-CF₃-Ph), O-(3-CF₃-Ph),O-(2-CF₃-Ph), O-THP

30

OCH₂Ph, OCH₂CH₂Ph, OCH(Me)CH₂Ph,OCH₂CH(Me)Ph, OCH(Me)Ph,

35

OCH₂-(4-Cl-Ph), OCH₂-(3-Cl-Ph),OCH₂-(2-Cl-Ph), OCH₂-(4-F-Ph),OCH₂-(3-F-Ph), OCH₂-(2-F-Ph),

40

OCH₂-(4-Me-Ph), OCH₂-(3-Me-Ph),OCH₂-(2-Me-Ph), OCH₂-(4-MeO-Ph),OCH₂-(3-MeO-Ph), OCH₂-(2-MeO-Ph),

45

OCH₂-(2,4-Cl₂-Ph), OCH₂-(3,4-Cl₂-Ph)OCH₂-(3,5-Cl₂-Ph), OCH₂-(2,6-Cl₂-Ph)OCH₂-(2,3-Cl₂-Ph), OCH₂Pr^{sec},

50

OCH₂CH=CH₂, OCH₂C≡CH, OCH(Me)C≡CH,

55

(Table 1-3) continued

5

R 3

10

 $\text{OCH}(\text{Me})\text{CH}=\text{CH}_2$, $\text{OC}(\text{Me})_2\text{C}\equiv\text{CH}$, $\text{OC}(\text{Me})_2\text{CH}=\text{CH}_2$, $\text{OCH}_2\text{CO}_2\text{Me}$, $\text{OCH}_2\text{CO}_2\text{Et}$,

15

 $\text{OCH}(\text{Me})\text{CO}_2\text{Me}$, $\text{OCH}(\text{Me})\text{CO}_2\text{Et}$, OCO_2Me , OCO_2Et , OCH_2OMe , OCH_2OEt , OCH_2SMe ,

20

 OCH_2SEt , $\text{OC}(\text{Me})_2\text{OMe}$, $\text{OC}(\text{Me})_2\text{Pr}$, $\text{OC}(\text{Me})_2\text{C}\equiv\text{N}$, $\text{OCH}_2\text{C}\equiv\text{N}$, $\text{OCH}(\text{Me})\text{C}\equiv\text{N}$, $\text{OC}(=\text{O})\text{N}(\text{Me})_2$, $\text{OC}(=\text{O})\text{NHMe}$, $\text{OC}(=\text{O})\text{NHEt}$,

25

 $\text{OC}(=\text{O})\text{NHPr}^n$, $\text{OC}(=\text{O})\text{NHPr}^{1''}$, $\text{OC}(=\text{O})\text{N}(\text{Et})_2$, $\text{OC}(=\text{O})\text{NHBu}^{1''}$,

30

 $\text{OC}(=\text{O})\text{N}(\text{Pr}^n)_2$, $\text{OC}(=\text{O})\text{N}(\text{Pr}^{1''})_2$, $\text{OC}(=\text{S})\text{NHMe}$, $\text{OC}(=\text{S})\text{NHEt}$, $\text{OC}(=\text{S})\text{NHPr}^n$, $\text{OC}(=\text{S})\text{NHPr}^{1''}$, $\text{OC}(=\text{S})\text{NHBu}^{1''}$,

35

 $\text{OC}(=\text{S})\text{N}(\text{Me})_2$, $\text{OC}(=\text{O})\text{Bu}^{1''}$, $\text{OC}(=\text{O})\text{Bu}^{1''}$, $\text{OC}(=\text{O})\text{Bu}^{1''}$, $\text{OC}(=\text{O})\text{Bu}^n$, $\text{OC}(=\text{O})\text{Pr}^{1''}$, $\text{OC}(=\text{O})\text{Pr}^n$, $\text{OC}(=\text{O})\text{Et}$, $\text{OC}(=\text{O})\text{Me}$,

40

 $\text{OC}(=\text{S})\text{N}(\text{Et})_2$, OSO_2Me , OSO_2Et , $\text{OSO}_2\text{N}(\text{Me})_2$, $\text{OSO}_2\text{N}(\text{Et})_2$,

45

 SH , SMe , SEt , SPr^n , $\text{SPr}^{1''}$, $\text{SBu}^{1''}$, SBu^n , $\text{SBu}^{1''}$, $\text{SBu}^{1''}$, SPh , SCH_2Ph , $\text{SCH}_2\text{CH}=\text{CH}_2$, $\text{SCH}_2\text{C}\equiv\text{CH}$, $\text{SCH}(\text{Me})\text{C}\equiv\text{CH}$,

50

 $\text{SCH}(\text{Me})\text{CH}=\text{CH}_2$, $\text{SC}(\text{Me})_2\text{C}\equiv\text{CH}$, $\text{SC}(\text{Me})_2\text{CH}=\text{CH}_2$, $\text{SCH}_2\text{CO}_2\text{Me}$, $\text{SCH}_2\text{CO}_2\text{Et}$,

55

(Table 1-3) continued

5

R 3

10

15

20

25

30

35

40

45

50

55

SCH (Me) CO₂ Me, SCH (Me) CO₂ Et, SCO₂ Me,
 SCO₂ Et, SCH₂ OMe, SCH₂ OEt, SCH₂ SMe,
 SCH₂ SEt, SC (Me)₂ OMe, SC (Me)₂ Pr,
 SC (Me)₂ C≡N, SCH₂ C≡N, SCH (Me) C≡N,
 SC (=O) N (Me)₂, SC (=O) N (Et)₂,
 SC (=O) NHMe, SC (=O) NHPrⁿ,
 SC (=O) NHPr^{iso}, SC (=O) NHBu^{tert},
 SC (=O) NHEt, SC (=S) N (Me)₂,
 SC (=S) N (Et)₂, SC (=O) Bu^{tert}, SC (=O) Pr^{iso},
 SC (=S) Bu^{tert}, SC (=S) Pr^{iso},
 NH₂, NHMe, NHEt, NHPr^{iso}, NHPrⁿ, NHBu^{tert},
 NHBu^{tert}, NHBu^{iso}, NHBuⁿ, NMe₂, NEt₂,
 N (Me) Et, N (OMe) Me, NHOMe, NHCH₂ CH₂ OH,
 NHCH₂ CH=CH₂, NHCH₂ C≡CH, NHC (Me)₂ C≡CH,
 NHC (Me)₂ CH=CH₂, NHCH (Me) C≡CH,
 NHCH (Me) CH=CH₂, NHC (Me)₂ CO₂ H,
 N (Me) CH₂ CO₂ Et, NHPnⁿ, NHPn^{cyclo},
 NHPr^{cyclo}, NHBu^{cyclo}, NHPn^{tert}, NHPn^{iso},
 NHPn^{tert}, NHHexⁿ, MHHeptⁿ, NHHex^{cyclo},
 NHOCtⁿ, NHPh, NHCH₂ Ph, NHCH₂ CH₂ Ph,
 NHC (Me)₂ Ph, N (Pr^{iso})₂, N (Prⁿ)₂,
 NHC (Me)₂ CO₂ Me, NHC (Me)₂ CO₂ Et,
 N (Me) CH₂ CO₂ Et, N (Me) CH₂ CO₂ Me,
 N (CH₂ C≡CH)₂, N (CH₂ CH=CH₂)₂.

(Table 1-3) continued

5

R 3

10

NHCH₂ - (4-Cl-Ph), NHCH₂ - (3-Cl-Ph),NHCH₂ - (2-Cl-Ph), NHCH₂ - (4-F-Ph),NHCH₂ - (3-F-Ph), NHCH₂ - (2-F-Ph),

15

NHCH₂ - (4-Me-Ph), NHCH₂ - (3-Me-Ph),NHCH₂ - (2-Me-Ph), NHCH₂ - (4-MeO-Ph),NHCH₂ - (3-MeO-Ph), NHCH₂ - (2-MeO-Ph),

20

N (Me) CH₂ Ph, N (CHO) CH₂ Ph, N (CHO) Ph,NHSO₂ Me, NHSO₂ Et, NHSO₂ N (Me),NHSO₂ N (Et), NHC (Me)₂ C≡N,

25

NHC (=O) Me, NHC (=O) Et, NHC (=O) Prⁿ,NHC (=O) Prⁱ, NHC (=O) Buⁱ,NHC (=O) N (Me)₂, NHC (=O) N (Et)₂,

30

NHC (=O) NHMe, NHC (=O) NHEt,

NHC (=O) NHPrⁱ, NHC (=O) NHPrⁿ,NHC (=O) NHBuⁱ, NHC (=S) NHMe,

35

NHC (=S) NHEt, NHC (=S) NHPrⁿ,NHC (=S) NHPrⁱ, NHC (=S) NHBuⁱ,NHC (=S) N (Me)₂, NHC (=S) N (Et)₂,

40

NHN (Me)₂, NHNHBuⁱ, NHCH₂ C≡N,NHCH (Me) C≡N, N (Me) Buⁱ, N (Et) Buⁱ,N (Me) Prⁱ, N (Et) Prⁱ,

45

1-imidazolyl, 1,2,4-triazol-1-yl, morpholino,

2,6-dimethylmorpholino, piperazino, piperidino, pyrrolidinyl,

50



aziridinyl

55

(Table 1-4)



5

10





15

20



25



30



35

40

45




50

55

(Table 1-4) continued


5

10




15

20



25


30



35





40

45









50

55



(Table 1-4) continued



R 3

R 4

-OCH₂CH₂O--OCH₂CH₂CH₂O--OCH₂CH(Me)O--OCH₂CH(Et)O--OCH₂CH(Prⁿ)O--OCH₂CH(Prⁱ)O--OCH₂CH(Buⁿ)O--OCH₂C(=CH₂)CH₂O--OCH₂CH(CH₂Br)O--OCH₂CBr₂CH₂O--OCH₂CH(Hexⁿ)O--OCH₂CH(CH₂OCH₃)O--OCH₂CH(CH₂CH=CH₂)O-

(Table 2-3)

5

10

15

20

25

30









35

40

45

50

55



(Table 2-3) continued

5

10

15

20

25

30











35

40

45

50

55



(Table 2-3) continued

5

10

15

20

25

30









35

40

45


50

55




(Table 2-3) continued


5




10




15




20




25




30



35



40



45

50

55

EP 0 764 641 A1

(Table 2-3) continued

5

R 8

10

H

Me

Et

15

Prⁿ

Pr^{iso}

Buⁿ

20

Bu^{sec}

Bu^{iso}

Bu^{tert}

25

Pnⁿ

Pn^{sec}

Hexⁿ

30

n-C₁₀H₂₁

n-C₁₄H₂₉

35

n-C₁₂H₂₅

n-C₈H₁₇

n-C₉H₁₉

40

n-C₁₆H₃₃

Ph

2-NO₂-Ph

45

CH₂CH₂CH=CH₂

CH₂CH₂CH₂CH₂CH=CH₂

50

CH₂F

CH₂Cl

55

EP 0 764 641 A1

(Table 2-3) continued

5

R 8

10

$\text{CH}_2 \text{ Br}$

$n\text{-C}_8\text{F}_{17}\text{-CH}_2\text{CH}_2$

$n\text{-C}_8\text{F}_{17}$

15

$\text{CH}_2 \text{ O Ph}$

$\text{CH}_2 \text{ O} - (2\text{-Me-Ph})$

$\text{CH}_2 \text{ O} - (n\text{-C}_{12}\text{H}_{25})$

20

$\text{CH}_2 \text{ OC}_2\text{H}_5$

$\text{CH}_2 \text{ OCH}_2 \text{ Ph}$

$\text{CH}_2 \text{ O} - (2\text{-MeO-Ph})$

25

$\text{CH}_2 \text{ O} - (3\text{-MeO-Ph})$

$\text{CH}_2 \text{ OCH}_2 - (2\text{-MeO-Ph})$

$\text{CH}_2 \text{ OCH}_2 - (2\text{-Me-Ph})$

30

$\text{CH}_2 \text{ O} - (2\text{-Et-Ph})$

$\text{CH}_2 \text{ O} - (2\text{-F-Ph})$

35

$\text{CH}_2 \text{ O} - (4\text{-F-Ph})$

$\text{CH}_2 \text{ O} - (2\text{-Cl-6-Me-Ph})$

$\text{CH}_2 \text{ O} - (n\text{-C}_{16}\text{H}_{33})$

40

$\text{CH}_2 \text{ O} - (4\text{-MeO-Ph})$

$\text{CH}_2 \text{ O} - (n\text{-C}_{10}\text{H}_{21})$

$\text{CH}_2 \text{ O} - (n\text{-C}_{12}\text{H}_{25})$

45

$\text{CH}_2 \text{ O} - (4\text{-NO}_2\text{-Ph})$

$\text{CH}_2 \text{ O} - (n\text{-C}_{12}\text{H}_{25})$

50

$\text{CH}_2 \text{ O} - \text{Bu}^{\text{tert}}$

$\text{CH}_2 \text{ O} - (2, 4, 6\text{-tri-Me-Ph})$

55




EP 0 764 641 A1

(Table 2-3) continued




5

R 8




10






15






20





25





30





35




40



45



50



55

EP 0 764 641 A1

(Table 2-3) continued

5

R 8

10

$\text{CH}_2 \text{ N (Me) CH}_2 \text{ Ph}$

$\text{CH}_2 \text{ NEt}_2$

$\text{CH}_2 - (4 - \text{morpholino})$

15

$\text{CH}_2 - (1 - \text{piperizino})$

$\text{CH}_2 \text{ N (Pr}^{iso})_2$

$\text{CH}_2 \text{ N (Pr}^n)_2$

20

$\text{CH}_2 - (1 - \text{piperazino})$

$\text{CH}_2 \text{ NH-Me}$

$\text{CH}_2 \text{ NH} - (2 - \text{NO}_2 - \text{phenyl})$

25

$\text{CH}_2 \text{ NHCH}_2 \text{ Ph}$

$\text{CH}_2 \text{ NH-Bu}^n$

$\text{CH}_2 \text{ NH-He}^{cyclo}$

30

$\text{CH}_2 \text{ N (Bu}^n)_2$

$\text{CH}_2 \text{ NH (n-C}_{12}\text{H}_{25})$

35

$\text{CH}_2 \text{ NH-Et}$

$\text{CH}_2 \text{ NH-Ph}$

$\text{CH}_2 \text{ NH-Pr}^{iso}$

40

$\text{CH}_2 \text{ NH}_2$

$\text{CH}_2 \text{ NHCH}_2 - (2 - \text{Cl-Ph})$

$\text{CH}_2 \text{ NHCH}_2 - (3 - \text{Cl-Ph})$

45

$\text{CH}_2 \text{ NHCH}_2 - (4 - \text{Cl-Ph})$

$\text{CH}_2 \text{ NHCH (Me) Ph}$

$\text{CH}_2 \text{ NHC (Me) : Ph}$

50

$\text{CH}_2 \text{ SMe}$

55

EP 0 764 641 A1

(Table 2-3) Continued

5

R 8

10

CH₂ SEt

CH₂ SPh

CH₂ SBuⁿ

15

CH₂ SPr^{iso}

CH₂ SPrⁿ

CH₂ SH

20

CH₂ CH₂ Ph

CH₂ S- (4-Cl-Ph)

CH₂ OCOCH₃

25

CH₂ OCOPrⁿ

CH₂ OCO- (n-C₁₇H₃₅)

CH₂ OCO- (n-C₁₉H₃₉)

30

CH₂ OCO- (n-C₁₅H₃₁)

CH₂ OCO- (n-C₁₃H₂₇)

35

CH₂ OCO- (n-C₉H₁₉)

CH₂ OCO- (n-C₈H₁₈)

CH₂ OCO- (n-C₇H₁₅)

40

CH₂ OCO- (n-C₁₂H₂₅)

CH₂ OCOC (=CH₂) CH₃

CH₂ OCOCH=CH₂

45

CH₂ OCOEt

CH₂ OCO (n-C₁₄H₂₉)

50

CH₂ OCOPr^{iso}

CH₂ OCOBu^{tert}

55

(Table 2-3) continued

5

R 8

10

CH₂ OCOPh



2-piperidyl

2-pyridyl


15

2-pyridylmethyl


20




25




30





35





40



45



50



55

(Table 2-4)

5

10

15

20

25

30






35

40

45

50

55




R 9


Me, Et, Prⁿ, Pr^{iso}, Buⁿ, Bu^{sec}, Bu^{neo}, Bu^{tert}
 Pnⁿ, Pn^{neo}, Hexⁿ, Hepⁿ, Octⁿ, Pr^{cyclo}, Bu^{cyclo}

(Table 3-3)


5




10




15




20



25




30




35

40



45





50

55



(Table 3-3) continued

5





10

15



20



25



30

35

40




45

50


55

(Table 3-3) continued


5




10




15




20




25




35



40



45



50

55

EP 0 764 641 A1

(Table 3-3) continued

5

R 7

10

NHCH₂ Ph

N (Me) CH₂ Ph

N (Et) CH₂ Ph

15

NHCH₂ - 2 - Cl - Phenyl

NHCH₂ - 3 - Cl - Phenyl

NHCH₂ - 4 - Cl - Phenyl

20

NHCH₂ - 2 - F - Phenyl

NHCH₂ - 3 - F - Phenyl

NHCH₂ - 4 - F - Phenyl

25

NHCH₂ - 2, 4 - Cl₂ - Phenyl

NHCH₂ - 2, 3 - Cl₂ - Phenyl

NHCH₂ - 2, 5 - Cl₂ - Phenyl

30

NHCH₂ - 2, 6 - Cl₂ - Phenyl

NHCH₂ - 3, 4 - Cl₂ - Phenyl

NHCH₂ - 3, 5 - Cl₂ - Phenyl

35

NHCH₂ CH₂ Ph

NHCH₂ CH₂ - 2 - Cl - Phenyl

40

NHCH₂ CH₂ - 3 - Cl - Phenyl

NHCH₂ CH₂ - 4 - Cl - Phenyl

NHCH₂ CH₂ - 2 - F - Phenyl

45

NHCH₂ CH₂ - 3 - F - Phenyl

NHCH₂ CH₂ - 4 - F - Phenyl

NHCH₂ CH₂ CH₂ Ph

50

NHCH₂ CH₂ CH₂ CH₂ Ph

55

(Table 3-3) continued

5

R 7

10

NHCH (Me) Ph

NHC (Me) : Ph

NHC (Me) : C \equiv CH

15

NHCH₂ C \equiv CHNHCH₂ CH=CH₂NHCH (Me) C \equiv CH

20

morphorino

2, 6-dimethylmorphorino

thiomorphorino

25

piperidino

2, 6-dimethylpiperidino

3, 5-dimethylpiperidino

30

3, 3-dimethylpiperidino

aziridyl

2, 2-dimethylaziridyl

35

pyrrolyl

pyrrolydyl

40

4-methylpiperidyl

2-ethylpiperidyl

4-methylpiperadyl

45

4-phenylpiperadyl

heptamethyleneimino

hexamethyleneimino

50

imidazole-1-yl

55

(Table 3-3) continued

5

R 7

10

pyrazole-1-yl

1, 2, 4-triazole-1-yl

4-phenylpiperidyl

15

4-benzylpiperidyl

4-dimethylaminopiperidyl

perhydroquinolyl

20

1, 2, 3, 4-tetrahydroquinoline-1-yl

1, 2, 3, 4-tetrahydro-2-methylquinoline-1-yl

1, 2, 3, 4-tetrahydro-2, 2-dimethylquinoline-1-yl

25

4-trifluoromethylpiperidyl

1, 2-dihydro-2, 2-dimethylquinoline-1-yl

1, 2-dihydro-2, 2-dimethyl-6-chloroquinoline-1-yl

30

N (Me) CH₂-2-Cl-PhenylN (Me) CH₂-3-Cl-PhenylN (Me) CH₂-4-Cl-Phenyl

35

N (Me) CH₂ CH₂ Ph

N (Me) CH (Me) Ph

40

N (Me) C (Me)₂ PhN (Me) CH₂ CH₂ CH₂ PhNHCH (Ph)₂

45

NHCH₂- (2-thienyl)NH₂, NHMe, NHMe · HCl, NHEt,NMe₂, NHPrⁿ, NHPr^{iso},

50

N (Me) Et, N (Et)₂, NHBu^{tert},

55

(Table 3-3) continued

5

R 7

10

NHPr^{iso}, N (Me) CH₂ CO₂ Et,NHCH₂ CH₂ OH,

15

NHPr^{cyclo}, NHPn^{cyclo},NHHex^{cyclo},

20

N (CHO) CH₂ Ph, N (CHO) Bu^{tert},

N (CHO) Me,

N (CHO) Et

25

N (CHO) CH₂ - 2 - Cl - PhenylN (CHO) CH₂ - 3 - Cl - Phenyl

30

N (CHO) CH₂ - 4 - Cl - Phenyl

NH - 4 - Cl - Phenyl

NHPh

35

NHCH₂ - 4 - Me - PhenylNHCH₂ - 4 - Br - Phenyl

40

NHCH₂ - 4 - CF₃ - PhenylNHCH₂ - 4 - MeO - Phenyl

45

NHCH₂ - 2 - F - 4 - Cl - PhenylNHCH₂ - 3 - F - 4 - Cl - PhenylNHCH₂ C≡N

50

NHC (Me)₂ C≡N

55

(Table 4-3)

5

10

15

20

25

30









35

40

45

50

55



(Table 4-3) continued

5

10

15

20

25

30









35

40

45

50

55



(Table 4-3) continued

5

10

15

20

25

30









35

40

45

50



55



(Table 4-3) continued



5

10





15

20





25

30



35

40



45

50

55

(Table 4-3) continued

5

R 6

10

15

20

25

30

35

40

45

50

55

Me, Et, Prⁿ, Pr^{iso}, Buⁿ, Bu^{iso}, Bu^{sec}, Bu^{tert},
 Pnⁿ, Pn^{sec}, Pn^{iso}, Hexⁿ, Pr^{cyclo}, Pn^{cyclo},
 Hex^{cyclo}, CH₂CH=CH₂, CH(Me)CH=CH₂,
 C(Me)₂CH=CH₂, CH₂C≡CH, CH(Me)C≡CH,
 C(Me)₂C≡CH, CH₂CF₃, CH(Me)CF₃,
 CH₂C(Cl)=CH₂, Ph, 2-Cl-Phenyl,
 3-Cl-Phenyl, 4-Cl-Phenyl, 2-F-Phenyl,
 3-F-Phenyl, 4-F-Phenyl, 2-Me-Phenyl,
 3-Me-Phenyl, 4-Me-Phenyl, 2-MeO-Phenyl,
 3-MeO-Phenyl, 4-MeO-Phenyl,
 2,3-Cl₂-Phenyl, 2,4-Cl₂-Phenyl,
 2,5-Cl₂-Phenyl, 2,6-Cl₂-Phenyl,
 3,4-Cl₂-Phenyl, 3,5-Cl₂-Phenyl, CH₂Ph,
 CH₂CH₂Ph, COCH₂Ph, 2-Cl-Benzyl,
 3-Cl-Benzyl, 4-Cl-Benzyl, 2-F-Benzyl,
 3-F-Benzyl, 4-F-Benzyl, 2-Me-Benzyl,
 3-Me-Benzyl, 4-Me-Benzyl, 2-MeO-Benzyl,
 3-MeO-Benzyl, 4-MeO-Benzyl, COMe, COEt,
 COPrⁿ, COPr^{iso}, COPr^{cyclo}, COBuⁿ, COBu^{sec},
 COBu^{iso}, COBu^{tert}, CPh, CO-(2-Cl-Phenyl),
 CO-(3-Cl-Phenyl), CO-(4-Cl-Phenyl),
 CO-(2-F-Phenyl), CO-(3-F-Phenyl),
 CO-(4-F-Phenyl), CO-(2-Me-Phenyl),
 CO-(3-Me-Phenyl), CO-(4-Me-Phenyl).

(Table 4-3) continued

R 6

CO- (2-MeO-Phenyl), CO- (3-MeO-Phenyl),
 CO- (4-MeO-Phenyl), SO₂ Me, SO₂ Et, SO₂ Prⁿ,
 SO₂ Prⁱ, SO₂ Ph, SO₂ - (2-Cl-Phenyl),
 SO₂ - (3-Cl-Phenyl), SO₂ - (4-Cl-Phenyl),
 SO₂ - (2-F-Phenyl), SO₂ - (3-F-Phenyl),
 SO₂ - (4-F-Phenyl), SO₂ - (2-Me-Phenyl),
 SO₂ - (3-Me-Phenyl), SO₂ - (4-Me-Phenyl),
 SO₂ - (2-MeO-Phenyl),
 SO₂ - (3-MeO-Phenyl),
 SO₂ - (4-MeO-Phenyl), CH₂ OMe, CH₂ SMe,
 CH₂ OBu^t, CH₂ SBu^t,
 Tetrahydropyrane-2-yl,
 Tetrahydrothiopyrane-2-yl,
 Tetrahydrofuranyl,
 Tetrahydrothiofuranyl,
 1, 4-dioxane-2-yl,
 3-Bromotetrahydropyrane-2-yl,
 1-Methoxycyclohexyl, Benzyloxymethyl,
 4-Methoxytetrahydropyranyl,
 1-Ethoxyethyl,
 4-Methoxytetrahydrothiopyranyl,
 2, 2, 2-Trichloroethoxymethyl,
 1-Methyl-1-methoxyethyl,
 Bis (2-Chloroethoxy) methyl.

(Table 4-3) continued

R 6

1 - (2-Chloroethoxy) ethyl,
2-Methoxyethoxymethyl,
1-Methyl-1-benzyloxyethyl,
tert-Butyldimethylsilyl,
Trimethylsilyl, Triethylsilyl
C (Me) , OMe, C (Me) , Prⁿ , C (Me) , Et,
C (=O) N (Me) , , C (=O) NHEt, C (=S) NHPr^{iso} ,
CO₂ Et, CH₂ CO₂ Et, C (=O) NHBu^{tert} ,
C (=O) NEt, , CH₂ CN

(Table 5-3)

5

10

15

20

25

30











35

40

45

50


55



(Table 5-3) continued


5

10




15

20




25

30




35

40








45

50





55



(Table 5-3) continued



5

10





15

20





25

30




35

40



45

50



55

(Table 5-3) continued

5

R 5

10

OMe, OEt, OPrⁿ, OPr^{iso}, OBuⁿ, OBu^{iso},
 OBu^{tert}, OBu^{tert}, OPr^{cyclo}, OBu^{cyclo}, OCH₂ Ph,
 OPh, OCH₂ CO₂ Me, OCH₂ CO₂ Et, OCH₂ CO₂ H,
 OCH (Me) CO₂ Me, OCH (Me) CO₂ Et,
 OCH₂ - (4-Cl-Ph), OCH₂ - (3-Cl-Ph),
 OCH₂ - (2-Cl-Ph), OH, OCH₂ C≡CH,
 OCH₂ CH=CH₂,

20

25

NHMe, N (Me)₂, NEt, NHPⁿ, NHP^{iso},
 NHBu^{tert}, NHPh, NHCH₂ Ph,
 NHCH₂ - (4-Cl-Ph), NHCH₂ - (3-Cl-Ph),
 NHCH₂ - (2-Cl-Ph), NH - (4-Cl-Ph),
 NH - (3-Cl-Ph), NH - (2-Cl-Ph),
 NH - (4-CF₃ - Ph), NH - (3-CF₃ - Ph),
 NH - (2-CF₃ - Ph), NH - (4-Me-Ph),
 NH - (3-Me-Ph), NH - (2-Me-Ph),
 NH - (4-MeO-Ph), NH - (3-MeO-Ph),
 NH - (2-MeO-Ph), NH - (4-F-Ph),
 NH - (3-F-Ph), NH - (2-F-Ph),
 OCH₂ - (4-Me-Ph), OCH₂ - (3-Me-Ph),
 OCH₂ - (2-Me-Ph), OCH₂ - (4-F-Ph),
 OCH₂ - (3-F-Ph), OCH₂ - (2-F-Ph),
 OCH₂ - (4-MeO-Ph), OCH₂ - (3-MeO-Ph),
 OCH₂ - (2-MeO-Ph)

30

35

40

45

50

55

The symbols in Tables indicated in the present application have the following meanings.

Ph, phenyl: C₆H₅, provided that 2,4-Cl₂-Ph or 2,4-Cl₂-phenyl means 2,4-Cl₂-C₆H₃.

Me : CH₃
 Et : C₂H₅
 Pr, Prⁿ : CH₂CH₂CH₃
 Pr^{iso} : CH(CH₃)₂
 5 Pr^{cyclo} : CH(CH₂)₂
 Bu, Buⁿ : CH₂CH₂CH₂CH₃
 Bu^{iso} : CH₂CH(CH₃)₂
 Bu^{sec} : CH(CH₃)CH₂CH₃
 Bu^{tert} : C(CH₃)₃
 10 Bu^{cyclo} : CH(CH₂)₃
 Pn, Pnⁿ : CH₂CH₂CH₂CH₂CH₃
 Pn^{iso} : CH₂CH₂CH(CH₃)₂
 Pn^{neo} : CH₂C(CH₃)₃
 Pn^{cyclo} : CH(CH₂)₄
 15 Pn^{tert} : C(CH₃)₂CH₂CH₃
 Hex, Hexⁿ : CH₂(CH₂)₄CH₃
 Hex^{cyclo} : CH(CH₂)₅
 Hep, Hepⁿ : CH₂(CH₂)₅CH₃
 Oct, Octⁿ : CH₂(CH₂)₆CH₃
 20 THP : Tetrahydropyranyl
 φ : Aromatic ring

When the compound of the present invention is used as a herbicide, it is usually mixed with a suitable carrier, for instance, a solid carrier such as clay, talc, bentonite, diatomaceous earth or white carbon, or a liquid carrier such as water, an alcohol (such as isopropanol, butanol, benzyl alcohol or furfuryl alcohol), an aromatic hydrocarbon (such as toluene or xylene), an ether (such as anisole), a ketone (such as cyclohexanone or isophorone), an ester (such as butyl acetate), an acid amide (such as N-methylpyrrolidone) or a halogenated hydrocarbon (such as chlorobenzene). If desired, a surfactant, an emulsifier, a dispersing agent, a penetrating agent, a spreader, a thickener, an antifreezing agent, an anticaking agent, or a stabilizer may be added to prepare an optional formulation such as a liquid formulation, an emulsifiable concentrate, a wettable powder, a dry flowable, a flowable, a dust or a granule.

Further, the compound of the present invention may be combined with other herbicides, various insecticides, miticides, nematocides, fungicides, plant growth regulators, synergists, fertilizers, antidotes, or soil conditioning materials at the time of the preparation of the formulations or at the time of the application, as the case requires.

Particularly, combined use of the compound of the present invention with another agricultural chemical can be expected to result in lower cost attributable to reduction in the dose, a broader spectrum and a higher herbicidal effect attributable to synergistic action of the combined chemicals. In such a case, the compound of the present invention can be combined with plural known agricultural chemicals simultaneously. The agricultural chemicals which may be used in combination with the compound of the present invention, may, for example, be compounds disclosed in Farm Chemicals Handbook (1994).

The dose of the compound of the present invention varies depending upon the application site, the season for application, the manner of application, the type of crop plants and the like. However, it is usually within a range of from 0.00001 to 10 kg, preferably from 0.0001 to 5 kg per hectare (ha) as the amount of the active ingredient.

Now, examples of formulations of the compounds of the present invention will be given. However, it should be understood that the present invention is by no means restricted to such specific examples. In the following Formulation Examples, "parts" means parts by weight.

Wettable powder

50

55

Compound of the present invention	0.1 - 80 parts
Solid carrier	10 - 90 parts
Surfactant	1 - 10 parts
Others	1 - 5 parts

EP 0 764 641 A1

As the others, for example, an anticaking agent may be mentioned.

Emulsifiable Concentrate

5

10

Compound of the present invention	0.1 - 30 parts
Liquid carrier	30 - 95 parts
Surfactant	5 - 15 parts

15

Flowable

20

25

Compound of the present invention	0.1 - 70 parts
Liquid carrier	15 - 65 parts
Surfactant	5 - 12 parts
Others	5 - 30 parts

As the others, for example, an antifreezing agent and a thickner may be mentioned.

30

Granular wettable powder (dry flowable)

35

40

Compound of the present invention	0.1 - 90 parts
Solid carrier	10 - 70 parts
Surfactant	1 - 20 parts

Granule

45

50

Compound of the present invention	0.0001 - 10 parts
Solid carrier	90-99.9999 parts
Others	0.1 - 10 parts

55

EP 0 764 641 A1

Formulation Example 1 Wettable powder

5

Compound No. 1-9 of the present invention	50 parts
Zeekite PFP (tradename for a kaolin-type clay, manufactured by Zeekite Industries, Co., Ltd.)	43 parts
Sorpol 5050 (tradename for an anionic surfactant, manufactured by Toho Chemical Industry Co., Ltd.)	2 parts
Lunox 1000C (tradename for an anionic surfactant, manufactured by Toho Chemical Industry Co., Ltd.)	3 parts
Carplex #80 (anticaking agent)(tradename for a white carbon, manufactured by Shionogi Pharmaceutical Co., Ltd.)	2 parts

15

The above ingredients are homogeneously pulverized and mixed to form a wettable powder.

Formulation Example 2 Wettable powder

20

25

Compound No. 1-15 of the present invention	50 parts
Zeekite PFP (tradename for a kaolin-type clay, manufactured by Zeekite Industries, Co., Ltd.)	43 parts
Sorpol 5050 (tradename for an anionic surfactant, manufactured by Toho Chemical Industry Co., Ltd.)	2 parts
Lunox 1000C (tradename for an anionic surfactant, manufactured by Toho Chemical Industry Co., Ltd.)	3 parts
Carplex #80 (anticaking agent)(tradename for a white carbon, manufactured by Shionogi Pharmaceutical Co., Ltd.)	2 parts

30

35

The above ingredients are homogeneously pulverized and mixed to form a wettable powder.

Formulation Example 3 Emulsifiable concentrate

40

45

Compound No. 1-35 of the present invention	3 parts
Xylene	76 parts
Isophorone	15 parts
Sorpol 3005X (tradename for a mixture of a nonionic surfactant and an anionic surfactant, manufactured by Toho Chemical Industry Co., Ltd.)	6 parts

50

The above ingredients are homogeneously mixed to form an emulsifiable concentrate.

55

EP 0 764 641 A1

Formulation Example 4 Emulsifiable concentrate

5

10

Compound No. 1-68 of the present invention	3 parts
Xylene	76 parts
Isophorone	15 parts
Sorpol 3005X (tradename for a mixture of a nonionic surfactant and an anionic surfactant, manufactured by Toho Chemical Industry Co., Ltd.)	6 parts

15

The above ingredients are homogeneously mixed to form an emulsifiable concentrate.

Formulation Example 5 Flowable

20

25

30

Compound No. 2-8 of the present invention	35 parts
Agrizole S-711 (tradename for a nonionic surfactant, manufactured by Kao Corporation)	8 parts
Lunox 1000C (tradename for an anionic surfactant, manufactured by Toho Chemical Industry Co., Ltd.)	0.5 part
1% Rodopol water (tradename for a thickner, manufactured by Rhone-Poulenc)	20 parts
Ethylene glycol (antifreezing agent)	8 parts
Water	28.5 parts

The above ingredients are homogeneously mixed to obtain a flowable.

35

Formulation Example 6 Flowable

40

45

Compound No. 3-2 of the present invention	35 parts
Agrizole S-711 (tradename for a nonionic surfactant, manufactured by Kao Corporation)	8 parts
Lunox 1000C (tradename for an anionic surfactant, manufactured by Toho Chemical Industry Co., Ltd.)	0.5 part
1% Rodopol water (tradename for a thickner, manufactured by Rhone-Poulenc)	20 parts
Ethylene glycol (antifreezing agent)	8 parts
Water	28.5 parts

50

The above ingredients are homogeneously mixed to obtain a flowable.

55

EP 0 764 641 A1

Formulation Example 7 Granular wettable powder (dry flowable)

5

10

Compound No. 3-8 of the present invention	75 parts
Isoban No. 1 (tradename for an anionic surfactant, manufactured by Kuraray Isoprene Chemical Co., Ltd.)	10 parts
Vanilex N (tradename for an anionic surfactant, manufactured by Sanyo-Kokusaku Pulp Co., Ltd.)	5 parts
Carplex #80 (tradename for a white carbon, manufactured by Shionogi Pharmaceutical Co., Ltd.)	10 parts

15

The above ingredients were homogeneously pulverized and mixed to form a dry flowable.

Formulation Example 8 Granular wettable powder (dry flowable)

20

25

Compound No. 4-1 of the present invention	75 parts
Isoban No. 1 (tradename for an anionic surfactant, manufactured by Kuraray Isoprene Chemical Co., Ltd.)	10 parts
Vanilex N (tradename for an anionic surfactant, manufactured by Sanyo-Kokusaku Pulp Co., Ltd.)	5 parts
Carplex #80 (tradename for a white carbon, manufactured by Shionogi Pharmaceutical Co., Ltd.)	10 parts

30

The above ingredients were homogeneously pulverized and mixed to form a dry flowable.

Formulation Example 9 Granule

35

40

45

Compound No. 4-15 of the present invention	0.1 part
Bentonite	50.0 parts
Talc	44.9 parts
Toxanone GR-31A (tradename for an anionic surfactant, manufactured by Sanyo Chemical Industries LTD.)	5 parts

50

The above ingredients are homogeneously mixed and pulverized. A small amount of water was added, and the mixture was stirred, mixed and kneaded, and then granulated by an extrusion-type granulating machine, followed by drying to obtain a granule.

55

EP 0 764 641 A1

Formulation Example 10 Granule

5

10

Compound No. 4-16 of the present invention	0.1 part
Bentonite	50.0 parts
Talc	44.9 parts
Toxanone GR-31A (tradename for an anionic surfactant, manufactured by Sanyo Chemical Industries LTD.)	5 parts

15

The above ingredients are homogeneously mixed and pulverized. A small amount of water was added, and the mixture was stirred, mixed and kneaded, and then granulated by an extrusion-type granulating machine, followed by drying to obtain a granule.

20

The above wettable powders, emulsifiable concentrates, flowables and granular wettable powders are diluted with water from 50 to 1,000 times before application, and are applied at a dose of from 0.00001 to 10 kg per hectare (ha) as the amount of the active ingredient.

Now, the usefulness of the compounds of the present invention as herbicides will be described in detail with reference to the following Test Examples.

25

Test Example 1 Test on the herbicidal effects in preemergence treatment on weeds under submerged conditions

30

Wagner pots of 1/5000 are filled with alluvial soil, and water was admixed to form a submerged state with a water depth of 4 cm. Seeds of barnyardgrass, bulrush, ducksalad and toothcup, and tubers of japanese ribbon wapato and perennial flat sedge were planted in the pots, respectively. Then, rice seedlings of 2 leaf stage were transplanted in the pots. The pots were placed in a greenhouse at a temperature of from 25 to 30°C, to culture the plants. A day after the planting, compounds of the present invention formulated in accordance with Formulation Examples were applied to the water surfaces at predetermined doses. Three weeks after the application, the herbicidal effects against various weeds and the influences on rice were determined on the basis of the 5-rank grading such that 0 means no effect, and 5 means complete death. The results are shown in Tables 1-5, 2-5, 3-4, 4-4 and 5-4.

35

Each No. indicated in these tables corresponds to the compound No. in Examples. The symbols have the following meanings.

A: barnyardgrass, B: bulrush, C: ducksalad, D: toothcup, E: japanese ribbon wapato, F: perennial flat sedge, a: rice

40

Test Example 2 Test on the herbicidal effects in post-emergence treatment on weeds under submerged conditions

45

Wagner pots of 1/5000 are filled with alluvial soil, and water was admixed to form a submerged state with a water depth of 4 cm. In each of the above pots, seeds of barnyardgrass, bulrush, ducksalad and toothcup were sown. The pots were placed in a greenhouse at a temperature of from 25 to 30°C to culture the plants. 14 days after the seeding, the compound of the present invention formulated in accordance with Formulation Examples were applied to the water surfaces at predetermined doses. Three weeks after the application, the herbicidal effect against various weeds were determined on the basis of the 5-rank grading such that 0 indicates no effect, and 5 indicates complete death. The results are shown in Tables 1-6, 2-6, 3-5, 4-5 and 5-5.

Each No. indicated in these tables corresponds to the compound No. in Examples. The symbols have the following meanings.

A: barnyardgrass, B: bulrush, C: ducksalad, D: toothcup

50

Test Example 3 Test on the herbicidal effects in soil treatment

55

Plastic boxes having a length of 33 cm, a width of 33 cm and a depth of 8 cm were filled with diluvial soil, and seeds of barnyardgrass, green foxtail, wild oat, blackgrass, velvetleaf, common cocklebur, redroot pigweed, morningglory, persian speedwell, common chickweed, rice, corn, wheat, soybean, cotton and sugar beet were sown and covered with soil in a thickness of about 1.5 cm, and then the compounds of the present invention formulated in accordance with Formulation Examples were applied onto the surfaces of the soil uniformly at predetermined doses. Four weeks after the application, the herbicidal effects against each weed and the influences on each crop plant were determined on the basis of the 5-rank grading such that 0 indicates no effect, and 5 indicates complete death. The results are shown in

EP 0 764 641 A1

Tables 1-7, 2-7, 3-6, 4-6 and 5-6.

Each No. indicated in these tables corresponds to the compound No. in Examples. The symbols have the following meanings.

5 G: barnyardgrass, H: green foxtail, I: wild oat, J: blackgrass, K: velvetleaf, L: common cocklebur, M: redroot pigweed, N: morningglory, O: persian speedwell, P: common chickweed, a: rice, b: corn, c: wheat, d: soybean, e: cotton, f: sugar beet

Test Example 4 Test on the herbicidal effects in foliage treatment

10 A plastic boxes having a length of 33 cm, a width of 33 cm and a depth of 8 cm were filled with a sterilized diluvial soil, and seeds of barnyardgrass, green foxtail, wild oat, blackgrass, velvetleaf, common cocklebur, redroot pigweed, morningglory, persian speedwell, common chickweed, rice, corn, wheat, soybean, cotton and sugar beet were sown, and covered with soil in a thickness of about 1.5 cm. And the boxes were placed in a greenhouse at a temperature of
15 from 25 to 30°C for 14 days to culture the plants, and the compounds of the present invention formulated in accordance with Formulation Examples were applied to the foliages uniformly at predetermined doses. Four weeks after the application, the herbicidal effects against each weed and the influences on each crop plant were determined on the basis of the 5-rank grading such that 0 indicates no effect, and 5 indicates complete death. The results are shown in Tables 1-8, 2-8, 3-7, 4-7 and 5-7.

20 Each No. indicated in these tables corresponds to the compound No. in Examples. The symbols have the following meanings.

G: barnyardgrass, H: green foxtail, I: wild oat, J: blackgrass, K: velvetleaf, L: common cocklebur, M: redroot pigweed, N: morningglory, O: persian speedwell, P: common chickweed, a: rice, b: corn, c: wheat, d: soybean, e: cotton, f: sugar beet

25

30

35

40

45

50

55

EP 0 764 641 A1

(Table 1-5)

	No.	Dose(g/a)	A	B	C	D	E	F	a
5									
10	1-1	10	5	5	5	5	0	3	0
	1-2	10	5	5	5	5	2	3	0
	1-3	10	5	5	5	5	0	2	0
15	1-4	10	5	5	5	5	0	2	0
	1-5	10	5	5	5	5	0	3	0
	1-6	10	2	0	2	0	2	0	0
20	1-7	10	5	5	5	5	0	0	0
	1-8	10	0	0	0	2	0	0	0
	1-9	10	5	5	5	5	0	0	0
25	1-10	2.5	2	0	—	—	0	0	0
	1-12	2.5	5	0	5	5	0	0	0
	1-14	10	5	5	5	5	2	5	0
30	1-15	10	5	5	5	5	2	3	0
	1-16	10	5	5	5	5	2	3	0
35	1-17	10	5	5	5	5	0	3	0
	1-18	10	5	5	5	5	5	3	1
	1-19	10	5	5	5	5	2	3	0
40	1-20	10	5	5	5	5	4	3	1
	1-21	10	5	5	5	5	0	5	0
	1-22	10	5	5	5	5	3	5	0
45	1-23	10	5	5	5	5	4	5	0
	1-24	10	5	5	5	5	5	0	0
	1-25	10	5	5	5	5	0	5	0
50	1-25	10	5	5	5	5	0	5	0

55

EP 0 764 641 A1

(Table 1-5) continued

	No.	Dose (g/a)	A	B	C	D	E	F	a
5									
10	1 - 27	10	5	5	5	5	4	4	1
	1 - 28	10	5	5	5	5	5	0	0
	1 - 29	10	5	5	5	5	5	3	0
15	1 - 30	10	5	5	5	5	5	5	0
	1 - 31	10	5	5	5	5	5	3	1
	1 - 32	10	5	5	5	5	5	3	0
20	1 - 33	10	5	5	5	5	5	5	0
	1 - 34	2.52	5	3	5	5	0	0	0
	1 - 35	10	5	5	5	5	5	5	0
25	1 - 36	10	5	5	5	5	5	5	0
	1 - 37	10	5	5	5	5	-	5	1
	1 - 38	10	5	5	5	5	5	4	1
30	1 - 39	10	5	5	5	5	0	4	1
	1 - 40	10	5	5	5	5	5	5	1
35	1 - 41	10	3	2	3	5	5	0	0
	1 - 42	10	5	5	5	5	5	2	0
	1 - 43	10	5	5	5	5	5	3	0
40	1 - 44	10	5	5	5	5	5	3	0
	1 - 45	10	5	5	5	5	-	-	0
	1 - 46	10	5	-	5	-	4	-	1
45	1 - 47	10	5	5	5	-	-	-	0
	1 - 48	10	5	5	5	5	5	2	0
	1 - 49	10	5	5	5	5	0	5	0
50	1 - 50	10	5	5	5	5	0	0	3

55

EP 0 764 641 A1

(Table 1-5) continued

	No.	Dose (g/a)	A	B	C	D	E	F	a
5									
10	1-51	10	5	5	5	5	0	3	0
	1-52	10	5	5	5	5	0	3	0
	1-53	10	5	5	5	5	0	0	1
15	1-54	10	5	5	5	5	-	-	0
	1-55	6	5	5	5	5	-	-	0
	1-56	2.52	5	5	5	5	-	-	1
20	1-57	10	5	5	5	5	0	0	0
	1-58	10	5	5	5	5	0	0	0
	1-59	10	5	5	5	5	-	-	0
25	1-60	10	5	5	5	5	0	0	0
	1-61	10	5	5	5	5	0	0	0
	1-62	10	5	5	5	5	0	2	0
30	1-63	10	5	5	5	5	0	0	0
	1-64	10	5	5	5	5	0	3	0
35	1-65	10	5	5	5	5	0	3	1
	1-66	10	5	5	5	5	0	0	0
	1-67	10	5	5	5	5	0	0	0
40	1-68	10	5	5	5	5	0	3	0
	1-69	10	5	5	5	5	0	0	0
	1-70	10	5	5	5	5	3	0	0
45	1-71	10	5	5	5	5	0	0	0
	1-72	10	5	5	5	5	0	0	0
	1-73	10	5	5	5	5	0	0	0
50	1-74	10	5	5	5	5	0	0	0

55

EP 0 764 641 A1

(Table 1-5) continued

5	No. Dose (g/a)		A	B	C	D	E	F	a
10	1 - 75	10	5	5	5	5	0	0	0
	1 - 76	10	5	5	5	5	0	1	0
	1 - 77	10	5	5	5	5	0	—	0
15	1 - 78	10	5	5	5	5	2	1	0
	1 - 79	10	5	5	5	5	0	0	0
	1 - 80	10	5	4	4	5	4	3	2
20	1 - 81	10	5	5	5	5	2	0	0
	1 - 82	10	5	5	5	5	0	0	0
	1 - 83	10	5	5	5	5	3	—	0
25	1 - 84	10	5	5	5	5	0	0	0
	1 - 85	10	5	5	5	5	0	0	0
	1 - 86	10	5	5	5	5	2	—	3
30	1 - 87	10	3	3	4	5	0	0	0
	1 - 88	10	5	5	5	5	0	0	0
	1 - 89	10	5	5	5	5	0	—	0
35	1 - 90	10	5	5	5	5	0	0	0
	1 - 91	10	5	5	5	5	0	0	0
	1 - 92	10	5	5	5	5	0	3	0
40	1 - 93	10	5	5	5	5	2	0	0
	1 - 94	10	5	5	5	5	0	0	0
	1 - 95	10	5	5	5	5	0	5	0
45	1 - 96	10	5	5	5	5	0	0	0
	1 - 97	10	5	5	5	5	4	5	3
	1 - 98	10	2	3	3	5	0	0	0

55

EP 0 764 641 A1

(Table 1-5) continued

	N o .	Dose (g/a)	A	B	C	D	E	F	a
5									
10	1 - 99	10	2	3	3	5	0	0	0
	1 - 100	10	3	5	5	5	0	2	0
15	1 - 101	10	5	5	5	5	0	2	0
	1 - 102	10	3	2	5	5	0	0	0
20	1 - 103	4.4	3	3	5	5	0	0	0
	1 - 104	10	5	5	5	5	0	0	0
	1 - 105	10	5	5	5	5	0	0	0
25	1 - 106	10	5	5	5	5	0	0	0
	1 - 107	10	3	0	0	5	0	0	0
30	1 - 108	10	5	5	5	5	0	0	0
	1 - 109	10	5	5	5	5	0	0	0
	1 - 110	10	4	3	5	5	0	0	0
35	1 - 111	10	4	5	5	5	0	3	0
	1 - 112	10	0	0	3	5	0	0	0
40	1 - 113	10	5	5	5	5	0	0	0
	1 - 114	10	2	4	4	5	0	0	0
45									
50									
55									

EP 0 764 641 A1

(Table 1-6)

5

10

15

20

25

30

35

40

45

50

55

N o .	Dose (g/a)	A	B	C	D
1 - 1	10	5	3	5	4
1 - 2	10	5	2	5	4
1 - 3	10	3	0	5	4
1 - 4	10	5	0	4	4
1 - 5	10	5	0	5	4
1 - 7	10	0	0	4	4
1 - 9	10	5	5	5	5
1 - 12	2.5	0	0	0	5
1 - 14	10	5	3	5	5
1 - 15	10	5	4	5	5
1 - 16	10	5	2	4	5
1 - 17	10	5	5	5	5
1 - 18	10	5	4	5	5
1 - 19	10	5	5	5	5
1 - 20	10	5	5	5	5
1 - 21	10	5	5	5	5
1 - 22	10	5	5	5	5
1 - 23	10	5	5	5	5
1 - 24	10	5	5	5	5
1 - 25	10	5	3	5	5
1 - 26	10	5	5	5	5
1 - 27	10	5	5	5	5
1 - 28	10	5	4	5	5
1 - 29	10	5	4	5	5

EP 0 764 641 A1

(Table 1-6) continued

	No.	Dose (g/a)	A	B	C	D
5						
	1 - 30	10	5	4	5	5
10	1 - 31	10	3	3	5	5
	1 - 32	10	5	4	5	5
15	1 - 33	10	5	4	5	5
	1 - 34	2.52	5	5	5	5
	1 - 35	10	5	5	5	5
20	1 - 36	10	5	5	5	5
	1 - 37	10	4	5	5	5
	1 - 38	10	3	4	5	5
25	1 - 39	10	5	4	5	5
	1 - 40	10	5	3	5	5
	1 - 41	10	2	0	0	5
30	1 - 42	10	5	3	5	5
	1 - 43	10	5	4	5	5
35	1 - 44	10	5	3	5	5
	1 - 45	10	5	3	5	5
	1 - 46	10	5	3	5	5
40	1 - 47	10	5	3	5	5
	1 - 48	10	5	3	5	5
	1 - 49	10	5	4	5	5
45	1 - 50	10	5	3	5	5
	1 - 51	10	5	2	5	5
	1 - 52	10	5	3	5	5
50	1 - 53	10	4	5	5	5

55

EP 0 764 641 A1

(Table 1-6) continued

	No.	Dose (g/a)	A	B	C	D
5						
10	1 - 54	10	5	3	5	5
	1 - 55	10	5	3	5	5
	1 - 56	2.52	5	3	5	5
15	1 - 57	10	5	5	5	5
	1 - 58	10	3	5	5	5
	1 - 59	10	5	3	5	5
20	1 - 60	10	5	5	5	5
	1 - 61	10	5	3	5	5
	1 - 62	10	5	3	5	5
25	1 - 63	10	5	3	5	5
	1 - 64	10	5	3	5	5
	1 - 65	10	5	3	5	5
30	1 - 66	10	5	4	5	5
	1 - 67	10	5	4	5	5
35	1 - 68	10	5	3	5	5
	1 - 69	10	5	3	5	5
	1 - 70	10	5	3	5	5
40	1 - 71	10	5	3	5	5
	1 - 72	10	4	3	5	5
	1 - 73	10	5	4	5	5
45	1 - 74	10	5	5	5	5
	1 - 75	10	5	3	5	5
	1 - 76	10	5	3	5	5
50	1 - 77	10	5	3	5	5

55

EP 0 764 641 A1

(Table 1-6) continued

5						
	No.	Dose (g/a)	A	B	C	D
10	1-78	10	5	3	5	5
	1-79	10	5	4	5	5
	1-80	10	3	3	5	5
15	1-81	10	5	4	5	5
	1-82	10	5	3	5	5
	1-83	10	5	5	5	5
20	1-84	10	5	5	5	5
	1-85	10	5	5	5	5
	1-86	10	5	4	5	5
25	1-87	10	0	3	3	3
	1-88	10	5	3	5	5
	1-89	10	4	4	5	5
30	1-90	10	3	3	5	5
	1-91	10	4	5	5	5
	1-92	10	5	3	5	5
35	1-93	10	5	3	5	5
	1-94	10	5	3	5	5
	1-95	10	5	5	5	5
40	1-96	10	0	2	5	5
	1-97	10	5	3	5	5
	1-98	10	0	2	3	4
45	1-99	10	0	2	4	5
	1-100	10	2	4	5	5
50	1-101	10	5	5	5	5

55

EP 0 764 641 A1

(Table 1-6) continued

	No.	Dose (g/a)	A	B	C	D
5						
10	1 - 102	10	2	3	5	5
	1 - 103	4.4	0	0	5	5
15	1 - 104	10	5	4	5	5
	1 - 105	10	5	3	5	5
	1 - 106	10	5	3	5	5
20	1 - 107	10	0	0	0	4
	1 - 108	10	2	2	5	5
25	1 - 109	10	5	3	5	5
	1 - 110	10	4	3	5	5
30	1 - 111	10	3	3	5	5
	1 - 112	10	0	0	0	5
	1 - 113	10	5	4	5	5
35	1 - 114	10	1	5	5	5

40

45

50

55

EP 0 764 641 A1

(Table 1-7)

	No.	Dose G (g/a)	H	I	J	K	L	M	N	O	P	a	b	c	d	e	f
5																	
10	1-1	25	5	4	0	2	0	0	5	0	5	5	0	0	0	0	2
	1-2	25	5	5	0	0	4	4	5	5	5	1	0	0	0	0	4
	1-3	25	0	0	0	0	0	0	5	0	5	5	0	0	0	0	0
15	1-4	25	0	0	0	0	0	0	5	0	5	5	0	0	0	0	1
	1-5	25	5	5	0	2	4	0	5	2	5	5	0	0	0	0	2
	1-7	25	5	0	0	0	0	0	5	0	2	5	0	0	0	0	0
20	1-9	25	5	5	0	3	4	0	5	0	5	5	0	0	0	0	4
	1-10	6.3	0	0	0	0	0	2	0	0	0	0	0	0	1	0	0
25	1-14	25	5	5	3	5	5	4	5	5	5	5	1	3	1	3	4
	1-15	25	5	5	4	5	5	5	5	5	5	5	1	5	2	4	5
	1-16	25	5	5	0	5	5	0	5	5	5	5	1	0	5	0	2
30	1-17	25	0	0	0	0	0	0	5	2	5	5	0	0	0	1	3
	1-18	25	5	5	3	5	5	5	5	4	5	5	3	3	3	3	5
	1-19	25	5	5	0	3	4	3	5	3	5	5	1	1	0	0	1
35	1-20	25	5	4	3	5	0	3	5	3	5	5	1	0	2	0	5
	1-21	25	5	5	5	5	5	5	5	5	5	5	2	5	4	5	5
40	1-22	25	5	5	3	5	5	5	5	5	5	5	3	3	3	4	4
	1-23	25	5	5	3	5	5	0	5	4	5	5	3	0	3	1	3
	1-24	25	5	5	5	5	5	5	5	5	5	5	2	5	3	5	5
45	1-25	25	5	5	2	4	5	4	5	0	5	5	3	0	1	0	5
	1-26	25	5	5	5	5	5	3	5	0	5	5	5	0	1	0	5
	1-27	25	5	5	5	-	5	4	5	5	5	5	1	-	1	1	5
50	1-28	25	5	5	5	-	5	4	5	5	5	5	2	-	0	2	5

55

EP 0 764 641 A1

(Table 1-7) continued

	No.	Dose	G	H	I	J	K	L	M	N	O	P	a	b	c	d	e	f
		(g/a)																
5																		
10	1-29	25	5	5	3	-	3	3	5	3	5	5	-	0	2	0	0	5
	1-30	25	5	5	4	5	5	3	5	4	5	5	-	1	5	0	1	5
	1-31	25	5	4	2	3	4	3	5	0	5	5	-	0	1	0	1	4
15	1-32	25	5	5	3	4	5	5	5	4	5	5	-	0	4	0	0	5
	1-33	25	5	0	2	3	5	3	5	2	5	5	-	2	2	0	4	4
20	1-34	6.3	5	5	3	-	5	4	5	0	5	5	-	0	5	0	0	4
	1-35	25	5	5	5	-	5	5	5	5	5	5	-	5	5	3	4	5
	1-36	25	5	5	5	-	5	5	5	5	5	5	-	1	5	0	0	5
25	1-37	25	5	4	2	-	5	5	5	5	5	5	-	3	4	1	4	4
	1-38	25	3	0	0	-	5	3	4	2	5	5	-	0	0	0	0	3
	1-39	25	4	3	0	-	4	4	5	3	5	5	-	1	5	0	1	4
30	1-40	25	5	5	2	-	3	4	5	2	5	5	-	0	3	0	0	5
	1-41	25	3	5	0	-	0	4	5	0	5	5	-	0	0	0	0	0
	1-42	25	5	5	4	0	3	5	5	0	5	5	-	0	2	0	0	3
35	1-43	25	5	5	5	-	5	4	5	5	5	5	-	0	4	0	2	5
	1-44	25	5	5	4	-	5	5	5	5	5	5	-	0	2	0	0	3
40	1-45	25	5	5	5	5	5	5	5	5	5	5	-	0	5	0	2	5
	1-46	25	5	5	5	5	5	4	5	5	5	5	-	0	5	0	1	4
	1-47	25	5	5	5	5	5	3	5	2	5	5	-	0	3	0	0	4
45	1-48	25	5	5	3	4	5	4	5	5	5	5	-	1	1	0	2	4
	1-49	25	5	5	0	-	5	4	5	5	5	5	-	2	1	0	3	5
	1-50	25	5	5	2	0	4	3	5	2	5	5	-	0	0	0	0	4
50	1-51	25	0	0	3	-	2	0	5	0	5	5	-	0	0	3	0	4

55

EP 0 764 641 A1

(Table 1-7) continued

	No.	Dose (g/a)	G	H	I	J	K	L	M	N	O	P	a	b	c	d	e	f
5																		
10	1-52	25	3	2	0	-	5	4	5	0	5	5	-	3	0	1	2	4
	1-53	25	4	3	2	-	5	2	5	0	5	5	-	0	0	0	0	3
	1-54	25	5	5	5	5	3	2	5	0	5	5	-	0	5	0	0	4
15	1-55	15	5	5	5	5	5	4	5	5	5	5	-	0	5	0	2	5
	1-56	6.3	5	5	0	5	5	0	5	3	5	5	-	0	3	0	2	4
	1-57	25	5	5	4	0	5	5	5	5	5	5	5	2	2	2	3	3
20	1-58	25	3	0	3	-	0	0	5	0	5	5	5	0	0	0	0	3
	1-59	25	5	5	5	5	5	4	5	5	5	5	-	0	5	0	3	5
25	1-60	25	5	5	4	-	5	4	5	5	5	5	-	3	-	0	2	4
	1-61	25	5	5	5	-	5	5	5	5	5	5	-	2	5	0	4	5
	1-62	25	5	5	5	-	5	3	5	5	5	5	-	2	5	0	4	5
30	1-63	25	5	5	3	-	5	5	5	5	5	5	-	2	5	3	5	5
	1-64	25	5	5	0	-	5	5	5	5	5	5	-	4	3	3	4	4
	1-65	25	5	5	3	-	5	5	5	5	5	5	-	2	-	1	5	5
35	1-66	25	5	5	3	-	5	1	5	2	5	5	-	0	5	0	0	5
	1-67	25	5	5	5	-	5	2	5	5	5	5	-	0	5	0	3	4
40	1-68	25	5	5	4	-	5	5	5	5	5	5	-	5	4	0	5	4
	1-69	25	5	5	3	-	5	5	5	5	5	5	-	1	5	0	3	4
	1-70	25	5	5	4	-	5	5	5	5	5	5	-	2	5	1	4	5
45	1-71	25	5	5	5	-	4	4	5	5	5	5	-	1	5	0	2	4
	1-72	25	5	4	0	-	4	3	5	0	5	5	-	0	3	0	1	4
	1-73	25	5	5	4	0	5	0	0	1	4	5	-	0	5	0	0	4
50	1-74	25	5	5	3	2	4	3	5	0	5	5	-	0	4	0	0	4

55

EP 0 764 641 A1

(Table 1-7) continued

	No.	Dose G (g/a)	H	I	J	K	L	M	N	O	P	a	b	c	d	e	f
5																	
10	1-75	25	5	5	3	3	5	3	5	3	5	5	-	0	2	0	4
	1-76	25	5	5	3	-	4	3	5	2	5	5	-	0	2	0	5
	1-77	25	5	5	3	-	5	2	5	3	4	5	-	1	2	0	4
15	1-78	25	5	5	0	-	2	3	5	3	4	5	-	0	4	0	4
	1-79	25	5	5	2	-	5	5	5	3	5	5	-	0	4	0	4
	1-80	25	3	4	3	-	3	3	5	3	5	5	-	0	3	0	4
20	1-81	25	5	5	4	-	5	3	5	4	5	5	-	0	5	0	5
	1-82	25	5	5	0	0	5	5	5	2	5	5	-	0	0	0	4
25	1-83	25	5	5	5	-	5	5	5	5	5	5	3	3	0	2	4
	1-84	25	5	5	3	-	5	5	5	3	5	5	5	0	1	0	3
	1-85	25	5	5	3	0	5	3	4	0	5	5	-	0	4	0	4
30	1-86	25	5	5	3	-	5	5	5	5	5	5	-	2	5	0	4
	1-87	25	0	0	0	-	3	0	5	0	5	0	0	0	0	0	0
	1-88	25	5	5	0	-	5	2	5	2	5	5	0	0	1	0	5
35	1-89	25	5	5	0	-	5	1	5	4	5	5	0	0	0	0	4
	1-90	25	4	5	2	-	4	1	5	0	5	5	1	0	1	0	3
40	1-91	25	3	0	3	-	0	4	5	4	5	5	0	0	1	0	3
	1-92	25	5	5	5	-	4	0	5	2	5	5	2	0	0	0	4
	1-93	25	5	5	5	-	5	3	5	0	5	5	0	4	0	0	4
45	1-94	25	5	5	5	-	5	0	5	-	5	5	-	0	4	0	4
	1-95	25	5	5	4	-	5	5	5	5	5	5	1	2	1	3	4
	1-96	25	0	3	0	0	5	0	5	0	4	5	-	0	0	0	2
50	1-97	25	5	5	5	-	5	5	5	5	5	5	2	4	0	5	4

55

EP 0 764 641 A1

(Table 1-7) continued

	No.	Dose	G	H	I	J	K	L	M	N	O	P	a	b	c	d	e	f
		(g/a)																
5	1-98	25	0	0	0	-	0	0	3	3	5	5	0	0	0	0	0	0
10	1-99	25	0	0	0	0	0	0	3	0	2	5	0	0	0	0	0	1
15	1-100	25	5	5	5	-	3	4	5	5	5	5	5	0	0	0	2	3
	1-101	25	5	5	5	-	5	3	5	5	5	5	5	0	2	0	1	3
20	1-102	25	5	3	0	0	3	0	5	0	5	5	5	0	0	0	0	2
	1-103	11	3	4	3	-	0	0	5	2	5	5	5	0	0	0	0	3
	1-104	25	5	5	3	-	0	0	4	0	5	5	5	0	3	0	0	2
25	1-105	25	5	5	0	0	4	4	5	0	2	2	-	0	0	0	0	0
	1-106	25	5	5	0	0	5	5	5	0	3	5	-	0	0	0	0	2
30	1-107	25	0	0	0	0	0	0	4	0	5	5	0	0	0	0	0	1
	1-108	25	0	4	-	0	0	0	5	0	3	5	-	0	0	0	0	0
35	1-109	25	5	5	3	-	4	1	5	0	5	5	0	0	1	0	1	3
	1-110	25	3	3	3	1	3	0	5	-	5	5	1	0	0	0	0	4
40	1-111	25	5	1	0	3	3	2	5	0	5	5	0	0	0	0	2	4
	1-112	25	0	0	2	3	2	0	5	-	3	5	0	0	0	0	0	2
	1-113	25	5	5	3	4	5	4	5	5	5	5	5	0	4	0	3	4
45	1-114	25	5	5	3	5	5	1	5	5	5	5	1	0	2	0	3	4

50

55

EP 0 764 641 A1

(Table 1-8)

	No.	Dose	G	H	I	J	K	L	M	N	O	P	a	b	c	d	e	f
		(g/a)																
5																		
10	1-2	25	5	3	0	4	3	2	4	3	5	5	4	1	2	2	1	3
	1-4	25	0	0	0	0	0	0	0	0	4	4	0	0	0	0	0	2
	1-5	25	0	0	0	2	0	0	0	0	2	0	0	0	0	0	0	0
15	1-9	25	1	2	0	0	3	2	3	3	5	2	1	0	0	0	0	1
	1-12	6.3	0	0	0	0	0	0	2	0	3	3	0	0	0	0	0	1
	1-14	25	3	3	2	4	3	2	4	2	5	5	1	0	2	0	0	2
20	1-15	25	4	4	4	4	5	3	5	5	5	5	2	3	2	2	4	3
	1-16	25	3	3	0	3	4	2	3	0	5	5	1	0	2	0	0	3
	1-18	25	3	3	3	4	3	2	2	1	5	5	2	2	1	1	0	2
25	1-19	25	0	0	0	3	0	0	0	0	4	4	0	1	1	0	0	2
	1-20	25	1	1	3	4	0	2	0	0	5	5	0	0	0	0	0	2
30	1-21	25	4	4	3	3	4	4	4	2	5	5	4	2	2	1	1	2
	1-22	25	5	4	2	4	3	3	3	2	5	5	3	3	1	2	1	2
	1-23	25	3	3	2	3	4	2	2	0	4	5	2	2	2	1	0	-
35	1-24	25	4	4	4	5	4	4	3	1	5	5	3	2	2	1	1	3
	1-25	25	0	0	0	0	0	1	2	0	4	4	0	0	0	0	0	1
	1-26	25	0	0	1	2	0	1	1	1	4	5	0	0	0	0	0	1
40	1-27	25	3	3	0	5	1	3	2	0	5	5	2	1	1	2	1	2
	1-28	25	3	4	2	4	4	4	3	1	5	5	2	1	2	0	0	2
45	1-29	25	0	0	0	3	0	2	0	0	0	4	0	0	0	0	0	1
	1-30	25	4	0	3	4	3	2	1	0	5	4	2	0	2	0	0	2
	1-31	25	0	0	3	3	2	0	2	0	4	5	0	0	1	0	0	2
50	1-32	25	2	2	0	5	0	4	2	2	5	5	2	1	1	0	0	2
	1-33	25	3	0	2	3	2	1	0	0	3	5	2	1	0	0	1	2
55																		

EP 0 764 641 A1

(Table 1-8) continued

	No.	DoseG (g/a)	H	I	J	K	L	M	N	O	P	a	b	c	d	e	f
5																	
10	1-34	6.3 5	0	2	3	0	5	0	0	3	4	1	0	1	0	0	2
	1-35	25 5	2	4	5	5	4	5	3	5	5	2	4	2	1	2	3
	1-36	25 5	0	3	4	2	0	2	5	5	5	3	2	2	0	0	3
15	1-37	25 0	0	2	5	2	0	1	0	5	5	1	1	2	0	0	3
	1-38	25 0	0	0	2	0	0	0	0	0	5	0	0	0	0	0	0
	1-39	25 0	0	0	5	0	0	0	0	3	5	0	0	0	0	0	1
20	1-40	25 0	0	0	4	0	1	2	0	2	5	2	0	0	0	1	2
	1-41	25 0	0	0	4	2	1	0	0	3	5	1	0	0	0	0	1
25	1-42	25 0	0	0	5	0	4	3	0	5	5	1	0	0	0	0	1
	1-43	25 0	3	0	4	0	2	0	0	5	5	2	0	1	1	1	2
	1-44	25 2	2	2	5	2	3	3	0	5	5	2	1	2	0	1	3
30	1-45	25 0	0	0	3	0	1	1	0	5	4	0	0	2	0	0	1
	1-46	25 0	0	0	3	0	1	0	0	3	4	0	0	0	0	0	1
	1-47	25 0	0	0	3	1	1	2	0	5	5	0	0	0	0	0	2
35	1-48	25 2	1	0	0	2	1	1	0	4	4	1	0	0	0	0	1
	1-49	25 4	3	0	3	3	2	2	2	4	5	1	2	1	0	0	2
40	1-50	25 4	4	0	—	4	1	4	2	4	5	2	2	0	0	1	1
	1-51	25 0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0
	1-52	25 0	0	0	—	0	0	0	0	3	3	0	0	0	0	0	0
45	1-53	25 0	0	0	4	0	2	0	0	4	5	0	0	0	0	0	2
	1-54	25 0	0	0	3	3	0	2	0	5	4	0	0	0	0	0	2
	1-55	15 2	3	2	4	4	2	2	0	5	5	2	0	0	0	0	2
50	1-56	6.3 0	0	0	3	0	0	0	0	5	5	0	0	0	0	0	0

55

EP 0 764 641 A1

(Table 1-8) continued

	No.	DoseG (g/a)	H	I	J	K	L	M	N	O	P	a	b	c	d	e	f	
5																		
10	1-57	25	5	—	2	—	0	3	3	0	4	5	2	0	0	1	2	1
	1-58	25	0	0	0	—	0	0	0	0	3	2	0	0	0	0	0	1
	1-59	25	0	0	4	4	0	1	0	0	5	5	1	0	2	0	0	2
15	1-60	25	0	0	0	—	0	0	1	0	4	4	0	1	1	0	0	2
	1-61	25	0	0	5	—	0	2	2	0	5	5	1	1	2	0	0	2
	1-62	25	2	2	2	—	2	1	2	0	5	4	2	0	2	0	0	2
20	1-63	25	3	3	2	—	2	2	2	1	5	5	3	3	1	0	1	3
	1-64	25	3	3	5	0	3	2	1	0	5	5	1	2	2	0	1	3
25	1-65	25	3	3	3	—	4	3	3	1	5	5	3	3	3	1	1	4
	1-66	25	0	0	2	—	3	1	3	0	5	5	0	0	2	0	0	2
	1-67	25	0	0	4	—	2	0	2	0	5	5	2	0	2	0	0	2
30	1-68	25	3	3	1	—	4	3	3	2	5	5	3	3	2	2	0	2
	1-69	25	3	4	3	—	4	4	1	1	5	5	2	2	2	1	0	3
	1-70	25	4	3	5	—	5	5	5	—	5	5	3	3	3	1	1	4
35	1-71	25	0	0	3	—	3	1	2	1	4	5	1	0	3	0	0	1
	1-72	25	0	0	1	—	0	0	0	0	4	5	0	0	2	0	0	2
	1-73	25	0	0	2	—	0	0	0	0	5	5	0	0	2	2	0	1
40	1-74	25	0	0	0	—	1	1	1	0	5	5	0	1	1	0	0	3
	1-75	25	0	0	0	2	0	2	1	0	2	5	0	0	0	0	0	1
45	1-76	25	3	4	0	—	0	4	1	2	5	5	3	2	1	0	0	1
	1-77	25	3	3	2	—	0	2	2	1	5	5	2	3	1	1	1	2
	1-78	25	0	1	0	—	2	3	1	1	4	5	0	0	0	—	0	2
50	1-79	25	0	3	2	—	3	2	2	0	4	5	1	1	0	0	1	2

55

EP 0 764 641 A1

(Table 1-8) continued

5

10

15

20

25

30

35

40

45

50

55

No.	Dose G (g/a)	H	I	J	K	L	M	N	O	P	a	b	c	d	e	f
1-80	25	2	2	3	-	2	2	1	1	5	5	1	0	3	0	2
1-81	25	0	0	0	-	0	2	1	0	5	5	1	2	4	0	3
1-82	25	3	3	0	-	0	2	2	0	4	5	2	2	0	0	1
1-83	25	4	4	3	-	3	4	3	0	5	5	1	1	2	1	1
1-84	25	3	-	2	-	3	3	2	0	4	4	2	1	1	1	1
1-85	25	0	0	4	4	0	0	0	0	5	5	0	0	0	0	1
1-86	25	3	3	2	-	2	2	2	0	5	5	1	3	2	1	2
1-88	25	0	0	0	-	0	1	1	0	0	-	0	0	0	0	0
1-89	25	0	-	0	-	2	2	2	0	4	1	0	0	0	0	0
1-90	25	0	0	0	-	4	0	0	0	0	2	0	0	0	0	0
1-91	25	0	0	2	-	0	0	0	0	3	3	0	0	1	0	1
1-92	25	0	3	0	-	5	3	5	4	5	5	0	0	0	1	2
1-93	25	0	5	0	-	5	4	4	5	5	5	0	0	1	0	2
1-94	25	0	0	2	-	4	4	3	4	5	5	0	0	2	0	3
1-95	25	4	4	5	-	3	3	3	3	5	5	3	2	2	1	3
1-96	25	0	0	0	0	0	0	4	0	0	2	0	0	0	0	2
1-97	25	5	5	2	5	5	5	4	3	5	5	3	3	0	1	3
1-98	25	0	0	0	-	0	0	0	0	3	3	0	0	0	0	0
1-99	25	0	0	0	-	0	0	2	0	3	3	0	0	0	0	0
1-100	25	0	0	0	-	0	2	4	0	5	4	0	0	0	1	1
1-101	25	5	5	2	-	3	5	3	4	5	5	3	2	0	1	1
1-102	25	0	0	0	-	0	0	2	0	5	5	1	0	0	0	0
1-103	11	0	0	0	-	0	0	0	0	4	-	0	0	0	0	0

EP 0 764 641 A1

(Table 1-8) continued

	No.	Dose	G	H	I	J	K	L	M	N	O	P	a	b	c	d	e	f
		(g/a)																
5	1-104	25	0	0	0	—	0	0	0	0	2	2	0	0	0	0	0	1
10	1-105	25	3	5	0	2	5	5	5	0	5	3	1	1	0	2	0	0
15	1-106	25	0	4	0	0	5	3	3	2	0	3	0	0	0	1	0	1
	1-107	25	0	0	0	0	0	0	0	0	3	3	0	0	0	0	0	0
20	1-108	25	0	0	0	0	0	0	2	0	4	5	0	0	0	0	0	0
	1-109	25	5	4	3	3	5	5	2	3	2	4	2	3	2	0	1	1
	1-110	25	3	3	2	3	2	4	1	0	3	4	1	0	1	0	2	1
25	1-111	25	2	2	0	4	4	0	3	0	5	4	1	0	0	0	1	1
	1-112	25	0	0	1	4	0	0	0	0	4	2	0	0	0	0	0	0
30	1-113	25	2	3	0	5	4	4	3	1	3	4	2	0	2	0	0	2
	1-114	25	5	4	3	4	4	5	5	1	4	4	2	0	0	0	3	2

EP 0 764 641 A1

(Table 2-5)

No.	Dose (g/a)	A	B	C	D	E	F	a
2-1	20	5	4	5	4	0	5	2
2-2	10	5	5	5	5	5	5	5
2-3	20	5	5	5	5	5	5	2
2-4	20	5	5	5	5	5	5	3
2-5	10	5	5	5	5	2	5	2
2-6	10	5	5	5	5	5	5	3
2-7	10	5	5	5	5	5	0	3
2-8	10	5	5	5	5	5	4	1
2-9	10	5	5	5	5	3	5	2
2-10	10	5	5	5	5	2	4	1
2-11	10	5	5	5	5	3	3	0
2-12	2.5	5	5	5	5	0	0	0
2-13	2.5	5	5	5	5	0	0	0
2-14	10	5	5	5	5	5	3	4
2-15	10	5	5	5	5	4	5	1
2-18	10	5	5	5	5	2	2	0
2-19	10	5	5	5	5	0	0	0
2-20	10	5	5	5	5	3	0	0
2-21	10	5	5	5	5	0	0	0
2-22	10	5	5	5	5	3	3	0
2-23	10	5	4	5	5	0	0	0
2-24	10	5	5	5	5	0	0	0
2-25	10	5	5	5	5	0	2	0
2-26	10	5	5	5	5	0	0	0

EP 0 764 641 A1

(Table 2-6)

No.	Dose (g/a)	A	B	C	D
2-1	20	5	3	3	3
2-2	10	5	5	5	5
2-3	20	5	2	5	5
2-4	20	5	4	-	5
2-5	10	5	0	4	4
2-6	10	5	5	5	4
2-7	10	5	5	5	4
2-8	10	5	3	5	5
2-9	10	5	5	5	5
2-10	10	5	2	5	3
2-11	10	5	0	5	4
2-12	2.5	5	3	4	5
2-13	2.5	5	4	5	5
2-14	10	5	0	3	5
2-15	10	5	5	5	5
2-18	10	5	3	5	5
2-19	10	3	3	3	5
2-20	10	5	4	5	5
2-21	10	4	3	5	5
2-22	10	5	3	5	5
2-23	10	5	3	5	5
2-24	10	5	3	5	5
2-25	10	5	3	5	5
2-26	10	5	3	5	5

EP 0 764 641 A1

(Table 2-7)

	No.	Dose G (g/a)	H	I	J	K	L	M	N	O	P	a	b	c	d	e	f
5																	
10	2-1	50	5	5	2	3	5	4	5	4	5	5	5	2	5	5	5
	2-2	25	5	5	2	2	5	5	5	5	5	5	4	1	4	4	2
	2-3	50	5	5	5	5	5	4	5	5	5	5	3	3	3	3	4
15	2-4	50	5	5	5	5	5	5	4	5	5	5	3	3	3	4	4
	2-5	25	5	5	2	4	5	4	5	5	5	4	1	2	3	4	4
20	2-6	25	5	5	—	4	5	4	5	4	5	5	1	1	0	4	4
	2-7	25	5	5	—	3	5	3	5	5	5	5	0	2	0	3	4
	2-8	25	5	5	3	4	5	4	5	5	5	5	0	3	1	3	4
25	2-9	25	5	5	0	4	5	4	5	5	5	5	0	3	0	2	4
	2-10	25	5	5	—	5	0	5	0	5	5	0	2	0	—	0	4
	2-11	25	5	5	0	4	5	0	5	3	5	5	3	0	3	0	5
30	2-12	6.3	5	5	3	3	5	2	5	2	5	5	2	0	1	0	1
	2-13	6.3	5	5	3	3	5	0	5	2	5	5	2	0	2	0	1
35	2-14	25	5	4	0	4	4	2	5	2	5	5	1	1	1	0	4
	2-15	25	5	5	2	5	5	5	5	5	5	5	2	4	1	3	4
	2-17	25	0	0	3	0	0	0	3	0	0	0	0	0	0	0	1
40	2-18	25	5	5	5	—	5	2	5	0	5	5	—	0	5	0	5
	2-19	25	2	2	3	0	2	0	5	0	0	5	—	0	1	0	4
	2-20	25	5	5	0	—	5	3	5	2	5	5	0	0	0	0	5
45	2-21	25	2	5	0	—	4	2	5	2	5	4	1	0	1	0	4
	2-22	25	5	5	0	—	5	2	5	2	5	5	1	0	3	0	5
50	2-23	25	5	5	3	—	4	0	5	0	5	5	1	0	2	0	4
	2-24	25	5	5	5	—	3	2	5	3	5	5	0	0	5	0	4

55

EP 0 764 641 A1

(Table 2-7) continued

5

10

15

20

25

30

35

40

45

50

55

No.	Dose	G	H	I	J	K	L	M	N	O	P	a	b	c	d	e	f
	(g/a)																
2-25	25	5	5	5	-	5	2	5	5	5	5	5	0	5	0	5	4
2-26	25	5	5	3	-	5	4	5	0	5	5	2	0	1	0	0	4

EP 0 764 641 A1

(Table 2-8)

	No. Dose	G	H	I	J	K	L	M	N	O	P	a	b	c	d	e	f	
	(g/a)																	
5																		
10	2-1	50	2	3	2	5	2	1	1	0	2	4	1	2	1	1	0	2
	2-2	25	4	5	0	5	3	5	3	3	4	4	0	2	1	4	1	0
	2-3	50	5	3	3	4	4	4	4	4	4	5	1	2	1	2	1	1
15	2-4	50	5	5	2	4	4	5	4	5	4	4	1	1	2	2	0	2
	2-5	25	4	3	4	0	4	5	4	3	3	4	2	0	0	2	0	1
	2-6	25	4	5	3	4	4	3	4	4	3	3	3	1	0	1	2	2
20	2-7	25	5	5	3	5	4	0	4	3	4	4	2	0	2	0	0	3
	2-8	25	4	4	0	2	3	2	4	2	3	2	1	0	0	-	0	2
	2-9	25	4	3	0	3	3	2	3	0	3	4	2	0	1	1	0	1
25	2-10	25	0	0	0	2	3	0	2	-	5	3	0	0	0	0	0	2
	2-11	25	4	0	0	4	3	2	2	0	4	4	1	0	1	0	0	1
30	2-12	6.3	0	0	0	0	0	2	2	0	5	4	2	0	1	0	0	1
	2-13	6.3	0	0	0	0	2	2	3	3	3	3	1	0	1	0	0	2
	2-14	25	4	4	3	3	3	3	3	2	5	5	2	0	2	2	2	2
35	2-15	25	4	3	2	4	4	5	2	2	5	5	2	2	1	2	1	2
	2-18	25	0	0	0	-	0	2	0	0	3	4	0	1	0	0	0	0
	2-19	25	0	0	0	0	0	0	0	0	3	1	0	0	0	0	0	1
40	2-20	25	0	0	0	-	0	3	1	0	5	3	2	0	3	0	0	0
	2-21	25	4	-	0	-	0	2	2	0	4	3	2	0	0	0	0	0
	2-22	25	0	-	0	-	3	2	2	0	5	5	0	0	0	0	0	1
45	2-23	25	0	-	0	-	0	1	1	0	5	5	0	0	0	0	0	0
	2-24	25	0	2	0	5	3	2	2	2	4	4	2	0	1	1	1	0
50	2-25	25	0	3	0	4	2	4	3	2	5	5	3	0	1	0	0	1
	2-26	25	0	0	0	-	3	4	4	3	5	5	2	0	2	1	2	2

EP 0 764 641 A1

(Table 3-4)

No.	Dose (g/a)	A	B	C	D	E	F	a
3-1	10	5	5	5	5	0	0	1
3-2	10	5	5	5	5	5	5	2
3-3	10	5	5	5	5	0	0	0
3-4	10	4	3	5	5	2	0	0
3-5	10	5	5	5	5	3	3	2
3-6	10	5	5	5	5	0	0	0
3-7	10	5	5	5	5	0	0	0
3-8	10	5	5	5	5	0	0	0
3-9	10	5	5	5	5	4	2	0
3-10	10	5	5	5	5	0	0	0
3-11	10	5	5	5	5	0	0	0
3-12	10	5	5	5	5	2	3	0
3-13	10	5	5	5	5	0	0	0
3-14	10	5	5	5	5	0	0	0
3-15	10	5	5	5	5	2	5	0
3-16	20	4	1	5	5	1	5	2
3-17	20	4	5	5	5	1	2	1
3-18	10	5	2	4	4	0	0	0
3-19	10	4	0	0	3	0	0	0
3-20	10	5	5	5	5	0	1	0
3-21	10	5	5	5	5	4	4	0

EP 0 764 641 A1

(Table 3-5)

No.	Dose (g/a)	A	B	C	D
3-1	10	5	3	5	5
3-2	10	5	5	5	5
3-3	10	5	2	4	5
3-4	10	2	0	3	4
3-5	10	5	3	5	4
3-6	10	5	2	5	5
3-7	10	5	2	5	4
3-8	10	5	3	5	4
3-9	10	4	0	4	4
3-10	10	5	0	4	4
3-11	10	5	3	5	5
3-12	10	5	3	5	5
3-13	10	4	2	5	5
3-14	10	5	5	5	5
3-15	10	5	3	5	5
3-16	20	2	1	4	5
3-17	20	2	-	-	4
3-18	10	2	0	3	2
3-19	10	0	2	2	4
3-20	10	4	3	5	4
3-21	10	5	4	5	5

EP 0 764 641 A1

(Table 3-6)

	No.	Dose	G	H	I	J	K	L	M	N	O	P	a	b	c	d	e	f
		(g/a)																
5																		
10	3-1	25	5	5	0	0	4	0	5	3	5	5	0	0	0	0	1	3
	3-2	25	5	5	2	2	5	4	5	3	5	5	3	2	2	0	2	4
15	3-3	25	5	5	0	3	2	3	5	0	5	5	1	0	0	1	0	2
	3-4	25	5	5	3	3	5	1	5	3	5	5	2	0	3	0	2	5
	3-5	25	5	5	5	5	5	5	5	5	5	5	5	2	4	1	4	4
20	3-6	25	5	5	0	2	5	0	5	0	5	5	0	0	2	0	0	4
	3-7	25	5	5	0	1	5	0	5	0	5	5	0	0	0	0	0	3
25	3-8	25	5	5	0	0	4	0	5	0	5	5	0	0	0	0	0	4
	3-9	25	5	5	0	0	5	0	5	2	5	5	1	0	1	0	0	3
	3-10	25	5	5	2	2	3	0	5	0	5	5	0	0	1	0	0	2
30	3-11	25	5	5	0	0	4	0	5	0	5	5	0	0	0	0	0	3
	3-12	25	5	5	5	5	5	5	5	5	5	5	5	2	4	2	4	4
35	3-13	25	5	5	0	3	4	0	5	1	5	5	1	0	0	0	0	4
	3-14	25	5	5	4	4	5	0	5	4	5	5	2	0	0	0	0	4
	3-15	25	5	5	4	3	5	3	5	4	5	5	3	0	1	0	0	4
40	3-16	50	3	4	—	0	3	0	5	0	4	4	1	1	0	1	0	0
	3-17	50	4	5	—	0	5	2	5	0	5	5	1	1	0	3	0	2
	3-18	25	0	0	0	0	2	0	4	0	5	0	0	0	0	0	0	0
45	3-19	25	3	0	0	0	2	0	4	0	5	3	0	0	0	0	0	0
	3-20	25	5	3	0	0	4	0	5	0	5	5	0	1	0	0	0	0
50	3-21	25	5	5	3	—	5	2	5	0	5	5	—	1	5	0	1	5

55

5

55

EP 0 764 641 A1

(Table 4-4)

No.	Dose (g/a)	A	B	C	D	E	F	a
4-1	20	5	5	5	5	5	5	2
4-2	20	5	5	5	5	3	5	3
4-3	10	5	5	5	5	4	5	3
4-4	20	5	1	5	5	4	3	3
4-5	10	5	3	5	5	0	1	3
4-6	10	5	2	4	5	3	1	3
4-7	10	5	3	2	5	0	0	3
4-8	10	4	3	2	5	3	0	2
4-9	10	5	4	5	5	4	0	0
4-10	10	5	5	5	5	3	5	3
4-11	10	5	5	5	5	2	5	0
4-12	10	5	5	5	5	0	0	0
4-13	10	5	3	5	5	0	2	0
4-14	10	5	5	5	5	5	5	3
4-15	10	5	5	5	5	0	0	0
4-16	10	5	5	5	5	5	5	1

(Table 4-5)

No.	Dose (g/a)	A	B	C	D
4-1	20	5	5	5	5
4-2	20	4	-	-	5
4-3	10	4	3	4	4
4-4	20	4	5	1	4
4-5	10	4	0	5	3
4-6	10	4	0	2	5
4-7	10	4	0	2	5
4-8	10	4	0	4	5
4-9	10	4	2	5	5
4-10	10	5	5	5	5
4-11	10	5	4	5	5
4-12	10	5	5	5	5
4-13	10	5	2	5	5
4-14	10	5	4	5	5
4-15	10	5	5	5	5
4-16	10	5	5	5	5

EP 0 764 641 A1

(Table 4-6)

5

10

15

20

25

30

35

40

45

50

55

No. Dose (g/a)	G	H	I	J	K	L	M	N	O	P	a	b	c	d	e	f
4-1	50	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
4-2	50	5	5	3	5	5	5	5	5	5	5	3	2	3	2	4
4-3	25	5	5	—	0	5	4	5	3	5	5	2	1	2	1	3
4-4	50	5	5	—	4	5	5	5	4	5	5	3	2	1	2	2
4-5	25	5	3	2	3	4	2	5	0	5	5	2	0	0	0	1
4-6	25	5	4	0	3	4	1	5	2	5	5	2	1	0	0	2
4-7	25	4	3	0	4	3	2	5	3	5	5	3	1	0	0	2
4-8	25	4	4	0	3	3	2	5	3	5	5	3	1	0	1	2
4-9	25	4	4	0	3	4	0	5	0	4	3	2	0	0	0	2
4-10	25	3	2	0	0	3	3	5	2	5	5	1	0	0	0	3
4-11	25	4	4	0	3	4	0	5	2	5	5	2	0	0	0	4
4-12	25	5	5	0	1	3	0	5	3	5	5	0	0	0	0	4
4-13	25	4	4	2	3	4	0	4	3	5	4	2	0	0	1	3
4-14	25	5	5	0	3	4	3	5	2	5	5	3	0	1	0	4
4-15	25	5	5	3	5	4	0	5	0	5	5	3	0	0	0	4
4-16	25	5	5	5	—	5	4	5	5	5	5	—	0	5	1	5

EP 0 764 641 A1

(Table 4-7)

	No. Dose	G	H	I	J	K	L	M	N	O	P	a	b	c	d	e	f
	(g/a)																
5																	
10	4-1	50	5	5	5	5	5	5	3	5	5	2	3	2	4	2	3
	4-2	50	4	3	3	4	2	5	3	4	4	5	1	2	1	2	2
15	4-3	25	0	3	2	2	3	2	2	0	0	1	0	1	0	0	1
	4-4	50	3	4	3	4	4	1	3	5	3	5	1	0	1	1	1
20	4-5	25	2	2	2	4	0	0	4	4	3	2	0	0	0	0	0
	4-6	25	2	2	1	4	2	0	3	4	3	3	0	0	0	3	1
	4-7	25	3	3	0	3	1	3	4	5	3	2	0	0	0	0	1
25	4-8	25	3	3	3	3	3	3	5	3	4	2	1	0	0	0	1
	4-9	25	2	3	3	3	2	2	3	0	3	3	0	0	0	0	2
30	4-10	25	1	1	0	0	2	0	3	4	0	0	0	0	0	0	0
	4-11	25	4	2	0	2	2	0	2	0	3	3	2	0	1	0	1
35	4-12	25	0	0	0	0	2	2	2	2	3	0	0	0	0	0	1
	4-13	25	2	0	0	0	2	0	0	0	0	0	0	0	0	0	1
	4-14	25	4	3	0	3	3	4	2	3	5	3	2	0	2	0	1
40	4-15	25	0	0	0	0	0	1	0	0	0	2	0	0	0	0	0
	4-16	25	4	4	3	5	4	4	2	2	5	5	2	2	1	1	0
45																	
50																	
55																	

EP 0 764 641 A1

(Table 5-4)

No.	Dose (g/a)	A	B	C	D	E	F	a
5-1	10	3	0	0	2	0	0	0
5-4	9.28	3	0	0	3	0	0	1
5-5	20	4	0	2	5	0	0	0
5-6	20	4	4	5	5	5	1	0
5-7	10	0	0	3	5	2	0	0

(Table 5-5)

No.	Dose (g/a)	A	B	C	D
5-4	9.28	1	1	1	2
5-5	20	2	2	5	3
5-6	20	2	4	5	5

EP 0 764 641 A1

(Table 5-6)


	No.	Dose	G	H	I	J	K	L	M	N	O	P	a	b	c	d	e	f
		(g/a)																
5-1	25	0	0	0	0	0	0	4	0	3	4	0	0	0	0	0	0	0
5-3	50	0	0	0	0	4	0	3	0	3	3	-	0	0	0	0	0	0
5-4	23.2	4	3	0	0	1	2	5	4	3	4	1	1	0	0	0	0	1
5-5	50	0	0	0	0	0	0	0	0	3	2	0	0	0	0	0	0	0
5-6	50	2	0	0	0	0	0	0	0	4	5	0	0	0	0	0	0	0

(Table 5-7)

	No.	Dose	G	H	I	J	K	L	M	N	O	P	a	b	c	d	e	f
		(g/a)																
5-3	50	0	0	0	0	1	0	0	0	0	1	0	0	0	2	0	0	0
5-4	23.2	2	0	0	2	3	3	3	5	0	0	0	0	0	2	1	0	0

Claims

1. A 4,5-disubstituted pyrimidine derivative of the formula (I):



wherein R1 is a C₁ or C₂ haloalkyl group,

R2 is a C₁-C₈ alkyl group, a C₃-C₈ cycloalkyl group, a C₃-C₈ cycloalkyl(C₁-C₄)alkyl group, a phenyl group which may be substituted [wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a C₁-C₄ haloalkyl group, a C₁-C₄ haloalkoxy group, a C₃-C₈ alkenyl group, a C₃-C₈ alkynyl group, a CO₂(C₁-C₄ alkyl) group, a N(C₁-C₃ alkyl)₂ group, a cyano group, a nitro group, a sulfo group, an amino group, a hydroxy group, a mercapto group, a SCH₃ group, a SO₂CH₃ group, a phenoxy group and a phenyl group], a thienyl group, a furyl group, a pyridyl group, a C₁-C₆ haloalkyl group, a C₃-C₆ halocycloalkyl group, a C₃-C₈ alkenyl group, a C₃-C₈ alkynyl group, a C₁-C₂ sulfonyl(C₁-C₄)alkyl group or C₁-C₄ alkylthio(C₃-C₆)cycloalkyl group,

R3 is a halogen atom, SH, NH₂,

- O-R11 [wherein R11 is a C₁-C₈ alkyl group, a C₃-C₈ alkenyl group, a C₃-C₈ alkynyl group, a C₃-C₆ cycloalkyl group, a C₃-C₆ cycloalkyl(C₁ or C₂)alkyl group, a C₁-C₆ haloalkyl group, a C₃-C₈ haloalkenyl group, a C₃-C₈ haloalkynyl group, a C₁-C₄ alkoxy(C₁-C₄)alkyl group, a cyano(C₁-C₄)alkyl group, a C₁-C₄ alkylthio(C₁-C₄)alkyl group, a C₁-C₄ alkoxycarbonyl(C₁-C₄)alkyl group, a C₁-C₄ alkoxycarbonyl group, a carboxy(C₁-C₄)alkyl group, a C₁-C₄ alkylcarbonyl group, a C(=O)NR21(R22) group (each of R21 and R22 is independently a hydrogen atom, a C₁-C₄ alkyl group, a C₃-C₈ alkenyl group or a C₃-C₈ alkynyl group), C(=S)NR21(R22) group (R21 and R22 are as defined above), a hydroxy(C₁-C₄)alkyl group, a SO₂N(C₁-C₆ alkyl)₂ group, CO(C₁-C₆ alkyl) group, a CO₂(C₁-C₆ alkyl) group, a SO(C₁-C₆ alkyl) group, a SO₂(C₁-C₆ alkyl) group, a phenethyl group, a phenacyl group, a 1- or 2-naphthyl group, a tetrahydropyranyl group, a tetrahydrothiopyranyl group, a 3-bromotetrahydropyranyl group, a 4-methoxytetrahydropyranyl group, a 4-methoxytetrahydrothiopyranyl group, a tetrahydrofuran group, a tetrahydrothiofuran group, a 1,4-dioxan-2-yl group, a 1-methoxycyclohexyl group, a benzyloxymethyl group, a 2,2,2-trichloroethoxymethyl group, a bis(2-chloroethoxy)methyl group, a 1-(2-chloroethoxy)ethyl group, a 2-methoxyethoxymethyl group, a 1-methyl-1-benzyloxyethyl group, a tertiary butyldimethylsilyl group, a trimethylsilyl group, a triethylsilyl group, a 2-thenyl group, a furfuryl group, a 2-thenoyl group, a phenyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a C₁-C₄ haloalkyl group, a C₁-C₄ haloalkoxy group, a C₃-C₈ alkenyl group, a C₃-C₈ alkynyl group, a CO₂(C₁-C₄ alkyl) group, a N(C₁-C₃ alkyl)₂ group, a cyano group, a nitro group, a SCH₃ group, a SO₂CH₃ group, a phenoxy group and a phenyl group), a benzyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a C₁-C₄ haloalkyl group, a C₁-C₄ haloalkoxy group, a C₃-C₈ alkenyl group, a C₃-C₈ alkynyl group, a CO₂(C₁-C₄ alkyl) group, a N(C₁-C₃ alkyl)₂ group, a cyano group, a nitro group, a SCH₃ group, a SO₂CH₃ group, a phenoxy group and a phenyl group), a -Q-phenyl group which may be substituted (wherein Q is a C₂-C₆ saturated or unsaturated carbon chain which may be branched, and the substituent of the phenyl group is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a C₁-C₄ haloalkyl group, a C₁-C₄ haloalkoxy group, a C₃-C₈ alkenyl group, a C₃-C₈ alkynyl group, a CO₂(C₁-C₄ alkyl) group, a N(C₁-C₃ alkyl)₂ group, a cyano group, a nitro group, a SCH₃ group, a SO₂CH₃ group, a phenoxy group and a phenyl group), a -Q-CO₂R23 group (wherein Q is a C₂-C₆ saturated or unsaturated carbon chain which may be branched, and R23 is a C₁-C₄ alkyl group), a benzoyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a C₁-C₄ haloalkyl group, a C₁-C₄ haloalkoxy group, a C₃-C₈ alkenyl group, a C₃-C₈ alkynyl group, a CO₂(C₁-C₄ alkyl) group, a N(C₁-C₃ alkyl)₂ group, a cyano group, a nitro group, a SCH₃ group, a SO₂CH₃ group, a phenoxy group and a phenyl group), or a benzenesulfonyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a C₁-C₄ haloalkyl group, a C₁-C₄ haloalkoxy group, a C₃-C₈ alkenyl group, a C₃-C₈ alkynyl group, a CO₂(C₁-C₄ alkyl) group, a N(C₁-C₃ alkyl)₂ group, a cyano group, a nitro group, a SCH₃ group, a SO₂CH₃ group, a phenoxy group and a phenyl group),

haloalkoxy group, a C₃-C₈ alkenyl group, a C₃-C₈ alkynyl group, a CO₂(C₁-C₄ alkyl) group, a N(C₁-C₃ alkyl)₂ group, a cyano group, a nitro group, a SCH₃ group, a SO₂CH₃ group, a phenoxy group and a phenyl group)],

- S-R11 (wherein R11 is as defined above),
- N(R11)R12 (wherein R11 is as defined above, and R12 is a hydrogen atom, a C₁-C₈ alkyl group, C₃-C₈ alkenyl group, a C₃-C₈ alkynyl group, a C₃-C₆ cycloalkyl group, a C₃-C₆ cycloalkyl(C₁ or C₂)alkyl group, a phenyl group, a benzyl group, a C₁-C₆ alkoxy group, a formyl group, a C₁-C₆ acyl group, a -NHR24 group (wherein R24 is a C₁-C₆ alkyl group), a C₁-C₆ alkylsulfonyl group or a benzoyl group), where in - N(R11)R12, R11 and R12 may form a 3- to 8-membered saturated, unsaturated or partially saturated heterocyclic ring together with the N atom to which R11 and R12 are bonded, where the constituting elements of the ring is selected from the group consisting of a nitrogen atom, an oxygen atom, a sulfur atom and a carbon atom, and the heterocyclic ring may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₈ alkyl group, a C₁-C₈ alkoxy group, a C₁-C₆ haloalkyl group, a C₁-C₆ haloalkoxy group, a C₁-C₈ acyl group, a C₃-C₈ alkenyl group, a C₃-C₈ alkynyl group, a benzoyl group and a phenyl group), or
- NH(R12) [R12 is as defined above].


R4 is a hydrogen atom, a halogen atom, a C₁-C₆ alkyl group, a C₁-C₆ alkoxy group, a C₃-C₆ cycloalkyl group, a C₃-C₈ alkenyl group, a C₃-C₈ alkynyl group, a C₁-C₆ haloalkyl group, a C₃-C₆ halocycloalkyl group, a C₃-C₆ cycloalkoxy group, a C₃-C₈ alkenyloxy group, a C₃-C₈ alkynyloxy group, a C₁-C₆ haloalkoxy group, a C₃-C₆ halocycloalkoxy group, a C₁-C₆ alkylthio group, or a phenyl group which may be substituted [wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a C₁-C₃ haloalkyl group, a C₁-C₃ haloalkoxy group, a C₃-C₈ alkenyl group, a C₃-C₈ alkynyl group, a CO₂(C₁-C₂ alkyl) group, a N(C₁-C₃ alkyl)₂ group, a phenoxy group and a phenyl group].

R3 and R4 may form a 5- to 6-membered ring which may be substituted, where the constituting elements thereof are groups selected from the group consisting of an oxygen atom, CH₂, CH₂CH₂, CH₂C(=CH₂) and CH₂CBr₂, together with the C atom to which R3 and R4 are bonded [wherein the substituent is selected from the group consisting of a halogen atom, a CH₂OH group, a CH₂SH group, a CH₂NH₂ group, a CH₂OSi(CH₃)₃ group, a CH₂O-tetrahydropyranyl group, a C₁-C₄ alkoxy C₁-C₂ alkoxymethyl group, a CH₂OCH₂-cyclopropyl group, a phenyl C₁-C₄ alkoxymethyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a C₁-C₄ haloalkyl group and a nitro group), a phenyl C₁-C₄ alkylthiomethyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a C₁-C₄ haloalkyl group and a nitro group), a phenylthiomethyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a C₁-C₄ haloalkyl group and a nitro group), a piperidyl group, a pyridylmethyl group, a morpholinomethyl group, a piperazinomethyl group, a pyrrolidinylmethyl group, a piperidinomethyl group, a pyrrolidinylmethyl group, a phenylaminomethyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a C₁-C₄ haloalkyl group and a nitro group), a phenyl C₁-C₄ alkylaminomethyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a C₁-C₄ haloalkyl group and a nitro group), a 4-phenylpiperazinomethyl group, a N-benzyl-N-methylaminomethyl group, a 4-(4-acylpiperazinyl)phenoxymethyl group, a 4-(4-isopropylpiperazinyl)phenoxymethyl group, a 4-[4-[2,4-dihydro-2-(1-methylpropyl)-3H-1,2,4-triazol-3-one-4-yl]phenyl]piperazino]phenoxymethyl group, a C₁-C₁₆ alkyl group, a C₁-C₁₈ alkoxy group, a C₁-C₈ haloalkyl group, a C₁-C₁₆ haloalkoxy group, a C₂-C₈ alkenyl group, a C₂-C₈ alkynyl group, a C₁-C₁₈ alkoxymethyl group, a C₂-C₁₈ alkenyloxymethyl group, a C₂-C₁₈ alkynyloxymethyl group, a C₂-C₁₈ alkenylthiomethyl group, a C₂-C₁₈ alkenylaminomethyl group, a 3-substituted-1-pyrrolylmethyl group, a C₁-C₄ alkylthiomethyl group, a C₁-C₆ alkylaminomethyl group, a C₁-C₁₉ alkylcarbonyloxymethyl group, a C₂-C₁₉ alkenylcarbonyloxymethyl group, a phenyl C₁-C₃ alkyl group, a (C₁-C₆ alkyl)₂ aminomethyl group (wherein the alkyl groups as substituents of the amino group may form a 5- or 6-membered cyclocyclic ring), a phenoxymethyl group which may be substituted (the substituent of the phenyl group is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a C₁-C₄ haloalkyl group, a C₁-C₄ haloalkoxy group, a C₃-C₈ alkenyl group, a C₃-C₈ alkynyl group, a CO₂(C₁-C₄ alkyl) group, a N(C₁-C₃ alkyl)₂ group, a cyano group, a nitro group, a SCH₃ group, a SO₂CH₃ group, a phenoxy group and a phenyl group), and a phenyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a nitro group, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a C₁-C₄ haloalkyl group, a C₁-C₄ haloalkoxy group, a N(C₁-C₃ alkyl)₂ group, a phenoxy group and a phenyl group)], provided that when the carbon atom substituted by R3 and R4 is an optically active carbon atom, the lacemate and both of the two isolated optical isomers are included, and when two optically active sites are present in the

molecule, the diastereomer mixture and all of the isolated two diastereomers and four optical isomers are included, and

R3 and R4 may together form =NH, =NNH₂, =NOH, =NOR11 (wherein R11 is as defined above, and the geometrical isomers include the E/Z mixture and both of the isolated E and Z), =NO-Q-R11 (wherein Q and R11 are as defined above, and the geometrical isomers include the E/Z mixture and both of the isolated E and Z), =NO-Q-CO₂-(C₁-C₄ alkyl group) (wherein Q is as defined above, and the geometrical isomers include the E/Z mixture and both of the isolated E and Z), or =NNR11(R16) (wherein R11 is as defined above, R16 is a hydrogen atom, a C₁-C₆ alkyl group, a C₃-C₈ alkenyl group, a C₃-C₈ alkynyl group, a benzyl group or a phenyl group, and the geometrical isomers include the E/Z mixture and both of the isolated E and Z).

2. The compound according to Claim 1, wherein R1 is CF₂X (wherein X is a chlorine atom or a bromine atom).
3. The compound according to Claim 2, wherein R2 is a phenyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a trifluoromethoxy group and a trifluoromethyl group), a thienyl group, a furyl group or a pyridyl group; R3 is a halogen atom, a C₁-C₈ alkoxy group, a C₃-C₆ cycloalkoxy group, a phenoxy group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group and a trifluoromethyl group), a tetrahydropyranyloxy group, a phenyl C₁-C₄ alkoxy group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group and a C₁-C₄ alkoxy group), a C₃-C₆ cycloalkyl C₁ or C₂ alkoxy group, a C₃-C₆ alkenyloxy group, a C₃-C₆ alkynyloxy group, a C₁-C₄ alkoxycarbonyl(C₁-C₄)alkoxy group, a C₁-C₄ alkoxycarbonyloxy group, a C₁-C₄ alkoxy(C₁-C₄)alkoxy group, a C₁-C₄ alkylthio(C₁-C₄)alkoxy group, a cyano C₁-C₄ alkoxy group, a mono or di C₁-C₄ alkylaminocarbonyloxy group, a mono or di C₁-C₄ alkylaminothiocarbonyloxy group, a C₁-C₄ alkylcarbonyloxy group, a C₁-C₄ alkylsulfonyloxy group, a di C₁-C₄ alkylaminosulfonyloxy group, a mercapto group, a C₁-C₄ alkylthio group, a phenylthio group, a benzylthio group, a C₃-C₆ alkenylthio group, a C₃-C₆ alkynylthio group, a C₁-C₄ alkoxycarbonyl(C₁-C₃)alkylthio group, a C₁-C₄ alkoxycarbonylthio group, a C₁-C₄ alkoxy C₁-C₄ alkylthio group, a cyano C₁-C₄ alkylthio group, a mono or di C₁-C₄ alkylaminocarbonylthio group, a mono or di C₁-C₄ alkylaminothiocarbonylthio group, a C₁-C₄ alkylthiocarbonylthio group, an amino group, a mono or di C₁-C₄ alkylamino group, a methyl(methoxy)amino group, a methoxyamino group, a hydroxy C₁-C₄ alkylamino group, a mono or di C₃-C₅ alkenylamino group, a mono or di C₃-C₅ alkynylamino group, a carboxy C₁-C₄ alkylamino group, a C₁-C₄ alkoxycarbonyl C₁-C₄ alkylamino group, a C₁-C₄ alkoxycarbonyl C₁-C₄ alkyl(methyl)amino group, a C₃-C₆ cycloalkylamino group, a phenylamino group, a phenyl C₁-C₄ alkylamino group which may be substituted (wherein the substituent is selected from the group consisting of a halogen, methyl and methoxy), a benzyl(methyl)amino group, a benzyl(formyl)amino group, a phenyl(formyl)amino group, a C₁-C₄ alkylsulfonylamino group, a mono or di C₁-C₄ alkylaminosulfonylamino group, a cyano C₁-C₄ alkylamino group, a C₁-C₄ alkylcarbonylamino group, a mono or di C₁-C₄ alkylaminocarbonylamino group, a mono or di C₁-C₄ alkylaminothiocarbonylamino group, a mono or di C₁-C₄ alkylhydrazino group, a di C₁-C₄ alkylamino group, an imidazolyl group, a triazol-1-yl group, a morpholino group, a dimethyl-substituted morpholino group, a piperazino group, a piperidino group, a pyrrolidinyl group or an aziridinyl group; and R4 is a hydrogen atom or a methyl group.
4. The compound according to Claim 2, wherein R2 is a phenyl group which may be substituted (wherein the substituent is a halogen, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group or a trifluoromethyl group), a thienyl group, a furyl group or a pyridyl group; and R3 and R4 form together with the carbon atom to which R3 and R4 are bonded, a 1,3-dioxane ring which may be substituted (wherein the substituent is a methylene group or a halogen atom), or a 1,3-dioxolan ring which may be substituted (wherein the substituent is a C₁-C₈ alkyl group, a halo C₁-C₄ alkyl group, a methoxymethyl group or a C₃-C₆ alkenyl group).
5. The compound according to Claim 2, wherein R2 is a C₁-C₈ alkyl group, a C₃-C₆ halocycloalkyl group, a C₃-C₆ cycloalkyl group or a C₃-C₆ cycloalkyl C₁ or C₂ alkyl group; and R3 and R4 together form a formula



together with the carbon atom to which R3 and R4 are bonded, wherein R8 is a hydrogen atom, a C₁-C₂₀ alkyl

- group, a phenyl group which may be substituted by a nitro group, a phenyl C₁₋₃ alkyl group, a C₃₋₆ alkenyl group, a halo C₁₋₈ alkyl group, a C₁₋₁₈ alkoxyethyl group, a benzyloxyethyl group which may be substituted (the substituent is selected from the group consisting of a methoxy group, a methyl group and a halogen atom), a phenoxymethyl group which may be substituted (wherein the substituent is selected from the group consisting of a methoxy group, a C₁₋₄ alkyl group, a halogen atom and a nitro group), an allyloxyethyl group, a propinyloxyethyl group, a hydroxyethyl group, a trimethylsilyloxyethyl group, a tetrahydropyranyloxyethyl group, a methoxyethoxyethyl group, a cyclopropylmethoxyethyl group, a mono or di C₁₋₁₂ alkylaminomethyl group, an aminomethyl group, a phenylamino C₁₋₄ alkyl group which may be substituted by a nitro group, a phenylalkylaminomethyl group which may be substituted by a halogen atom, a C₃₋₆ cycloalkylaminomethyl group, a pyrrolidinylmethyl group, a piperazinomethyl group, a morpholinomethyl group, a piperidinomethyl group, a C₁₋₄ alkylthiomethyl group, a mercaptomethyl group, a phenylthiomethyl group which may be substituted by a halogen atom, a phenyl C₁₋₄ alkylthiomethyl group which may be substituted by a halogen atom, a C₁₋₁₇ alkylcarbonyloxyethyl group, a C₃₋₆ alkenylcarbonyloxyethyl group, a benzyloxyethyl group, a piperidyl group, a 4-phenylpiperazinomethyl group, a 4-(4-acylpiperazinyl)phenoxyethyl group, a 3-substituted-1-pyrrolylmethyl group, a 4-[4-[2,4-dihydro-2-(1-methylpropyl)-3H-1,2,4-triazol-3-one-4-yl]phenyl]piperazino]phenoxyethyl group, a pyridyl group or a pyridylmethyl group.
6. The compound according to Claim 2, wherein R₂ is a C₁₋₈ alkyl group or a C₃₋₆ cycloalkyl group; and R₃ and R₄ together form a 1,3-dioxane ring which may be substituted (wherein the substituent is a methylene group or a halogen atom) together with the carbon atom to which R₃ and R₄ are bonded.
7. The compound according to Claim 2, wherein R₂ is a C₁₋₈ alkyl group, a C₃₋₆ cycloalkyl group or a C₃₋₆ cycloalkyl C₁ or C₂ alkyl group; R₃ is an amino group, a mono or di C₁₋₄ alkylamino group, a hydroxy C₁₋₄ alkylamino group, a cyano C₁₋₄ alkylamino group, a C₁₋₄ alkoxyethyl(methyl)amino group, a C₃₋₆ alkenylamino group, a C₃₋₆ alkynylamino group, a phenylamino group which may be substituted by a halogen atom, a phenyl C₁₋₄ alkylamino group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁₋₄ alkyl group, a trifluoromethyl group and a methoxy group), a phenyl C₁₋₄ alkyl(formyl)amino group which may be substituted by a halogen atom, a C₁₋₄ alkyl(formyl)amino group, a phenyl C₁₋₄ alkyl(C₁₋₄ alkyl)amino group which may be substituted by a halogen atom, a diphenylmethylamino group, a thienylmethylamino group, a morpholino group, a dimethyl-substituted morpholino group, a thiomorpholino group, a piperidino group, a dimethyl-substituted piperidino group, an aziridyl group, a dimethylaziridyl group, a pyrrolyl group, a pyrrolidyl group, a C₁₋₃ alkyl-substituted piperidyl group, a methyl-substituted piperazyl group, a phenyl-substituted piperazyl group, a C₆ or C₇ alkyleneimino group, an imidazol-1-yl group, a pyrazol-1-yl group, a triazol-1-yl group, a phenyl-substituted piperidyl group, a benzyl-substituted piperidyl group, a dimethylamino-substituted piperidyl group, a trifluoromethylpiperidyl group, a perhydroquinolyl group, a tetrahydroquinolyl group, a tetrahydro-mono or dimethyl-substituted quinolyl group, a dihydro-dimethyl-substituted quinolyl group or a dihydro-dimethyl-chloroquinolyl group; and R₄ is a hydrogen atom.
8. The compound according to Claim 2, wherein R₂ is a C₁₋₆ alkyl group, a C₃₋₆ cycloalkyl group or a C₃₋₆ cycloalkyl C₁ or C₂ alkyl group; R₃ is an O-R₆ group, wherein R₆ is a C₁₋₆ alkyl group, a C₃₋₆ cycloalkyl group, a C₃₋₅ alkenyl group, a C₃₋₅ alkynyl group, a halo C₁₋₄ alkyl group, a halo C₃₋₅ alkenyl group, a phenyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁₋₄ alkyl group and a methoxy group), a phenyl C₁₋₄ alkyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁₋₄ alkyl group and a methoxy group), a C₁₋₄ alkylcarbonyl group, a phenylcarbonyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁₋₄ alkyl group and a methoxy group), a benzylcarbonyl group, a C₁₋₄ alkylsulfonyl group, a phenylsulfonyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁₋₄ alkyl group and a methoxy group), a C₁₋₄ alkoxy C₁₋₄ alkyl group which may be substituted by a halogen, a C₁₋₄ alkylthiomethyl group, a mono or di C₁₋₄ alkylaminocarbonyl group, a mono or di C₁₋₄ alkylaminothiocarbonyl group, a C₁₋₄ alkoxyethyl group, a C₁₋₄ alkoxyethyl group, a C₁₋₄ alkoxyethyl group, a cyanomethyl group, a tetrahydropyranyl group, a 3-bromotetrahydropyranyl group, a methoxytetrahydropyranyl group, a tetrahydrothiopyranyl group which may be substituted by a methoxy group, a tetrahydrofuran group, a tetrahydrothiofuran group, a 1,4-dioxan-2-yl group, a methoxy-substituted cyclohexyl group, a C₁₋₂ alkoxy C₁₋₂ alkoxyethyl group, a benzyloxyethyl group or a C₁₋₄ trialkylsilyl group; and R₄ is a hydrogen atom.
9. The compound according to Claim 2, wherein R₂ is a C₁₋₆ alkyl group, a phenyl group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group and a trifluoromethyl group), a thienyl group, a furyl group or a pyridyl group; and R₃ and R₄ together

EP 0 764 641 A1

form a formula =N-R5, wherein R5 is a C₁-C₆ alkoxy group, a C₃-C₆ cycloalkyloxy group, a C₃-C₆ alkenyloxy group, a C₃-C₆ alkynyloxy group, a C₁-C₄ alkoxy carbonyl C₁-C₄ alkoxy group, a carbonylmethoxy group, a benzyloxy group which may be substituted by a halogen atom, a hydroxy group, a mono or di C₁-C₄ alkylamino group, a phenylamino group which may be substituted (wherein the substituent is selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a methoxy group and a trifluoromethyl group), a benzylamino group which may be substituted by a halogen atom or a benzyloxy group which may be substituted (wherein the substituent is selected from the group consisting of a C₁-C₄ alkyl group, a halogen atom and a methoxy group).

10. A herbicidal composition containing the compound according to any one of Claims 1 to 9 and an inert carrier.

11. The use of the compound according to any one of Claims 1 to 9 as a herbicide.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP94/01847

A. CLASSIFICATION OF SUBJECT MATTER Int. Cl ⁶ C07D239/26, A01N43/50 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Int. Cl ⁶ C07D239/26, A01N43/50 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS ONLINE		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Tetrahedron Letters, Vol. 26, (1973), R. D. Chambers, et al "PYRIDAZINE REARRANGEMENTS" P. 2405-2406	1
P, A	JP, A, 6-87821 (Kumiani Chemical Industry Co., Ltd.), March 29, 1994 (29. 03. 94), Claim, (Family: none)	1-11
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search December 16, 1994 (16. 12. 94)		Date of mailing of the international search report January 17, 1995 (17. 01. 95)
Name and mailing address of the ISA/ Japanese Patent Office Facsimile No.		Authorized officer Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)